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 ABSTRACT 
 
Glu-Leu-Arg (ELR)-CXC chemokine-mediated neutrophil migration and 
activation plays a key role in many inflammatory diseases.  Dysregulated neutrophil 
activation often leads to inflammatory responses such as acute lung injury (ALI) or 
acute respiratory distress syndrome (ARDS).  
Previously, we generated a bovine drug (i.e., bovine CXCL8(3-74)K11R/G31P, 
bG31P) by mutating the first two amino acids at the beginning of the N-terminus of 
bovine CXCL8/IL-8 and later substituting Arg for Lys11 and Pro for Gly31.  Bovine 
G31P was shown to be a highly effective ELR-CXC chemokine and neutrophil 
antagonist in cattle & guinea pigs, but a human equivalent thereof would be of 
significantly more use in human medicine.  Published studies on the structure and 
function of human CXCL8 suggest that human CXCL8(3-72)K11R/G31P (i.e., hG31P) 
would not be a particularly effective chemokine antagonist.  Thus, development of a 
humanized form of bG31P became a primary goal.  I first examined the effect of 
wholesale ligation of the carboxy half of hCXCL8 onto the amino half of bG31P and 
generated a human-bovine chimeric G31P (hbG31P; i.e., bCXCL8(3-44)K11R/G31P-
hCXCL8(45-72)).  I also made substitutions at each remaining human-discrepant amino 
acid (i.e., T3K, H13Y, T15K, E35A, and S37T) within the 5’ half of the hbG31P 
cDNA.  The results showed that hbG31P and its analogues blocked CXCL8-induced 
human neutrophil chemotactic responses, reactive oxygen intermediate (ROI) release, 
and intracellular calcium flux.  Humanized bovine G31P was also shown to 
significantly block pulmonary neutrophilic pathology in a guinea pig model of airway 
endotoxemia.  
  As bG31P, hbG31P and its further humanized forms showed essentially equivalent 
ELR-CXC chemokine antagonist activity, Dr. Fang Li, Ms Jennifer Town and I then 
generated a fully human form of bG31P, hG31P.  In vitro, hG31P was shown to effectively 
inhibit CXCL-1-, -5-, and -8-induced neutrophil chemotactic responses, intracellular Ca2+ 
flux, and ROI release.  Human G31P also desensitized heterologous G protein-coupled 
receptors (GPCR) including bacterial peptides (e.g., N-formyl-methionine-leucine-
 ii
 phenylalanine, fMLP), anaphylatoxin (e.g., complement 5a, C5a), lipid mediators (e.g., 
leukotriene B4, LTB4; platelet-activating factor, PAF) receptors.  Moreover, hG31P, in a 
dose-dependent manner suppressed CXCL1 and CXCL8 expression by LPS-challenged 
airway epithelial cells and reversed the anti-apoptotic influence of ELR-CXC chemokines 
on neutrophils.  In vivo, hG31P was significantly effective in blocking the pathology 
associated with airway endotoxemia, aspiration pneumonia, and intestinal ischemia and 
reperfusion injury, including neutrophil recruitment (70-95% reduction) into, and 
activation within, the airways or gut, chemokine or cytokine expression, and pulmonary 
vascular complications.  The blockade of neutrophil recruitment by hG31P in aspiration 
pneumonia animals did not increase airway bacterial growth.  The G31P treatment was 
protective in both mesenteric (i.e., local) and remote organ injury.  These findings suggest 
that hG31P is not only a potent neutrophil antagonist, but an effective blocker of other 
inflammatory responses.  These comprehensive anti-inflammatory effects indicate that 
hG31P could potentially provide a viable therapeutic approach for inflammatory diseases 
such as ALI /ARDS. 
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CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW 
 
1.1. INTRODUCTION  
 Inflammation is a protective immune response by the organism to remove harmful 
stimuli such as pathogens, damaged cells, or irritants.  It is characterized by the exudation 
and extravasation of plasma and leukocytes respectively from vascular tissues into injured 
tissues.  Even though this normal physiological response is designed to fight infection, 
remove damaged cells, and stimulate healing, the excessive recruitment of leukocytes often 
exacerbates tissue damage, slows healing, and in some cases leads to host death (Williams, 
Kus et al. 1994).  Among these cells, neutrophils are considered major effector in acute 
inflammatory diseases, such as acute lung inury (ALI) and aspiration pneumonia (AP) 
(Sibille and Marchandise 1993; Abraham, Carmody et al. 2000).  They are also important 
in autoimmune diseases (e.g., rheumatoid arthritis, RA), chronic inflammatory diseases 
(e.g., inflammatory bowel diseases, IBD), and non-infectious diseases (e.g., ischemia-
reperfusion [I/R] injury) (Johnston, Burns et al. 1999; Lefkowitz and Lefkowitz 2001; 
Kalia, Brown et al. 2003). 
 There are many mediators that are involved in mediating neutrophil recruitment, 
such as bacterial peptides (e.g., N-formyl-methionine-leucine-phenylalanine, fMLP), 
anaphylatoxin (e.g., complement factor 5a, C5a), lipid mediators (e.g., leukotriene B4, 
LTB4; platelet-activating factor, PAF), and Glu-Leu-Arg (ELR)-CXC chemokines (e.g., 
interleukin-8, IL-8) (Bless, Warner et al. 1999; Crooks, Bayley et al. 2000).  Among these 
mediators the ELR-CXC chemokines (e.g., CXCL8/IL-8) have been considered to be 
particularly important in many settings (Harada, Mukaida et al. 1996; Baggiolini 1998; 
Shames, Zallen et al. 2000).  This group of CXC chemokines bind to either the CXCR1 or 
CXCR2 receptors (Loetscher, Seitz et al. 1994; Ahuja and Murphy 1996; Baggiolini 1998; 
Richardson, Pridgen et al. 1998; Wuyts, Proost et al. 1998; McColl and Clark Lewis 1999) 
and thereby induce largely overlapping effects.  Their importance in neutrophilic 
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 inflammation suggests that development of an antagonist should be a research priority 
(Harada, Mukaida et al. 1996; Baggiolini 1998; Shames, Zallen et al. 2000). 
 To ameliorate the pathology induced by overly exuberant neutrophil activation and 
recruitment, many therapeutic tools have been developed in the past few years.  Steroids, 
such as dexamethasone, are widely used anti-inflammatory drugs used for treating 
inflammatory and autoimmune diseases such as RA and lupus.  Although effective, steroid 
use often has many side effects such as stomach upset, diabetes and immunosuppressant 
actions.  Since proinflammatory cytokines such as TNFα and IL-1β are extremely 
important in mediating inflammatory diseases, the antagonists of these cytokines and their 
receptors have been extensively examined and some of these are already being used 
clinically (van Deventer 1999).  In order to block neutrophil-mediated inflammatory 
disease, research has also targeted neutrophil chemoattractants such as C5a, LTB4, and 
PAF with the goal of developing antagonists for these important mediators.  They are 
found to be able to prevent C5a-induced injury during sepsis, ameliorate I/R-induced 
neutrophil-mediated tissue injury, or reverse arthritis pathology (Karasawa, Guo et al. 1991; 
Huber-Lang, Riedeman et al. 2002; Moreno, Alves-Filho et al. 2006; Diaz-Gonzalez, Alten 
et al. 2007).  Targeted to inhibit the function of CXCL8 in inflammatory diseases, a 
CXCL8 monoclonal antibody was developed and found to be able to prevent neutrophil 
infiltration and tissue injury (Sekido, Mukaida et al. 1993).  Other CXCL8 receptor 
antagonists such as SB-26510, a non-peptide CXCR2 antagonist, and repertaxin, a 
CXCR1/R2 receptor antagonist, have recently been developed to inhibit neutrophil-
mediated pathology (Auten, Richardson et al. 2001; Casilli, Bianchini et al. 2005). 
 Our laboratory had engineered a high affinity analogue of bovine CXCL8, 
CXCL8(3-74) K11R (Li and Gordon 2001), from which we have generated a very high 
affinity antagonist, CXCL8(3-74)K11R/G31P (Li and Gordon 2002) (hereafter referred to as 
‘bG31P’).  bG31P binds to bovine neutrophils via both the CXCR1 and CXCR2 and 
thereby blocks the chemotactic activities of multiple ELR-CXC chemokines.  Very low 
doses of bG31P block all of the chemotactic activities present in extracts from bovine 
pneumonic pasteurellosis or endotoxin-induced mastitis lesions, as well as neutrophil 
infiltration of intradermal endotoxin-challenge sites in cattle (Li, Zhang et al. 2002).  Since 
bovine and human CXCL8 share relatively high amino acid sequence identity, with most 
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 of the discrepant amino acids residing in the carboxyl half of the molecule (Tabel 3.1) 
(Morsey, Popowych et al. 1996), I hypothesized that simply replacing the bovine carboxyl 
half of bG31P with that of human CXCL8 would make a similarly effective ELR-CXC 
chemokine antagonist (the amino terminal half of bG31P contained all of the previously 
introduced substitutions).  In Chapter 3 of my thesis, I developed a humanized form of 
bG31P through wholesale ligation of the carboxy half of human CXCL8 onto the amino 
half of bG31P and characterized its activity through in vitro and in vivo experiments.  I 
demonstrated that this human-bovine chimeric G31P (hbG31P; i.e., bCXCL8(3-
44)K11R/G31P-hCXCL8(45-72)) fully retained the ELR-CXC chemokine antagonist activity 
of bG31P.  Meanwhile, our lab had created a fully human form of bG31P (hG31P; i.e., 
CXCL8(3-72) K11R/G31P) which has also shown effective antagonist activity in 
preliminary in vitro experiments.  Thereafter, I carried on characterizing this hG31P’s 
antagonist activity in in vitro experiments and several in vivo model systems including 
airway endotoxemia and aspiration pneumonia in guinea pigs, and superior mesenteric 
artery ischemia and reperfusion injury in rats (Chapter 4, 5, 6).  The remainder of this 
chapter (Chapter 1) and next chapter (Chapter 2) are the project literature review, research 
hypothesis and objectives.  
 
1.2. LITERATURE REVIEW  
1.2.1. Proinflammatory inflammatory mediators 
1.2.1.1. Cytokines 
Proinflammatory cytokines are a group of cytokines that function as amplifiers of 
inflammatory reactions.  These include TNFα, IL-1β, and IL-6 (Malaviya 2006).  Among 
these cytokines, TNFα and IL-1β are the so-called “early response cytokines” because of 
their roles in initiating and furthering inflammatory responses (Dinarello 2000).  They also 
serve to regulate other cellular functions and tissue repair in cases of local inflammation 
(Le and Vilcek 1987).  However, excessive release of these cytokines can result in tissue 
injury and even host death (Abraham, Carmody et al. 2000).  
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 TNFα 
TNFα is produced by many different cell types such as monocytes/macrophages 
(Ulich, Watson et al. 1991; Beck-Schimmer, Schwendener et al. 2005), endothelial cells 
(Ranta, Orpana et al. 1999), smooth muscle cells (Newman, Zhang et al. 1996), and 
neutrophils (Lapinet, Scapini et al. 2000; Sohn, Paape et al. 2007).  Brochial fibroblasts 
and epithelial cells from cancer patients in coculture, but not in monoculture, also release 
TNFα (~ 100pg/ml).  But the main source of  TNFα in vivo is stimulated-
monocytes/macrophages, especially in endotoxin-induced lung injury (Beck-Schimmer, 
Schwendener et al. 2005).  TNFα is multifunctional.  Like IL-1β, it is an endogenous 
pyrogen.  Both can induce fever after being injected intravenously (Dinarello, Cannon et al. 
1986).  TNFα also stimulates macrophages (Strieter, Chensue et al. 1990; Ciesielski, 
Andreakos et al. 2002), endothelial cells (Smart and Casale 1994), and pulmonary 
epithelial cells (Allen, Menendez et al. 2000) to release chemokines such as CXCL8, 
growth-related oncogene (GRO) α and epithelial neutrophil-activating peptide (ENA)-78.  
These ELR-chemokines along with TNFα are important neutrophil chemotactic factors in 
inflammation (Ming, Bersani et al. 1987; Rekdal, Konopski et al. 1994).  TNFα also 
stimulates endothelial cells to produce PAF (Bussolino, Camussi et al. 1988) and express 
adhesion molecules such as intercellular adhesion molecule (ICAM)-1 and vascular cell 
adhesion molecule (VCAM)-1 (McHale, Harari et al. 1999).  These findings indicate that 
TNFα is a very important inflammatory mediator and plays critical roles in mediating 
neutrophil recruitment to inflammation sites, both directly and indirectly.  
In addition to its role in facilitating neutrophil transendothelial migration 
(Bussolino, Camussi et al. 1988; McHale, Harari et al. 1999), TNFα also stimulates 
endothelial cells and neutrophils to generate large amounts of reactive oxygen 
intermediates (ROI) (reviewed in (Mukhopadhyay, Hoidal et al. 2006)), which are 
involved in TNFα-induced endothelial cell apoptosis.  Apoptotic vascular endothelial cells 
express procoagulant activities and thereby may be associated with atherosclerosis 
(Bombeli, Karsan et al. 1997; Deshpande, Angkeow et al. 2000).  TNFα also plays an 
important role in intestinal I/R injury.  Elevated local and systemic TNFα levels can be 
found in intestinal I/R injury models, where its production facilitates neutrophil influx and 
contributes to tissue injury (Souza, Cassali et al. 2001).  TNFα inhibition studies showed 
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 that it is also highly associated with ischemia reperfusion injury-induced lethality (Souza, 
Cassali et al. 2001; Souza, Pinho et al. 2003).  Moreover, it is indicated that TNFα plays a 
major role in RA and Crohn’s diseases (van Deventer 1999; Edrees, Misra et al. 2005). 
 Strategies to inhibit TNF function, such as monoclonal anti-TNF antibodies and 
soluble TNF receptors (sTNF-R), are widely studied and used for treating RA, Crohn’s 
disease and other dieases (van Deventer 1999; Kadokami, McTiernan et al. 2001; 
Bartolucci, Ramanoelina et al. 2002; Edrees, Misra et al. 2005).  However, the potential 
side effects of long-term use of anti-TNF treatment include the risk of serious infections 
and malignancies (Costenbader, Glass et al. 2006). 
 
IL-1β 
IL-1β is another important proinflammatory cytokine.  IL-1β can be produced by 
monocytes/macrophages (Arend, Gordon et al. 1989; Ulich, Watson et al. 1991), 
neutrophils (Parsey, Tuder et al. 1998) and endothelial cells (Nawroth, Bank et al. 1986) 
when stimulated by LPS or TNFα.  It is also found to be expressed in intestinal epithelial 
cells following challenge with LPS in vitro (Waterhouse and Stadnyk 1999).  But the main 
source of IL-1β is considered to be neutrophils, especially in hemorrhagic or endotoxemic 
lung tissue (Parsey, Tuder et al. 1998).  IL-1β has functions similar to TNFα such as 
induction of fever, chemokine production (e.g., IL-8, macrophage inflammatory protein 
[MIP]-2) by alveolar macrophages and pulmonary epithelial cells (Strieter, Chensue et al. 
1990; Ishii, Fujii et al. 2004; Manzer, Wang et al. 2006), and expression of adhesion 
molecules (e.g., ICAM-1 and VCAM-1) by endothelial cells (McHale, Harari et al. 1999).  
In general, IL-1β also plays a crucial role in initiating inflammatory responses and in 
recruitment and activation neutrophils to inflammation sites. 
Studies show that intratracheal instillation of IL-1β induces more acute lung injury 
than does TNFα (Ulich, Watson et al. 1991).  And clinically, IL-1β, rather than TNFα, is 
found to be a major inflammatory cytokine and associated with higher risk of death in 
ARDS patients (Goodman, Strieter et al. 1996; Pugin, Ricou et al. 1996).  IL-1β is also 
involved in ischemia and reperfusion injury, but its precise role is still uncertain.  Some 
studies using IL-1 receptor antagonist (IL-1ra) and IL-1 inhibitor have demonstrated that 
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 IL-1β plays deleterious roles in renal and intestinal I/R injuries, repectively (Haq, Norman 
et al. 1998; Yamamoto, Tanabe et al. 2001).  Other studies have mentioned that inhibition 
of IL-1 by use of anti-IL-1 antiserum or IL-1ra exacerbated the I/R tissue injury (e.g., 
increasing vascular permeability), TNFα expression, and lethality (Souza, Guabiraba et al. 
2003).  
 
IL-6 
IL-6 is a pleiotropic cytokine produced during inflammatory responses.  It can be 
produced by a variety of cells such as alveolar macrophages, monocytes, fibroblasts, 
epithelial cells and other cells.  The IL-6 inducers include bacterial products (e.g., LPS) or 
cytokines (e.g., TNFα, IL-1β) (Barton 1996; Larsson, Larsson et al. 1999).  IL-6 is 
considered to be a prototypic proinflammatory cytokine because of its high production 
after LPS exposure (Barton 1996; Tominaga, Kirikae et al. 1997).  In acute inflammatory 
responses, it induces fever and increases acute phase protein expression by the liver 
(Barton 1996).  IL-6, combined with sIL-6R is also involved in neutrophil recruitment in 
local inflammation by inducing CXCL8 and adhesion molecule production by endothelial 
cells (Romano, Sironi et al. 1997).  The induction of chemokine expression (e.g., 
macrophage inflammatory protein-2, MIP-2) by IL-6 is also found in virus (e.g., Herpes 
simplex virus -1, HSV-1)-induced inflammation (Fenton, Molesworth-Kenyon et al. 2002). 
IL-6 has been demonstrated to significantly contribute to lung injury and neutrophil 
recruitment in a rat hemorrhagic shock model (Hierholzer, Kalff et al. 1998).  It has also 
been shown that IL-6 plays an important role in mediating lung leakage, neutrophil 
infiltration, and chemokine expression in lung injury following kidney I/R (Klein, Hoke et 
al. 2008). 
Recently, it is believed that IL-6 also plays an important role in regulating 
inflammation. For instance, IL-6 can inhibit TNFα production induced by endotoxin 
challenge in human and mouse model systems (Aderka, Le et al. 1989; Starkie, Ostrowski 
et al. 2003). Intratracheal instillation of IL-6 leads to dramatic reductions in vascular 
permeability and neutrophil sequestration in the lung, and in the levels of TNFα and MIP-2 
 6
 expression in bronchoalveolar lavage (BAL) fluids in an immunoglobulin G immune 
complex-induced lung injury model (Shanley, Foreback et al. 1997). 
 
1.2.1.2. Complement 
The complement system includes some 35 linked soluble plasma proteins and 
receptors (Sunyer, Boshra et al. 2005).  The complement cascade can be activated by 
classical, alternative or lectin pathways, which are initiated by antigen-antibody complexes, 
various types of microbial surface molecules (e.g., LPS), or microorganisms containing 
mannans on their surfaces, respectively (Guo and Ward 2005; Sunyer, Boshra et al. 2005). 
Upon initiation, complement cascade products play crucial roles in the phagocytosis of 
invading microorganisms, solubilization of immune complexes, and initiation of 
inflammatory responses (Sunyer, Boshra et al. 2005).  However, complement activation 
has also been demonstrated to be important in the pathogenesis of many inflammatory 
diseases, such as sepsis (Czermak, Sarma et al. 1999), acute respiratory distress syndrome 
(ARDS) (Stevens, O'Hanley et al. 1986), RA (Grant, Picarella et al. 2002), IBD (Woodruff, 
Arumugam et al. 2003), and I/R injury (Riedemann and Ward 2003).  The harmful roles 
that complement activation exerts are prominent in promoting and perpetuating 
inflammatory reactions (Guo and Ward 2005). 
Among the complement protein split products, C5a is one of the most potent 
peptides.  C5a is a powerful chemoattractant for neutrophils, monocytes, and macrophages 
and can also induce the respiratory burst and release of granule enzymes in neutrophils and 
facilitate their phagocytotic processes (Guo and Ward 2005).  C5a can modulate cytokine 
expression by inflamed respiratory epithelial cells and microvascular endothelial cells 
(Laudes, Chu et al. 2002; Riedemann, Guo et al. 2002).  It can stimulate neutrophils and 
enhance their expression of adhesion molecules such as CD11b/CD18 (Foreman, Glovsky 
et al. 1996), as well as delay neutrophil apoptosis.  It also functions as an important 
vasodilator during inflammation (Guo and Ward 2005).  C5a binds two kinds of receptors 
on neutrophils, the C5aR and the C5L2 (Sengelov 1995; Ohno, Hirata et al. 2000).  C5aR 
is a G protein-coupled receptor (GPCR) with seven transmembrane segments.  It is related 
to most of the proinflammatory functions of C5a in inflammatory diseases (Grant, Picarella 
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 et al. 2002; Riedemann and Ward 2003; Woodruff, Arumugam et al. 2003).  C5L2 is 
similar to C5aR and has been recently reported to be a critical regulator involved in C5a 
and LPS signaling (Chen, Mirtsos et al. 2007).  Since C5a is a GPCR, as are the receptors 
for other neutrophil chemoattractants such as CXCL8, fMLP, LTB4, and PAF, cross-
desensitization of their individual receptors has been carefully studied.  There is evidence 
that fMLP, C5a, and CXCL8 desensitize each others’ Ca2+-mobilizing responses; PAF and 
LTB4 were also desensitized by peptide chemoattractants, but not vice versa (Didsbury, 
Uhing et al. 1991; Tomhave, Richardson et al. 1994; Richardson, Ali et al. 1995).  This 
evidence affords the possiblity of studying the desensitization of heterologus 
chemoattractant receptors by chemokine receptor antagonists. 
As an important proinflammatory mediator, C5a plays key roles in exacerbating the 
pathology in inflammatory diseases through facilitating neutrophil recruitment and 
activation and inducing other inflammatory mediators’ release.  For instance, C5a is 
known to stimulate pulmonary macrophages to produce proinflammatory cytokines (e.g., 
TNFα and IL-1β), which cause up-regulation of vascular ICAM-1 and E-selectin on 
vascular endothelial cells (Mulligan, Schmid et al. 1996).  It interacts with endothelial cells 
through binding to the C5a receptor to induce P-selectin expression (Ward 1996).  It also 
up-regulates β2-integrin expression and induces shedding of L-selectin on neutrophils 
(Jagels, Daffern et al. 2000).  C5a also can stimulate neutrophils to release leukotrienes 
(including LTC4 and LTD4), and histamine to increase vascular permeability and slow 
blood flow (Markiewski and Lambris 2007).  In addition, C5a is an important neutrophil 
chemoattractant and forms a gradient to induce PMN motility in tissue.  C5a is also able to 
stimulate endothelial cells, epithelial cells, as well as alveolar macrophages to produce IL-
8 and indirectly contributes to neutrophil migration to inflammation sites (Markiewski and 
Lambris 2007).  C5a is reported to be able to bind C5aR on rat alveolar epithelial cells and 
stimulate them to release TNFα and IL-1β, which further excerbates inflammatory 
responses (Riedemann, Guo et al. 2002). 
In specific inflammatory disease models (e.g., I/R injury and aspiration pneumonia), 
the roles of C5a have been widely investigated.  In hindlimb I/R injury, neutralizing C5a 
antibody treatment indicates that C5a is involved in pulmonary neutrophil recruitment, 
tissue CXC chemokine expression, and vascular permeability changes. But blockade of 
 8
 C5a seems to be less effective than ELR-CXC chemokine inhibition (e.g., with anti-CINC 
and anti-MIP-2 antibodies) in ameolirating pulmary neutrophil recruitment and vascular 
permeability (Bless, Warner et al. 1999).  This finding indicates that ELR-CXC 
chemokines may play more important roles in the aforementioned pathological changes.  
In aspiration pneumonia, C5a contributes to the accumulation of both neutrophils and 
alveolar macrophages (Ishii, Kobayashi et al. 1989).  Interestingly, C5a is found not 
important for pulmonary neutrophil sequestration in endotoxin-induced lung injury 
(Rittirsch, Flierl et al. 2008).  
 
1.2.1.3. Lipid mediators 
Lipid mediators are derived from arachidonic acid (AA), a key lipid mediator 
released from the phospholipid cell membrane upon the action of phospholipase A2 (PLA2) 
during inflammation.  There is now considerable evidence to suggest that metabolites of 
the AA cascade, namely prostanoids, leukotrienes and lipoxins, play a critical role during 
inflammation.  AA can be metabolized by three pathways, including the cyclooxygenase, 
lipoxygenase (LO), and lipoxin cell-cell interaction pathways which lead to prostaglandin 
(PG), leukotriene (LT), and lipoxin (LX) production, respectively.  LTs and PGs amplify 
acute inflammation, whereas LXs have unique anti-inflammatory activities (Levy, Clish et 
al. 2001). 
 
LTB4 
Leukotriene B4 (LTB4) is a 5-LO-derived potent neutrophil chemoattractant. It can 
be produced by neutrophils, mast cells, eosinophils, and macrophages stimulated  by 
proinflammatory cytokines such as TNFα, IL-1β and chemoattractants such as CXCL8, 
C5a, PAF, and itself (Crooks and Stockley 1998; Serhan 2000).  In addition to its 
chemotactic activity, it can cause neutrophil aggregation, calcium mobilization, and release 
of granule products and superoxide anions (Levy, Clish et al. 2001).  Leukotrienes exert 
their effects through binding to two kinds of GPCRs, the BLT1 and the BLT2. The BLT1, a 
high-affinity receptor for LTB4 expressed on leukocytes, mast cells, and endothelial cells, 
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 mediates most LTB4-dependent inflammatory diseases such as asthma, RA, and 
arteriosclerosis.   BLT2 is a lower-affinity receptor for LTB4 (Lundeen, Sun et al. 2006; 
Qiu, Johansson et al. 2006; Shao, Del Prete et al. 2006) and its function is still not clear.  
LTB4 is well known to be significantly involved in neutrophil recruitment and 
activation during inflammatory responses.  But, the mechanism by which LTB4 recruits 
PMN is somewhat different from that of fMLP, CXCL8 and C5a.  Studies using a LTB4 
receptor antagonist demonstrates that LTB4 plays a more important role than fMLP in 
neutrophil transendothelial migration, although it has a lower capability to chemoattract 
neutrophils than fMLP (Nohgawa, Sasada et al. 1997).  Antibody blockade experiments 
indicate that ICAM-1 participates in LTB4-induced neutrophil transendothelial migration, 
but LTB4 does not directly induce ICAM-1 expression (Nohgawa, Sasada et al. 1997; 
Crooks and Stockley 1998).  LTB4 increases the expression of β2-integrin on neutrophils, 
which can facilitate neutrophil adherence and migration (Crooks and Stockley 1998), even 
though LTB4 and CXCL8 are reported to be able to stimulate β2-integrin-independent 
migration of PMN across human pulmonary endothelial cells in vitro (Mackarel, Russell et 
al. 2000).  LTB4 does not stimulate endothelial cells to produce CXCL8 or PAF (McIntyre, 
Zimmerman et al. 1986; Nohgawa, Sasada et al. 1997).  In addition, in vitro experiments 
indicate that human umbilical vein endothelial cells (HUVEC) express LTB4 receptors 
(BLT1 and BLT2), which are more highly expressed after LPS and TNFα stimulation and 
more responsive to LTB4.  LTB4 can augment nitric oxide and MCP-1 production from 
HUVEC stimulated by LPS (Qiu, Johansson et al. 2006).  This is an important feature of 
LTB4, because MCP-1 facilitates PMN transmigration across endothelial cells barriers 
(Maus, Waelsch et al. 2003).  This data suggests that LTB4 interaction with LPS (or 
TNFα)-stimulated endothelial cells through the BLT1 and the BLT2 can enhance PMN 
transmigration across endothelial cells.  LTB4 certainly forms a chemotactic factor gradient 
to attract PMN migration to the tissue.  LTB4 facilitates PMN transepithelial cell migration 
through the ROS-extracellular signal-regulated kinase-linked cascade (Woo, Yoo et al. 
2003).  
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 PAF 
Platelet-activating factor (PAF) is a member of a family of structurally-related 
phospholipids with various biological activities, including activation of platelets, 
leukocytes and endothelial cells (Soares, Pinho et al. 2002).  It is produced by a variety of 
cells that participate in the inflammatory responses, including neutrophils, platelets, mast 
cells, monocytes/macrophages, and endothelial cells.  There are several important 
mediators that induce endothelial cells to produce PAF, such as thrombin, histamine, IL-8, 
TNFα and IL-1α (Montrucchio, Alloatti et al. 2000).  PAF targets these and other cells via 
a specific GPCR (i.e. PAFR).  
PAF is a potent neutrophil chemoattractant, but also participates in neutrophil 
migration and activation in other ways, such as by activating endothelial cells.  Thrombin-
challenged endothelial cells secrete PAF, which stays on the surface of endothelial cells, 
and thereby can induce PMN adhesion via the neutrophils PAFR (Zimmerman, McIntyre 
et al. 1990).  The signaling component provided by endothelial cell-associated PAF may 
facilitate activation and polarization of the β2-intergrins on neutrophils and contribute to 
PMN rolling and firm adhesion (Lorant, Patel et al. 1991; Macconi, Foppolo et al. 1995). 
PAF also participates in the adhesion of PMNs to, and migration across, TNFα-stimulated 
HUVEC, but not in cell rolling (Macconi, Foppolo et al. 1995).  Endothelial cell-associated 
PAF co-stimulates TNFα-induced neutrophil respiratory burst activity during TNFα-
stimulated endothelial-neutrophil interactions (von Asmuth and Buurman 1995).  PAF  
may also promote TNFα-induced ICAM-1 and E-selectin expression on endothelial cells, 
thereby facilitating neutrophil adherence to the endothelium (Sterner-Kock, Braun et al. 
1996).  It also can activate neutrophils to produce elastase and thereby facilitate neutrophil 
transendothelial migration (Cepinskas, Sandig et al. 1999).  After neutrophils transmigrate 
across the endothelium, PAF also contributes to neutrophil adherence to fibroblasts (Burns, 
Simon et al. 1996).  PAF also works as a potent chemoattractant for neutrophils and 
stimulates lysosomal enzyme release and reactive oxygen product formation by neutrophils, 
eosinophils, and macrophages (Lad, Olson et al. 1985). 
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 1.2.1.4. Bacterial products 
fMLP 
The bacterial tripeptide formyl-Met-Leu-Phe (fMLP) has been discovered as the 
major peptide neutrophil chemotactic factor produced by Escherichia coli (Marasco, Phan 
et al. 1984).  In addition to chemotaxis, fMLP also plays an important role in inducing 
neutrophil superoxide release (e.g., O2-), proteolytic enzyme (e.g., lysosomal enzyme) 
release, degranulation (e.g., myeloperoxidase [MPO] release), metabolism of arachidonic 
acid, and calcium mobilization (Naccache, Showell et al. 1977; Hatch, Gardner et al. 1978; 
Bokoch and Reed 1980).  fMLP binds to the high-affinity formyl peptide receptor (FPR) 
and the low-affinity FPR-like-1 protein (FPRL1) on neutrophils (Selvatici, Falzarano et al. 
2006).  These two receptors are both GPCRs and share 69% homology at the amino acid 
level.  Compared to FPRL1, FPR plays a more important role in mediating neutrophil 
chemotaxis and Ca2+ mobilization.  In addition to the expression on the neutrophil, both 
receptors are expressed on monocytes, hepatocytes, and other resident tissue cells.  FPRL1 
is also expressed on epithelial cells and microvascular endothelial cells (Le, Yang et al. 
2002).  FPRL1 expression on monocytes and microglia may be involved in Alzheimer’s 
disease (Cui, Le et al. 2002).  Since fMLP, along with C5a, LTB4, PAF, and IL-8, binds 
GPCRs on neutrophils, their roles in mediating neutrophil signaling have been widely 
studied.  In vitro, they all undergo homologous desensitization of neutrophil Ca2+ 
mobilization.  Neutrophil peptide ligands (C5a, fMLP, and IL-8) can heterologously 
desensitize lipid ligand (PAF and LTB4) receptors.  Among peptide ligands, they can 
differentially desensitize each others ligand receptors, and fMLP is highly effective in 
desensitizing other peptide ligand receptors (Tomhave, Richardson et al. 1994).  In vivo, 
fMLP and chemokines (e.g., MIP-2, keratinocyte-derived cytokine [KC]) contribute 
differentially to neutrophil migration and activation in response to increasing levels of 
bacterial challenge and at different stages after challenge in pneumococcal pneumonia.  
fMLP seems to be important in situations with high bacterial inoculum and induces 
neutrophil migration and activation during the first 12 hours after bacterial challenge, 
whereas chemokines are important in low bacterial inoculum situations and contribute to a 
more sustained neutrophil response (Gauthier, Fortin et al. 2007). 
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 LPS 
Lipopolysaccharide (LPS), the endotoxin of gram-negative bacteria, is another 
important bacterial product that induces a variety of inflammatory responses.  It binds to 
LPS-binding proteins (LBP) in plasma and forms LPS-LBP complex, which further 
interacts with cluster of designation-14 (CD14) and toll-like receptor 4 (TLR4) and leads 
to activation of TLR4 on the cells (Miller, Ernst et al. 2005).  In the lung, TLR4 can be 
expressed on alveolar macrophages (Hollingsworth, Chen et al. 2005), endothelial cells 
(Andonegui, Bonder et al. 2003), and epithelial cells (Armstrong, Medford et al. 2004; 
Guillot, Medjane et al. 2004).  It also can be expressed on hematopoietic cells such as 
neutrophils (Sabroe, Jones et al. 2002; Sabroe, Prince et al. 2003) and monocytes (Sabroe, 
Jones et al. 2002).  
When the airway is exposed to LPS challenge, airway epithelial cells are the 
primary responders to the challenge.  When challenged with LPS, pulmonary epithelial 
cells, including tracheobronchial epithelium and alveolar epithelium, release ELR-CXC 
chemokines (e.g., IL-8, KC), cytokines (e.g., IL-6), and defensins (e.g., β defensin-2) 
(Becker, Diamond et al. 2000; Guillot, Medjane et al. 2004).  The production of these 
inflammatory mediators is dependent on TLR4 and CD14.  The alveolar macrophage is 
another important cell type involved in airway endotoxemia.  It plays a major role in 
producing proinflammatory cytokines (e.g., TNF, IL-1, and IL-6) and chemokines (e.g., 
IL-8, MCP-1) (Larsson, Larsson et al. 1999; Thorley, Ford et al. 2007).  These 
macrophage-derived mediators further stimulate alveolar epithelial cells to amplify 
production of these mediators and thereby exacerbate the LPS-induced inflammatory 
responses (Thorley, Ford et al. 2007).  Like airway epithelial cells, TLR4 is also 
significantly involved in macrophage activation and its functional roles. Studies have 
demonstrated that TLR4 expressed on macrophages is more important than that on other 
resident cells (e.g., epithelial cell, endothelial cell) in neutrophil recruitment during LPS-
induced airway inflammation (Hollingsworth, Chen et al. 2005). In addition to inducing 
epithelial cells to generate cytokines and facilitating neutrophil infiltration, LPS challenge 
also causes damage to airway epithelial cells, such as increasing epithelial permeability 
(Eutamene, Theodorou et al. 2005). 
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 Endothelial cell-expressed TLR4 is also involved in LPS-induced pulmonary 
neutrophil sequestration into the lung following both intraperitoneal and airway challenge 
(Andonegui, Bonder et al. 2003; Hollingsworth, Chen et al. 2005).  As discussed above, 
endothelial TLR4 is less important than macrophage TLR4 in airway endotoxemia-induced 
neutrophil infiltration (Hollingsworth, Chen et al. 2005).  But, it is particularly important in 
systemic endoxemia-induced pulmonary neutrophil infiltration (Andonegui, Bonder et al. 
2003).  One reason seems to be the increased expression of P-selectin and VCAM-1 by 
LPS-activated endothelial cells and their expression is TLR4-dependent (Andonegui, 
Goyert et al. 2002).  LPS challenge also causes pulmonary microvascular endothelial cell 
leakage, which is an important part of the pathophysiology of human lung injury (Shelton, 
Wang et al. 2006). 
LPS is also able to activate neutrophils, causing expression of β2-integrin, 
increased L-selectin shedding, respiratory burst, cytokine (e.g., TNFα, IL-β), and 
chemokine (e.g., IL-8) generation (Sabroe, Jones et al. 2002; Sabroe, Prince et al. 2003). 
Neutrophils also express TLR4 and CD14.  During LPS challenge in the lung, TLR4, 
CD14, and LBP are all significantly involved in neutrophil activation (Jack, Fan et al. 1997; 
Sabroe, Jones et al. 2002).  Notably, LPS activation of neutrophils through TLR4 can 
down-regulate ELR-CXC chemokine receptor (CXCR1 and CXCR2), expression by 
neutrophils, although CXCR1 expression is more resistant to such down-regulation 
(Sabroe, Jones et al. 2005).  This process may be caused by the role of TLR4 in down-
regulating G-protein receptor kinases.  Oddly, the down-regulation of CXCR1/2 
expression does not reduce, but rather, it enhances neutrophil responses to chemokines 
(Fan and Malik 2003; Sabroe, Jones et al. 2005).  
In summary, both systemic and airway administration of LPS can induce 
pulmonary neutrophil recruitment which is TLR4-dependent.  LPS, given through airway, 
can cause the recruitment and extravasation of neutrophils, injury to the alveolar 
epithelium and disruption of pulmonary capillary integrity, leading to a protein-rich fluid 
leakage into the alveolar space. 
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 1.2.1.5. Chemokines 
Chemokines are a family of small proteins (8-10 kDa) that have a common role in 
regulating leukocyte migration in normal or inflamed tissues.  However, the first member 
of the chemokine family, platelet factor 4 (PF4) (Poplawsky and Niewiarowaki 1964), was 
not recognized as a chemotactic cytokine until after IL-8 was discovered and characterized 
as a neutrophil chemotactic factor in 1987 (Yoshimura, Matsushima et al. 1987).  
Chemokines have conserved cysteine residues such that, based on their relative positioning, 
they are divided into four subgroups (CXC, CC, CX3C and C). CXC, CC, and CX3C 
chemokines have four to six cysteines, and C chemokines only have two.  To date, 
approximately 50 chemokines have been discovered (Allen, Crown et al. 2007).  In the 
new systematic chemokine nomenclature, chemokines are named based on their cysteine 
subclass roots, followed by “L” for ligand.  The assigned numbers correspond generally to 
that used in the corresponding gene nomenclature. For example, IL-8 is now called 
CXCL8 (Zlotnik and Yoshie 2000).  Chemokine receptors consist of a large group of the 
rhodopsin family of cell-surface G protein-coupled receptors with seven-transmembrane 
domains. Chemokines function through binding to these receptors on the surface of target 
cells. The nomenclature system of chemokine receptors follows the chemokine subclass 
specificity and followed by “R”. For example, the two CXCL8 receptors are CXCR1 and 
CXCR2 (Mukaida 2003).   
Chemokines have diverse roles in innate and adaptive immunity.  In addition to 
their roles in leukocyte migration, which include integrin activation during leukocyte-
endothelial interactions and leukocyte chemotaxis, chemokines are also involved in 
leukocyte degranulation and promotion of angiogenesis or angiostasis (Mackay 2001; 
Mukaida 2003). It is also believed that chemokines contribute to dendritic cell function, T 
cell differentiation and function, inflammatory diseases (e.g., rheumatoid arthritis and 
multiple sclerosis), mucosal and subcutaneous immunity, and subversion of immune 
responses by viruses (e.g., HIV-1) (Mackay 2001). Further discussion of the ELR subclass 
of chemokines is presented as below (§1.2.3.) 
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 1.2.2. Inflammatory cells 
1.2.2.1. Neutrophils 
1.2.2.1.1. General aspects of neutrophils 
Neutrophils play a critical role in fighting microorganisms, e.g., bacteria, fungi, and 
viruses in host innate immunity (Smith 1994).  Neutrophils can be activated by 
inflammatory mediators such as cytokines, complement components, arachidonic acid 
metabolites, or chemokines (Baggiolini 1995).  Following the gradients of 
chemoattractants, activated neutrophils migrate into infection sites and their release 
inflammatory mediators and antimicrobial products that contribute to pathogen clearance 
(Pettersen and Adler 2002).  However, excessive or inappropriate neutrophil activation can 
cause tissue damage or even host death (Smith 1994).  Many inflammatory diseases are 
exacerbated by neutrophil activation, such as ALI, AP (Sibille and Marchandise 1993; 
Abraham, Carmody et al. 2000), I/R injury (Kalia, Brown et al. 2003), chronic obstructive 
pulmonary diseases (COPD) (Stockley 2002), and ARDS (Lee and Downey 2001).  
Recently, neutrophils were also found to be involved in initiating and modulating adaptive 
immune responses, such as inducing maturation of dendritic cells (DC), which can trigger 
strong T cell proliferation (van Gisbergen, Sanchez-Hernandez et al. 2005).  
 
1.2.2.1.2. Neutrophil development 
Neutrophils develop from CD34+ progenitor cells in the bone marrow.  In this 
process, myeloid precursors undergo striking morphologic and functional changes 
characterized by significant alterations in cell size and nuclear shape (Lichtman and Weed 
1972; Lund-Johansen and Terstappen 1993).  They also develop stage-specific organelles 
containing proteins necessary for the highly specialized roles of neutrophils in 
phagocytosis, bacterial killing, and inflammatory response (Bainton, Ullyot et al. 1971).  
IL-1, IL-2, and IL-6 can foster neutrophil development (Heslop, Duncombe et al. 1991; 
Haylock, To et al. 1992), but many other cytokines, including SCF, G-CSF, and IL-3 are 
also involved in this process (Cannistra, Koenigsmann et al. 1990; Fibbe, Pruijt et al. 1999). 
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 Both GM-CSF (Lord 1992) and IL-8 (van Eeden and Terashima 2000) can induce 
dramatically augmented neutrophil mobilization from the marrow sinusoids. 
 
1.2.2.1.3. Neutrophil emigration and activation 
Neutrophils have a very short life-span (8-20 hr) in the circulation (Athens, Haab et 
al. 1961).  Once they have migrated into the tissues, they may live 1-4 days (Haslett 1999). 
Neutrophil transmigration from the vascular compartment into inflamed tissue is important 
for fighting invading microorganisms and protecting against tissue injury (Smith 1994). 
This process normally includes neutrophil margination, tethering, rolling, activation, firm 
adhesion, and transmigration through the vasculature wall, chemotaxis into the tissues, and 
phagocytosis of foreign microorganisms (Ley 1996).   
In the circulation, neutrophils reversibly move from the central blood stream to the 
periphery of a vessel to form marginating pools, which may contain 55% of the total 
neutrophils in the circulation (Suwa, Hogg et al. 2000).  Marginated neutrophils often 
reside in the capillaries of specific tissues, such as lung.  This special characteristic of the 
neutrophil facilitates its rapid responses to infection or other stresses (Seely, Pascual et al. 
2003).  During inflammation, neutrophils start an adhesion cascade comprising capture, 
rolling, activation and adhesion (Ley 1996).  The cascade is initially mediated by P-
selectin and E-selectin expressed on vascular endothelial cells, and L-selectin and P-
selectin glycoprotein ligand (PSGL)-1 expressed on neutrophils.  Expression of these 
molecules can be stimulated by ELR-CXC chemokines (IL-8, MIP-2), lipid 
chemoattractants (PAF, LTB4), cytokines (TNFα, IL-1β), or LPS in the capture and rolling 
stages.  Beta 2-integrins such as LFA-1 and MAC-1 also support rolling.  Intercellular 
adhesion molecule (ICAM)-1 binding to β2-integrins is also important in mediating 
neutrophil adhesion (reviewed in (Ley 2002; Ley, Laudanna et al. 2007)).  Neutrophil 
activation and arrest requires signaling through ICAM-1, VCAM-1 and integrins, triggered 
by LPS, IL-8 or other chemoattractants during rolling (Kerfoot and Kubes 2005; Ley, 
Laudanna et al. 2007).  Among these, LPS stimulation of TLR4 on endothelial cells 
induces rapid P-selectin and E-selectin expression, which results in neutrophil rolling and 
adhesion (Kerfoot and Kubes 2005).  A low concentration of IL-8 is able to stimulate 
 17
 surface expression and activation of the β2-integrin MAC-1, shedding of L-selectin, and 
also release of secretory granules.  At higher concentrations, IL-8 can induce release of 
ROS and primary granule mediators such as MPO.  C5a can up-regulate β2-integrins and 
cause shedding of L-selectin on neutrophils (Jagels, Daffern et al. 2000).  LTB4 can also 
contribute to increased expression of β2-integrin on the neutrophil, which can facilitate 
neutrophil adherence and migration (Crooks and Stockley 1998).  PAF, which is secrected 
by thrombin-challenged endothelial cells, remains on the surface of endothelial cells and 
can induce PMN adhesion via its receptor, PAFR (Zimmerman, McIntyre et al. 1990).  The 
signaling component provided by endothelial cell-associated PAF may facilitate activation 
of the β2-integrins and polarization on PMN and contribute to PMN rolling and firm 
adhesion (Lorant, Patel et al. 1991; Macconi, Foppolo et al. 1995).  PAF may promote 
TNFα-induced ICAM-1 and E-selectin expression on endothelial cells, which facilitates 
neutrophil adherence to the endothelium (Sterner-Kock, Braun et al. 1996). 
Neutrophil transendothelial migration includes crawling, which is a MAC-1- and 
ICAM-1-dependent process, and emigration.  Emigrating neutrophils need to migrate 
through three distinct barriers: the endothelium, endothelial basement membrane, and 
pericytes.  Transendothelial migration can be triggered by lumenal chemoattractants such 
as C5a, PAF, and IL-8 as mentioned above.  This process includes both paracellular and 
transcellular routes.  The paracellular route may be associated with increased levels of 
intracellular endothelial Ca2+, mobilization of platelet/endothelial-cell adhesion molecule 
(PECAM) -1, -2 and junctional adhesion molecules (JAM) -A, -B, -C.  Endothelial cell-
selective adhesion molecule (ESAM), as well as the non-immunoglobulin molecule CD99 
may be also involved (Ley, Laudanna et al. 2007).  The transcellular route is evident when 
neutrophils migrate into skin stimulated by fMLP (Feng, Nagy et al. 1998), and also occurs 
in the central nervous system (Engelhardt and Wolburg 2004). 
Transmigration through endothelial cells, with stimulation via GPCR ligands such 
as the ELR-CXC chemokines, C5a, LTB4, PAF, or fMLP, can lead to full neutrophil 
activation, rearrangement of their actin cytoskeleton, and migration along a concentration 
gradient to the sites of inflammation.  During this process, they undergo a respiratory burst 
and degranulation, releasing ROI, and granule components including lactoferrin (LF), 
myeloperoxidase (MPO), matrix metallopeptidase 9 (MMP-9) and other hydrolytic 
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 enzymes.  These inflammatory mediators work together to facilitate killing and digestion 
of  engulfed foreign particles and pathogens or destroying inflamed tissue (Zarbock and 
Ley 2008).   
In the case of pulmonary infections, neutrophils can also migrate through epithelial 
cell layers to fight invading bacteria or fungi in the airway.  Several studies have 
demonstrated that the ELR-CXC chemokine receptor CXCR2 has a critical role in LPS-
induced neutrophil migration into the airway (Reutershan, Morris et al. 2006).  C5a and 
LTB4 can also facilitate neutrophil transmigration through epithelial cells.  In the case of 
C5a, it can bind its receptor C5aR and stimulate rat alveolar epithelial cells (RAEC) to 
release TNFα, IL-1β, MIP-2 and CINC-1, which directly facilitate neutrophil 
transepithelial migration (Carolan, Mower et al. 1997; Riedemann, Guo et al. 2002).  LTB4 
contributes to neutrophil transepithelial migration by inducing extracellular signal-
regulated kinase (ERK)-mediated ROS signaling in neutrophils (Woo, Yoo et al. 2003). 
IL-8 and fMLP also induce neutrophil transepithelial migration (Carolan, Mower et al. 
1997). 
 
1.2.2.1.4. Neutrophil anti-bacterial mediators 
As noted above, once activated, neutrophils respond with an oxidative burst, 
degranulation of numerous antibacterial proteases, and phagocytosis of particles.  Even 
though these mechanisms play important roles in host defense, they can have the unwanted 
consequence of damaging normal host tissues as well (Kettritz, Falk et al. 1997).  In this 
section, the origins and the phyisological and pathological effects of neutrophil ROI and 
granules will be discussed. 
 
Neutrophil ROI release 
Reactive oxygen intermediates (ROI) are reactive molecules that can be generated 
by all mammalian cells.  Neutrophil-derived ROI include superoxide (O2-), H2O2, HO-, and 
HOCl (Rosen, Pou et al. 1995).  The process of generating these ROI by neutrophils is also 
termed the respiratory burst due to its associated 50- to 100-fold increase in oxygen 
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 consumption, which occurs after the cells have phagocytosed the invading organisms and 
incorporated them in their phagosomes.  ROI generation begins with the production of 
superoxide by a plasma membrane-associated, NADPH oxidase complex, during which 
NADPH oxidase uses NADPH as an electron donor and converts molecular oxygen to its 
single-electron reduced form, O2- (Fialkow, Wang et al. 2007).  Superoxide rapidly 
dismutates to H2O2.  In the presense of redox-active metal ions, H2O2 is converted into 
hydroxyl radicals (HO-).  When catalyzed by the neutrophil primary granule enzyme MPO 
in the presense of a halide, H2O2 is also converted into hypochlorous acid (HOCl) such as 
Cl- (Rosen, Pou et al. 1995; Fialkow, Wang et al. 2007).  These ROI are mainly released 
into phagosomes where they participate in killing bacteria by oxidizing their proteins and 
lipids.  This ROI generation also causes ion flux (e.g., K+, H+/Na+) and pH changes in the 
phagosome vacuole to promote microbial killing and digestion by optimizing 
environments for the activation of enzymes.  ROI are also released into the cytosol, where 
they oxidize cellular proteins and lipids thereby modifying their functions (Rosen, Pou et 
al. 1995; Segal 2006; Fialkow, Wang et al. 2007). 
Although ROI are believed to be involved in microbial killing simply by reacting 
with organic molecules, they actually contribute on several different levels.  Superoxide 
does not kill bacteria directly.  H2O2 has a bactericidal effect at high concentrations (e.g., 
100mM), but HOCl is the most lethal of the ROI to bacteria (Reeves, Nagl et al. 2003).  
Due to its short half-life and ability to diffuse only short distances, HO- may primarily act 
on alternate targets before actually reaching the bacterium, and therefore have little impact 
on the killing process (Hampton, Kettle et al. 1998).  But some studies question if these 
ROI have direct bactericidal effects in the phagosome.  They found that there is both a high 
concentration of granule proteins (e.g., 500 mg/ml) and a high pH (pH ~7.8) environment 
in the phagosome at the time of bacterial death, which may completely inhibit the 
bactericidal effects of ROI.  Some also think that MPO may play an important role in 
protecting the microbicidal enzymes against oxidative damage by ROI (Reeves, Nagl et al. 
2003; Segal 2005).  Other studies do not agree with this point and suggest that ROS and 
MPO are essential in killing some strains of bacteria.  The mechanism of protease release 
from neutrophils into the extracellular environment remains to be explored (Roos and 
Winterbourn 2002).     
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 High concentrations of ROI can be released into the extracellular environment and 
cause tissue injury.  ROI can directly activate the transcription factor NF-κB and thereby 
indirectly regulate proinflammatory cytokine and chemokine expression by neutrophils. 
ROI can induce phosporylation of focal adhesion kinase in endothelial cells, which leads to 
dysfunction of the pulmonary endothelial barrier and increases permeability.  ROI also 
participate in the regulation of neutrophil apoptosis through their impact on protein 
tyrosine kinases, protein tyrosine phosphatases, and inositol phosphatases (Kettritz, Falk et 
al. 1997; Moraes, Zurawska et al. 2006; Fialkow, Wang et al. 2007).  This process can be 
important for the removal of neutrophils that have lost function, but it can also damage 
other normal residential cells.  
ROI are essential for killing invading pathogens, but also damage normal host cells 
causing tissue injury, such that their regulation is extremely important.  Neutrophils have 
evolved pathways to restrict ROI-induced pathology as well, including superoxide 
dismutases for superoxide and glutathione peroxidase and catalase for hydrogen peroxide 
(Rosen, Pou et al. 1995; Fialkow, Wang et al. 2007).   
 
Neutrophil degranulation 
Another important neutrophil microbicidal mechanism is degranulation.  When 
neutrophils bind opsonized microorganisms and phagocytosis is triggered, neutrophils 
quickly release dramatic amounts of granule proteins (as high as 500 mg/ml) including 
MPO and elastase (primary granules), lactoferrin (secondary granules), and MMP-9 
(tertiary granules), into the phagosome to digest target proteins (Smith 1994; Segal 2005).  
 
MPO and Elastase 
Primary granules are also traditionally referred to as “azurophil granules” due to 
their affinity for the basic dye azure A.  Myeloperoxidase, elastase, and defensins are 
important components of this group of granules.  MPO is a 150-kDa microbicidal 
hemoprotein which can be released into the phagosome or to the extracellular space upon 
neutrophil activation.  MPO reaction with H2O2, as mentioned above, is an important 
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 mechanism to produce other more potent microbicidal ROI, such as HOCl and chlorination 
products.  These ROI can attack the surface membranes of microorganisms and, when 
released to the outside of the cells, cause damage to tissues, such as the epithelium 
(Faurschou and Borregaard 2003; Klebanoff 2005).  As previously mentioned, some 
reports suggest that MPO only functions as a catalase and protects digestive enzymes from 
oxidative denaturation.  But it has a microbicidal capacity in the extracellular environment 
where enzyme concentrations and the pH are low and it conducts halogenation reactions 
(Segal 2005).  Elastase, a serine proteinase, is also a component of the primary granule.  It 
plays an important role in killing bacterium in the phagosome.  Neutrophil elastase-
deficient mice were found to be excessively susceptible to infection by Gram-negative 
bacteria (e.g., E. coli), rather than Gram-positive bacteria (e.g., S. aureus).  But if released 
into the extracellular milieu, it can also damage host cells such as epithelial cells. Elastase 
can induce apoptosis of pulmonary epithelial cells in vitro, which indicates that elastase 
may contribute to disrupted epithelial cell barrier function and cause alveolar edema 
(Moraes, Zurawska et al. 2006).  Elastase may also be involved in upregulating IL-8 
production by the bronchial epithelium (Devaney, Greene et al. 2003). 
 
Lactoferrin 
One representative neutrophil specific granule component is LF, a 78-kDa 
glycoprotein.  It is also a member of a transferring family of ion-binding proteins. 
Lactoferrin functions as a bactericidal effector through sequestration of iron from bacteria, 
leading to impaired bacterial growth and finally, death.  Due to its ability to sequestrate 
environmental iron, it is involved in regulating H2O2 production.  It also can bind to 
bacterial cell membranes via an N-terminal amphipatic α-helical region, leading to cell 
membrane damage and lysis (Rosen, Pou et al. 1995; Faurschou and Borregaard 2003).  In 
addition, LF acts as a regulator for neutrophil aggregation and their adherence to 
endothelial cells thereby amplifying the inflammatory response (Oseas, Yang et al. 1981).  
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 MMP-9 and MMP-2 
Neutrophil tertiary granules contain metalloproteases such as MMP-9.  MMP-9 is a 
92 kDa protein and is also called gelatinase B, due to its ability to digest the extracellular 
matrix structure, gelatin (Gelatinase A is MMP-2, another kind of metalloprotease) 
(Opdenakker, Van den Steen et al. 2001; Faurschou and Borregaard 2003).  MMP-9 is 
mainly produced by inflammatory cells such as neutrophils and monocytes/macrophages. 
In neutrophils, MMP-9 is stored as an inactive proform in granules and is released during 
excyotosis, while macrophages synthesize MMP-9 de novo upon stimulation (Warner, 
Bhagavathula et al. 2004).  It is also released by resident cells such as pulmonary 
fibroblasts and type II bronchial epithelial cells, but not pulmonary artery endothelial cells 
(Warner, Bhagavathula et al. 2004).  The stimuli can be bacterial (e.g., LPS) or viral 
products (e.g., double-stranded RNA), cytokines (e.g., TNF, IL-1β) or chemokines (e.g., 
IL-8) (Opdenakker, Van den Steen et al. 2001).  MMP-2 is mainly produced by resident 
cells such as fibroblasts and epithelial cells (Warner, Bhagavathula et al. 2004).  MMP-9 
and MMP-2 play major roles in degrading vascular basement membranes and interstitial 
structures during neutrophil transendothelial and transepithelial cell migration.  Therefore, 
for neutrophils, they are the main granules that increase vascular permeability and 
pulmonary edema during neutrophilic inflammation and are often used as surrogate 
measures for inflammatory responses (Corbel, Boichot et al. 2000; Eichler, Bechtel et al. 
2003).  
MMP-9 has other functional roles.  It facilitates the activation of pro-IL-1β into 
active IL-1β. It can also truncate the amino terminus of IL-8 and convert IL-8(1-77) into IL-
8(7-77).  IL-8(7-77) possesses dramatically higher CXCR1/2 binding affinity and increased 
abilities to induce the intracellular calcium flux, chemotactic responses, and MMP-9 
release in neutrophils.  Thus, MMP-9 is not only an effector but also a regulator of 
neutrophil functions (Opdenakker, Van den Steen et al. 2001).  To prevent tissue injury by 
MMPs, tissue inhibitors of MMPs (TIMPs) are also generated by cells such as monocytes.  
Neutrophils do not produce TIMP-1 or the MMP/TIMP-1 complex (Opdenakker, Van den 
Steen et al. 2001). 
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 1.2.2.1.5. Neutrophil apoptosis 
Neutrophils have a specified short life-span in the circulation and tissues as 
mentioned previously.  A prolonged neutrophil life-span may be beneficial in the context 
of anti-microbial activities (Kobayashi, Voyich et al. 2005), but it also brings the risk of 
causing tissue damage, especially if excessive or inappropriate activation occurs.  For that 
reason, neutrophil homeostasis and turnover are elaborately regulated (Luo and Loison 
2008).  
Programmed cell death is the main mechanism that regulates neutrophil 
homeostasis.  During programmed cell death neutrophils die through apoptosis or other 
pathways, although apoptosis is the most important of these.  For neutrophils, the timing of 
apoptosis during the course of development is genetically determined (Tang, Mura et al. 
2008).  Generally, apoptosis is characterized by cell shringkage, DNA cleavage, nuclear 
fragmentation, and nuclear dissolution, although the plasma membrane remains intact and 
retains cytosolic enzymes and other pro-inflammtory agents.  However, cells lose their 
functions such as chemotaxis, respiratory burst, intracellular calcium flux and 
degranulation under the influence of external stimulation.  The cell surface receptors and 
adhesion molecules are also downregulated.  In the later stages, the cells break up into 
apoptotic bodies and are finally phagocytosed by macrophages, and other neutrophils 
(Haslett 1997; Seely, Pascual et al. 2003; Serhan and Savill 2005; Luo and Loison 2008).   
In addition to such genetically-controlled “programmed” death, neutrophils can be 
triggered by external stimuli such as soluble cell death ligands (e.g., TNF or Fas ligand) 
which bind TNF receptor I or Fas, respectively.  Neutrophil apoptosis can also be triggered 
by intrinsic stimuli such as ionizing radiation, or cytokine deprivation (Ashkenazi and 
Dixit 1998; Kroemer and Martin 2005).  Apoptosis is characterized by caspase activation 
and the lack of inflammation, which is distinct from other forms of cell death such as 
oncosis, autophagy, and capase-independent death (Simon 2003; Tang, Mura et al. 2008). 
Alteration of cell membrane expression is an important feature of apoptotic neutrophils, 
such that phosphatidylserine, which normally resides on the inner membrane leaflet, is 
expressed instead on the outer membrane at the early stage of neutrophil apoptosis. 
Therefore, macrophages can easily recognize apoptotic cells (Fadok, Savill et al. 1992). 
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 Phosphatidylserine expression on the outer membrane can be specifically detected by 
fluoresecent-labeled ligands (e.g., annexin V) as a means of detecting apoptotic cells 
(Vermes, Haanen et al. 1995).  
During inflammation, a number of inflammatory mediators have an anti-apoptotic 
effect on neutrophils, including ELR-CXC chemokines (IL-8, GROα) (Kettritz, Gaido et al. 
1998; Klein, Rane et al. 2000; Glynn, Henney et al. 2002), bacterial peptide (fMLP), C5a, 
LPS, and GM-CSF (Lee, Whyte et al. 1993; Kobayashi, Voyich et al. 2005).  Both IL-8 
and GROα are able to delay neutrophil apoptosis, but IL-8 is more effective than GROα. 
Noteably, IL-8 is also able to inhibit TNFα-mediated neutrophil apoptosis.  The neutrophil 
anti-apoptotic processes induced by IL-8 are mediated by the extracellular signal-regulated 
kinase (ERK) and phosphoinositide 3-kinase (PI3K) pathways (Kettritz, Gaido et al. 1998; 
Klein, Rane et al. 2000).  C5a is also able to dose-dependently delay neutrophil apoptosis, 
and this is also related to PI3K pathway activation (Perianayagam, Balakrishnan et al. 
2002).  Delayed neutrophil apoptosis can also be induced by LPS through binding TLR4 
on neutrophils, and activation of the NF-κB and mitogen-activated protein kinase (MAPK) 
pathways (i.e. not PI3K-independent pathway).  LPS-TLR4 binding plays a significant role 
in inducing anti-apoptotic effects in neutrophils although prolonged neutrophil survival 
requires both LPS-induced TLR4 activation and monocytes (leading to expression of 
additional survival factors; G-CSF) (Yamamoto, Yoshida et al. 1993; Sabroe, Prince et al. 
2003).  GM-CSF and G-CSF can also delay neutrophil apoptosis (Klein, Rane et al. 2000; 
van Raam, Drewniak et al. 2008), and in doing so contribute to the severity of pulmonary 
neutrophilia in ARDS patients, although G-CSF and IL-8 play more important roles than 
GM-CSF (Aggarwal, Baker et al. 2000).    
As activated neutrophils play a major role in the pathogenesis of many diseases 
(e.g., ARDS, sepsis), the resolution of neutrophil-induced inflammatory responses relies on 
reversing delayed neutrophil apoptosis.  Studies using the ELR-CXC chemokine receptor 
CXCR2 antagonist SB272844 demonstrated that blocking CXCR2 can effectively reverse 
IL-8- and GROα-induced anti-apoptotic effects in neutrophils (Glynn, Henney et al. 2002).  
This study indicated that strategies can be used to reverse the anti-apoptotic effects of 
ELR-CXC chemokines by blocking their receptors. 
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 1.2.2.1.6. Roles of neutrophils in inflammatory diseases 
It is well established that excessive neutrophil recruitment and activation can cause 
tissue injury and even host death (Lee and Downey 2001).  So far, neutrophils have been 
found to play a pivotal role in mediating the pathology of a number of inflammatory 
diseases, including ALI/ARDS (Lee and Downey 2001), COPD (Tetley 2005), I/R injury 
(Belperio, Keane et al. 2005), IBD (Ina, Kusugami et al. 1997), and RA (Grespan, Fukada 
et al. 2008).  Neutrophils function as important effector cells of tissue pathology by 
releasing cytotoxic mediators such as ROI, cationic peptides, eicosanoids, and proteolytic 
enzymes which can damage normal tissue and cause tissue injury (Lee and Downey 2001). 
ROI, including superoxide (O2-), H2O2, and HOCl, together with proteolytic enzymes such 
as MPO, elastase, and MMP-9, are responsible for oxidative tissue injury and digestion of 
intercellular and extracellular matrices.  The damage increases vascular permeability and 
causes endothelial and epithelial cell damage, leading to organ dysfunction.  For instance, 
MPO facilitation of HOCl and elastase production contributes to emphysema in COPD 
patients (Tetley 2005).  Elastase can also up-regulate IL-8 expression by epithelial cells in 
cystic fibrosis (Devaney, Greene et al. 2003), and MMP-9 is related to alveolar-capillary 
permeability increases in ARDS patients (Delclaux, d'Ortho et al. 1997).  Moreover, 
having activated circulating neutrophils is a prerequisite to multiple organ dysfunction 
syndromes (MODS) in ischemia and reperfusion injury (Carden and Granger 2000).  
Activated neutrophils can release cytokines (TNF, IL-1, and IL-6) (Nikolaus, Bauditz et al. 
1998), chemokines (IL-8) and other chemoattractants (e.g., LTB4) that amplify the 
pathology, as occurs in RA (Chen, Lam et al. 2006). Neutrophil release of  IL-8 and LTB4 
may also correlate with the level of neutrophil inflammation and the degree of airflow 
limitation in the lungs of COPD patients (Tetley 2005). 
 
1.2.2.2. Monocytes/macrophages 
Monocytes originate in the bone marrow from a common myeloid progenitor.  
After they are released into the blood, they circulate for several days before entering 
tissues and differentiating into a variety of tissue macrophage populations such as alveolar 
macrophages (AMs), or more specialized cells such as dendritic cells (DCs) (Gordon and 
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 Taylor 2005).  Alveolar macrophages can be derived both directly from precusors in the 
peripheral blood and from proliferation of local resident precursors.  In the short term, 
AMs arise mostly from local proliferation, but over a longer period, they can be 
replenished from the bone marrow (Kennedy and Abkowitz 1997).  In the physiological 
state, AMs are long-lived cells that turn-over slowly, with a replacement rate of ~40% per 
year (Kennedy and Abkowitz 1997; Maus, Janzen et al. 2006), but during acute lung 
inflammation (e.g., airway endotoxemia) 61% of these cells are replaced within two 
months (Maus, Janzen et al. 2006).  Further studies have demonstrated that blood 
monocytes are a heterogenous population.  Studies in mice have identified two functional 
subsets of blood monocytes, including CX3CR1loCCR2+Gr1+ (also referred to as CD14+) 
and CX3CR1hiCCR2-Gr1- (also referred to as CD16+) (Geissmann, Jung et al. 2003; 
Serbina, Jia et al. 2008).  CX3CR1loCCR2+Gr1+ monocytes are short-lived inflammatory 
monocytes and are actively recruited to inflammated tissues to differentiate into 
macrophages or antigen-presenting DCs.  CX3CR1hiCCR2-Gr1- monocytes persist longer 
in tissues and serve as precursors for resident macrophages (Geissmann, Jung et al. 2003; 
Landsman, Varol et al. 2007).  There is direct evidence that alveolar macrophages arise 
from blood monocytes, but via lung macrophage intermediaries (Landsman and Jung 
2007).  These studies suggested that blood monocytes are able to differentiate into normal 
tissue resident macrophages over a long term (e.g., 2 -12 mo), but differentiate into 
“inflammatory monocytes” rapidly (e.g., in 1 day). 
Blood monocytes already have phagocytic capabilities and express receptors for 
IgG Fc-domains (FcγR) and C3b.  After migrating into tissues, they undergo further 
differentiation to become multifunctional tissue macrophages.  Compared with tissue 
macrophages, monocytes retain greater proliferative capacity, but a decreased ability to 
phagocytose as well as fewer lysosomes and IgG receptors (Cline, Lehrer et al. 1978). 
They also express fewer TLRs and scavenger receptors (Gordon and Taylor 2005).  In 
addition to phagocytosis, alveolar macrophages have two other important functions, 
presentation of antigen to T-cells and immunomodulation.  Therefore, AMs function as the 
first line of cellular defense against respiratory pathogens.  In the functional role of 
phagocytosis, AMs phagocytose two kinds of material: waste and debris (e.g., dead cells) 
and invading pathogens.  As discussed above, the phagocytosis of apoptotic neutrophils by 
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 AMs plays a crucial role in maintaining the homeostasis of neutrophils and in the 
resolution of inflammation (Fadok, Savill et al. 1992; Haslett 1999).  Alveolar 
macrophages also phagocytose foreign pathogens by recognizing microbes through their 
cell surface receptors such as, TLRs (e.g., TLR2, TLR4), scavenger receptors (SR, e.g., 
SR-A), and Fc and C’ receptors (Palecanda, Paulauskis et al. 1999; Fujiwara and 
Kobayashi 2005).  They also produce large amounts of oxygen radicals and proteolytic 
enzymes to destroy engulfed foreign microorganisms.  Another role of AMs is to present 
antigens for recognition by T cells and to further activate lymphocytes, which in turn 
activate macrophages to kill the microbes.   
In addition to these two important functions, AMs can also release various 
proinflammatory cytokines (e.g., TNFα, IL-1β, IL-6) (Kotloff, Little et al. 1990; Ulich, 
Watson et al. 1991; Beck-Schimmer, Schwendener et al. 2005),  chemokines (IL-8, MIP-2) 
(Kooguchi, Hashimoto et al. 1998; Palmberg, Larsson et al. 1998), and other 
chemoattractants (e.g., LTB4) (Christman, Petras et al. 1989) upon contact with foreign 
pathogens or their products (e.g., LPS, bacteria).  Through these inflammatory mediators, 
AMs play a key role in initiating inflammatory responses and regulating pulmonary 
neutrophil migration and activation, and therefore exacerbation of lung pathology.  Among 
them, the chemokines (e.g., MIP-2, KC) play a major role in mediting neutrophil 
recruitment (Gupta, Feng et al. 1996).  On the other hand, a study found that AMs also 
play a regulatory role in inflammatory responses.  As noted above, AMs are able to engulf 
apoptotic neutrophils, but at the same time they release anti-inflammatory mediators (e.g., 
transforming growth factor β1; TGF β1) which suppress inflammatory responses.  At the 
same time, the production of proinflammtory cytokines is also inhibited through 
autocrine/paracrine mechanisms (Fadok, Bratton et al. 1998; Huynh, Fadok et al. 2002). 
Monocyte recruitment to the airway in acute inflammatory conditions (e.g., 24 h after 
monocyte chemotactic protein-1 [MCP-1] adminsitration) may amplify inflammatory 
responses through increased expression of TNFα, neutrophil chemokines (e.g., MIP-2, KC), 
and extracellular matrix degradation (Srivastava, Jung et al. 2005).  As mentioned earlier, 
monocyte recruitment by MCP-1 facilitates neutrophil migration and activation after 
intratracheal LPS challenge (Maus, Waelsch et al. 2003).  Neutrophil migration may also 
contribute to monocyte recruitment. Studies have found depletion of neutrophils before 
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 intratracheal administration of LPS abrogated the early (3 h) as well as late (24 h) 
monocyte/macrophage increases in the lung (Janardhan, Sandhu et al. 2006).  
As discussed above, monocytes and macrophages play crucial roles in phagocytosis 
of foreign microorganisms, regulation of neutrophil recruitment and activation, and 
immunomodulation of inflammation.  Compared with neutrophils, monocytes and 
macrophages have some distinct features.  First of all, they stay in the circulation or tissues 
longer and they can proliferate. Second, they, especially macrophages, can kill a more 
diverse array of microbes. Third, there are fewer monocytes in the blood (e.g., 10%, versus 
60-70% for neutrophils) and at the site of severe inflammation, macrophages need to 
recruit neutrophils to function as the primary phagocytes.  Fourth, they accumulate more 
slowly and have a less extreme metabolic burst. Finally, macrophages not only initiate, but 
also resolve, inflammation.  Neutrophils may be thought as the soldiers in an army, but 
macrophages have leadership roles.  Generally, neutrophils play a more important role in 
fighting foreign antigens and, if  inappropriately activated, also mediating excessive 
inflammatory responses (Dale, Boxer et al. 2008).  
 
1.2.2.3. Eosinophils 
Eosinophils are important effector cells in allergic diseases such as asthma and 
parasitic infections (Yang, Loy et al. 1998).  Studies have indicated that C-C chemokines 
are important for eosinophil recruitment and activation during allergic airway responses. 
These include eotaxin, RANTES (regulated upon activation, normal T cell expressed and 
secreted) and MIP-1α (macrophage inflammatory protein -1α) (Lukacs, Standiford et al. 
1996; Yang, Loy et al. 1998).  Eosinophils are considered to be important effector cells for 
killing certain parasitic pathogens, but can also cause direct damage to normal host tissues 
through a variety of mechanisms.  Activated eosinophils can release toxic products such as 
major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein 
(ECP), and oxygen radicals.  These molecules are toxic to the airway epithelium and can 
damage bronchial structures, thereby increasing bronchial hyperresponsiveness, resulting 
in lung dysfunction (Kroegel, Warner et al. 1994; Oddera, Silvestri et al. 1998).  In 
addition, eosinophils produce a variety of cytokines such as IL-4, -5, and -6 and interferon-
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 γ (IFN-γ) and play important roles in regulating the proliferation and differentiation of T 
and B lymphocytes (Kroegel, Warner et al. 1994). 
 
1.2.2.4. Mast cells 
Mast cells are another cell type that is important in allergic inflammatory diseases. 
Mast cells can be activated by cross-linking the FcεRI-receptor after binding of IgE, 
recognizing specific antigens.  They can also be activated by I/R-induced ROI and 
complement split products (Schramm and Thorlacius 2004).  The activation of mast cells 
results in the release of multiple cytokines including IL-4,-5,-6, and TNFα, and 
chemokines such as IL-8.  They also express CXCR1 and CXCR2 on their cell surface and 
can be chemoattracted by IL-8 binding CXCR2 (Lippert, Artuc et al. 1998; Nilsson, 
Mikovits et al. 1999).  Importantly, mast cells have been shown to contribute to 
recruitment of neutrophils through their released cytokines (e.g., TNFα) and chemokines 
(e.g., MCP-1) (Maus, Waelsch et al. 2003; Schramm and Thorlacius 2004). 
 
1.2.2.5. Endothelial cells 
Endothelial cells play a variety of roles in inflammation.  These include wound 
healing, angiogenesis, and leukocyte trafficking (Swerlick and Lawley 1993).  In acute 
lung injury, endothelial cells contribute to initiating inflammation, facilitating neutrophil 
migration, and increasing vascular permeability through the production of cytokines (e.g., 
TNFα, IL-1), chemokines (e.g., IL-8), adhesion molecules (e.g., VCAM-1), and 
vasodilator factors (e.g., prostacyclin; PGI2) (Mantovani, Bussolino et al. 1992).  
First of all, endothelial cells play an important role in initiating inflammation.  In 
ischemia/reperfusion injury, hypoxia-reoxygenation induces endothelial cells to generate 
ROI, resulting in production of proinflammtory mediatiors (e.g., TNFα, IL-1, PAF).  These 
molecules directly or indirectly amplify the inflammatory responses (Grace 1994).  Second, 
as mentioned above, endothelial cells generate a variety of inflammatory mediators, such 
as cytokines.  Studies have demonstrated that endothelial cells can produce TNFα and IL-1 
when challenged by LPS and TNFα, respectively (Nawroth, Bank et al. 1986; Ranta, 
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 Orpana et al. 1999).  These two cytokines can activate yet more endothelial and epithelial 
cells (Smart and Casale 1994; McHale, Harari et al. 1999) to produce chemokines (e.g., IL-
8).  Third, they significantly contribute to neutrophil migration by expressing adhesion 
molecules and releasing chemoattractants.  Endothelial cells express adhesion molecules 
such as ICAM-1 and VCAM-1 when stimulated by TNFα and IL-1 (McHale, Harari et al. 
1999), PAF and LTB4 under hypoxia-reoxygenation challenged conditions (Grace 1994), 
and chemokines such as IL-8 (Smart and Casale 1994).  These molecules are important in 
the facilitation of neutrophil activation and transendothelial migration.  
Human umbilical vein endothelial cells (HUVEC) express CXCR1 and CXCR2 
(Kalia, Brown et al. 2003; Li, Varney et al. 2005), while pulmonary endothelial cells 
reportedly express only the CXCR2 (Reutershan, Morris et al. 2006).  In a murine model 
of LPS-induced lung injury, endothelial cell CXCR2 was a crucial factor involved in 
neutrophil recruitment and pulmonary vascular leakage (Reutershan, Morris et al. 2006). 
Endothelial cell-derived IL-8 generates the required chemotactic gradients in the 
subendothelial matrix to regulate neutrophil transmigration (Detmers, Lo et al. 1990; 
Huber, Kunkel et al. 1991).  Endothelial cells also express C5a, LTB4, and PAF receptors 
(i.e. C5aR, BLT, and PAF), and their ligands can stimulate endothelial cells to produce 
adhesion molecules, cytokine, and chemokines, which facilitate neutrophil migration. For 
instance, C5a can interact with endothelial cells to stimulate P-selectin expression (Ward 
1996).  LTB4 does not stimulate endothelial cells to produce IL-8 or PAF (McIntyre, 
Zimmerman et al. 1986; Nohgawa, Sasada et al. 1997), but in vitro experiments indicate 
that HUVEC express LTB4 receptors (BLT1 and BLT2) when stimulated by LPS and TNFα 
and show higher responsiveness to LTB4.  LTB4 can augment nitric oxide and MCP-1 
production from HUVEC stimulated by LPS (Qiu, Johansson et al. 2006).  PAF may 
promote TNFα-induced ICAM-1 and E-selectin expression on endothelial cells, which 
facilitates neutrophil adherence to the endothelium (Sterner-Kock, Braun et al. 1996).  As 
discussed above (§ 1.2.1.4 and § 1.2.2.1.3), endothelial cell TLR4 signaling by LPS play  a 
major role in facilitating neutrophil migration in systemic endotoxemia, but play a less 
important role in airway endotoxemia when compared with LPS-TLR4 signaling on 
macrophages (Hollingsworth, Chen et al. 2005).    
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 Activation of endothelial cells with TNFα and IL-1 leads to increased vascular 
permeability through release of vasodilator factors such as PGI2 (Mantovani, Bussolino et 
al. 1992).  Neutrophil and endothelium interaction (via ICAM-1) is also an important 
factor that affects pulmonary vascular permeability (Sumagin, Lomakina et al. 2008).  
In general, endothelial cells contribute to inflammatory responses and tissue 
pathology in several ways.  Among these, the key roles are facilitating neutrophil 
activation and migration and changing vascular permeability, in which IL-8 and 
neutrophil-endothelial interactions are extremely important. 
 
1.2.2.6. Epithelial cells 
Epithelial cells make up the epithelia that line the cavities and surfaces of structures 
throughout the body, such as the lung and gastrointestinal tract.  In different tissues, 
epithelial cells may play different roles.  Those lining the airways, as a primary interface 
between pathogens and the environment, play a crucial role in the innate immune response 
(Becker, Diamond et al. 2000).  Ciliated epithelial cells in the upper airway play an 
important role in clearing materials with ciliary movement and form a biological barrier to 
protect against foreign pathogens (Cantin 2001).  The alveolar epithelium consists of 
alveolar type I and type II cells, which have distinct functions.  Type I cells comprise 90% 
of the alveolar surface and are important for the exchange of respiratory gases.  Type II 
alveolar cells are multifunctional cells. They can produce surfactant and play an important 
role in alveolar liquid and bacterial clearance (Cantin 2001; Geiser 2003). They also 
release cytokines and chemokines, the discussion of which will follow.  
Airway epithelial cells can be activated by AM-originated cytokines (e.g., TNFα 
IL-1β), complement (e.g., C5a), and bacterial products (e.g., LPS) to produce cytokines 
(TNFα, IL-1β, and IL-6), and chemokines (e.g., IL-8, MIP-2, CINC) (Liu, Mul et al. 1996; 
Allen, Menendez et al. 2000; Becker, Diamond et al. 2000; Riedemann, Guo et al. 2002). 
The human tracheobronchial epithelium also releases β defensin-2, a key antibacterial 
molecule, after challenge with LPS (Becker, Diamond et al. 2000).  Airway epithelial cells 
also express TLRs, such that when challenged by TLR ligands such as LPS or double 
stranded RNA (dsRNA), they can release IL-8 and IL-6.  Compared with other TLR 
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 ligands, dsRNA induces more IL-8 production (Sha, Truong-Tran et al. 2004). When 
exposed to foreign particulate matter, AMs and epithelial cells diplay a significant synergy 
in production of IL-1β, IL-6, IL-8 and GM-CSF (Fujii, Hayashi et al. 2002).  From these 
studies, it is easy to conclude that airway epithelial cells play a critical role in the 
production of cytokines and chemokines, particularly IL-8.  These mediators can amplify 
the inflammatory responses of epithelial cells and other resident cells (e.g., macrophages, 
endothelial cells) via further cytokine production and neutrophil activation and migration. 
 Similar to the endothelium, the epithelium is also actively involved during 
neutrophil infiltration into the sites of inflammation (e.g., airway), although epithelial cells 
express fewer types of adhesion molecules.  The adhesion molecule ICAM-1 is expressed 
on epithelial cells.  Its ligand on the neutrophil, CD11b/CD18, is critical to neutrophil 
transepithelial migration, but the role of ICAM-1 in mediating neutrophil migration still 
needs be further studied (Mul, Zuurbier et al. 2000; Chin and Parkos 2007).  
During neutrophil transepithelial migration, chemoattractants play important roles. 
fMLP is a potent chemotactic factor, as are LTB4, C5a, and IL-8 (Chin and Parkos 2006). 
fMLP has greater potency than LTB4 on chemoattracting neutrophils migration through the 
epithelium (Casale, Abbas et al. 1992).  LTB4 facilitates neutrophil transepithelial cell 
migration through a ROS-mediated ERK linked cascade (Woo, Yoo et al. 2003).  
Pulmonary epithelial cells express C5aR, such that C5a can activate rat alveolar epithelial 
cells.  It also has a synergistic effect with LPS and TNFα in the stimulation of epithelial 
cells to release cytokines (Riedemann, Guo et al. 2002), which facilitates neutrophil 
recruitment. As previously discussed, IL-8 is an extremely important product of and 
stimulus for epithelial cells.  Pulmonary epithelial cells reportedly express the neutrophil 
receptor CXCR2 (Reutershan, Morris et al. 2006), while intestinal tissue epithelial cells 
express only the CXCR1 (Sturm, Baumgart et al. 2005). Pulmonary epithelial cells that 
express CXCR2 are believed to be involved in neutrophil recruitment and lung 
permeability, which would implicate the ELR-CXC chemokines in this process.  IL-8 
production by both airway and intestinal epithelial cells can feed into an autocrine 
mechanism (Patel, Jiang et al. 1998; Maheshwari, Lacson et al. 2004), which is an 
important role for IL-8 in epithelium injury.  In the case of colonic epithelial cells, IL-8 has 
an important role in stimulating epithelial cell migration and helping to maintain the 
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 mucosal epithelial surface barrier, which may contribute to protecting the host against the 
penetration of inflammatory agents (Sturm, Baumgart et al. 2005).  
Epithelium damage significantly affects lung function, causing protein leakage into 
the airway.  Neutrophil transepithelial migration plays an important role in mediating 
epithelial permeability. Proteinases released by neutrophils (e.g., elastase) during 
transepithelial migration contribute to intestinal epithelial permeability.  It causes epithelial 
loss and the disruption of the epithelial barrier (Ginzberg, Cherapanov et al. 2001).  In the 
airway, neutrophil-derived elastase, acting via proteinase activated receptor-1, can induce 
apoptosis of lung epithelial cells, which thereby can increase the permeability of the 
alveolar capillary barrier, resulting in blood protein leakage (Suzuki, Moraes et al. 2005).  
Another study with using a neutrophil elastase inhibitor (ONO-5046) also supports that 
elastase is involved in increasing alveolar epithelial permeability (Miyazaki, Inoue et al. 
1998).  The tight adherence of stimulated neutrophils to epithelial cells and the production 
of serine proteases appear to promote epithelial cell killing (Simon, DeHart et al. 1986; 
Chin and Parkos 2007). 
 
1.2.3. ELR-CXC chemokine biology 
1.2.3.1. Human, rat and guinea pig ELR-CXC chemokines and their receptors 
The Glu-Leu-Arg (ELR)-CXC chemokines, a subfamily of the CXC chemokines, 
are known to be primary agonists for neutrophil recruitment.  In humans, ELR-CXC 
chemokines include CXC ligand 1 (CXCL1) (growth-related oncogene; GRO-α), CXCL2 
(GRO-β), CXCL3 (GRO-γ), CXCL5 (epithelial neutrophil-activating peptide-78; ENA-78), 
CXCL6 (granulocyte chemotactic protein-2; GCP-2), CXCL7 (neutrophil-activating 
peptide-2; NAP-2), and CXCL8 (IL-8).  Rats possess CINC-1 (GRO/KC), -2α, -2β, and -3 
(MIP-2) (Dunstan, Salafranca et al. 1996; Shibata, Konishi et al. 2000).  In guinea pigs, 
CXCL8 and GRO are important members and share 30-45% amino acid homology with 
their human homologues (Yoshimura, Takeya et al. 1999).  Human and guinea pig ELR-
CXC chemokines chemoattract and activate neutrophils via their CXCL8 receptors, 
CXCR1 and CXCR2 (Murphy and Tiffany 1991; Ahuja and Murphy 1996; Catusse, Faye 
et al. 2003; Takahashi, Jeevan et al. 2007) and also exhibit potent angiogenic activity.  Rat 
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 ELR-CXC chemokines bind to target cells only via the CXCR2, even though homologues 
of both CXCR1 and CXCR2 have been discovered (Dunstan, Salafranca et al. 1996; 
Shibata, Konishi et al. 2000).  Human CXCR1 is specific for CXCL8, to which it binds 
with high affinity, but it also binds GCP-2 and NAP-2 with lower affinity (Schnitzel, 
Garbeis et al. 1991; Ahuja and Murphy 1996).  CXCR2 similarly binds CXCL8 with high 
affinity, but also binds MIP-2, CINC-1 (rodents), GROα, -β, -γ, ENA-78, GCP-2, and 
NAP-2 with somewhat lower affinities (Schnitzel, Garbeis et al. 1991; Loetscher, Seitz et 
al. 1994; Ahuja and Murphy 1996; Richardson, Pridgen et al. 1998; Wuyts, Proost et al. 
1998; McColl and Clark Lewis 1999).  
 
1.2.3.2. The structure of ELR-CXC chemokines and their receptors 
As a subgroup of the CXC chemokine, the ELR-CXC chemokines contain four 
conserved cysteines and there is one alternate amino acid between first two cysteines (e.g., 
CXC).  In addition, the ELR-CXC chemokines have a special tripeptide motif, Glu-Leu-
Arg (ELR) motif in the amino-subterminal region, immediately distal to the first cysteine.  
These four cysteines form two disulphide bonds (Cys7-Cys34 and Cys9-Cys50) which confer 
three-dimensional folding that is essential for receptor recognition and biological activity 
(Baggiolini 2001).  
 
1.2.3.3. Molecular biology of CXCL8   
 Among the ELR-CXC chemokines, CXCL8’s structure and function are well 
studied.  The human CXCL8 cDNA encodes a 99-amino acid precursor protein with a 
signal sequence, which is cleaved to yield 77- or 72-residue mature proteins, of which the 
functional protein is 72 amino acids (Matsushima, Morishita et al. 1988).  CXCL8 exists as 
a monomer and dimer at nanomolar concentrations.  Its dimerization constants range from 
about 100nM to 100μM in vitro.  But basically, the monomer is the functional form of 
CXCL-8 (Rajarathnam, Sykes et al. 1994).  The monomeric unit contains a highly flexible 
NH2-terminal region followed by a series of loops and turns (also called an N-loop), three 
antiparallel β strands and an overlying COOH-terminal α-helix.  Among them, the NH2-
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 terminal Glu4-Leu5-Arg6 (ELR) motif and Ile10 are essential for receptor binding and 
signaling (Clark-Lewis, Dewald et al. 1994; Rajagopalan and Rajarathnam 2004).  The N-
loop formed by Tyr13, Ser14 Lys15, Phe17, His18 and Phe21 and the surface hydrophobic 
pocket formed by residues Tyr13, Ser14, Phe21, and Lys49 and/or adjacent residues including 
Leu25 and Leu43, participate in IL-8 receptor-selective recognition for both the CXCR1 and 
CXCR2.  It is thought that the hydrophobic pocket itself may be essential for CXCR1 
(Schraufstatter, Ma et al. 1995; Hammond, Shyamala et al. 1996; Wells, Power et al. 1996; 
Suetomi, Lu et al. 1999). Residues 30-35, especially Gly31 and Pro32, have important 
structural roles.  The Cys7-Cys34 disulfide bridge anchors the ELR region to the ‘30-35’ 
turn which provides the correct geometry for the Cys7-Cys34 disulfide bridge and 
determines the conformation of the ELR motif (Clark-Lewis, Dewald et al. 1994) (see 
Figure 1.1.).  The importance of Gly31 and Pro32 suggests that changing them may affect 
the framework for the receptor binding motif and receptor signaling as well.  This topic 
will be further discussed below. 
The ELR-CXC chemokines are expressed by many cell types in response to 
inflammatory stimuli (Gerard and B 2001).  CXCL8, for example, can be produced by 
leukocyte cells (monocytes, T cells, neutrophils, and natural killer cells) and non- 
leukocytic somatic cells (endothelial cells, fibroblasts, and epithelial cells) (Mukaida 2000; 
Mukaida 2003).  CXCL8, the prototypical ELR-CXC chemokine, is regulated by nuclear 
factor-κB ( NF-κB) and activator protein-1 (AP-1), each of which bind the distal (3’) end 
of the CXCL8 promoter as dimers, either individually or in collusion with one another 
(Roebuck 1999). Environmental factors can induce CXCL8 production in several types of 
cells. Hypoxic conditions induce tumor cells to produce high levels of CXCL8 through the 
cooperative activation of AP-1 and NF-κB (Xu, Xie et al. 1999). Because CXCL8 has 
potent angiogenic activities (Strieter, Polverini et al. 1995), hypoxic conditions may induce 
neovascularization by inducing the production of CXCL8. Reactive oxygen intermediates 
can activate NF-κB, an essential transcription factor for CXCL8 gene, and thereby induce 
CXCL8 gene transcription (Lee, Shin et al. 2008). These findings suggest that ELR-CXC 
chemokines may play an important role in cancer and ischemia/reperfusion injury (e.g., 
both characterized by hypoxia of the ischemic organ and large amounts of ROI production). 
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Figure 1.1.  Ribbon diagram of the human IL-8 molecule.  
 
The structure of IL-8 contains a flexible NH2-terminal section including a receptor 
signaling motif (E4-L5-R6) followed by loops (i.e., amino acid 11-17 loop, receptor 
recognition motif) and turns (e.g., 30-35 turn), three antiparallel β-strands, and an 
overlying COOH-terminal α-helix. Reproduced with minor modification from Rojo et al. 
(Rojo, Suetomi et al. 1999). 
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 1.2.3.4. CXCR1 and CXCR2 signaling 
IL-8 binds two distinct receptors, the CXCR1 and CXCR2, which comprise 
350 and 360 amino acids, respectively, and possess >77% sequence homology at the amino 
acid level (Baggiolini, Dewald et al. 1997). They are intramembranous GPCRs composed 
of seven-transmembrane domains (Mukaida 2003).  High resolution structural data for 
CXCR1 and CXCR2 have not been generated yet, but studies have shown that the N-
domain plays an important role in ligand binding (Suzuki, Prado et al. 1994), although its 
role in determining receptor selectivity is still not clear. Similar to that of other ELR-CXC 
chemokines, IL-8-stimulated CXCR1 or CXCR2 signaling consists of two steps (Figure 
1.2.). First, the IL-8 N-terminal loop, surface hydrophobic pocket and/or adjacent residues 
cooperate and selectively interact with N-terminal domain residues of the receptors (site I). 
Second, the IL-8 N-terminus, including the ELR motif and Ile10 (site II), interacts with the 
receptor exoloop and transmembrane (J-domain) residues, which signals into and activates 
the cell (Schraufstatter, Ma et al. 1995; Hammond, Shyamala et al. 1996; Wells, Power et 
al. 1996; Suetomi, Lu et al. 1999; Rajagopalan and Rajarathnam 2004).   
These interactions mediate ligand affinity, receptor selectivity, and cell activation. 
Whether binding at one site influences binding/function at the other site is still not clear 
(Rajagopalan and Rajarathnam 2004). 
 
1.2.3.5. CXCR1 and CXCR2 internalization and desensitization 
During inflammation, neutrophils receive multiple signals from inflamed tissues. 
Neutrophil chemoattractants such as IL-8, fMLP, C5a, PAF, and LTB4, are important 
signals that chemoattract neutrophil to the inflammation sites. They all bind their 
respective GPCRs on the cell surface to induce cellular responses via G protein and 
phopholipase C activation. In order to facilitate a single modified response in the face of 
exposure to multiple overlapping ligands, neutrophils can display differential GPCR 
desensitization (Blackwood, Hartiala et al. 1996; Ali, Richardson et al. 1999). Two types 
of desensitization have been noted: homologous and heterologous. Homologous 
desensitization occurs when receptor is occupied and becomes hyporesponsive to 
subsequent agonist stimulation through a process involving phospholation of GPCR kinase  
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Figure 1.2. The model of the interaction between IL-8 and CXR1 or CXCR2.  
 
IL-8 activatation of  the CXCR1 or CXCR2 may consist of two steps.  First, the IL-
8 N-terminal loop, surface hydrophobic pocket and /or adjacent residues cooperatively 
interact with N-terminal residues of the receptor.  Second, the IL-8 N-terminus, including 
the ELR motif and Ile10 interact with the receptors’ first and second extracellular loops and 
transmembrane (J-domain) residues, which induces signaling into and activation of the 
cells.  Edited from (Baggiolini 2001). 
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 (GRKs).  Heterologous desensitization describes a process whereby activation of one type 
of receptor (e.g., the CXCR1) results in loss of responsiveness to a different GPCR ligand 
(e.g., C5a). This process does not require receptor occupancy (i.e. of the second receptor) 
and involves phosphorylation of second messenger-activated kinases (e.g., protein kinase 
C; PKC) (Richardson, Ali et al. 1995; Ali, Richardson et al. 1999). Desensitized receptors 
can regain sensitivity in the absence of stimulation. 
GPCR desensitization usually involves a functional uncoupling from G proteins, 
receptor internalization into the intracellular compartment, and receptor down-regulation. 
Using calcium flux assays in receptor-transfected cell lines have shown that IL-8 can 
heterologously desensitize receptors for fMLP and C5a through CXCR1, and vice versa. 
The CXCR2 does not take part in the cross-regulate responses to other chemoattractant 
receptors.  IL-8 also can heterologously desensitize receptors for LTB4 and PAF, but not 
vice versa.  Studies using neutrophil chemotaxis assays also demonstrated that fMLP, C5a, 
and IL-8 can heterologous desensitize each other and fMLP is most efficient at this (Ali, 
Richardson et al. 1999).  However, IL-8 less potently induces heterologous desensitization 
than fMLP and C5a do between each other (Richardson, Pridgen et al. 1998; Ali, 
Richardson et al. 1999). 
Generally, these studies indicate that there is a hierarchy among neutrophil GPCRs.  
The potency of receptors to heterologous desensitize one another is fMLP > C5a > IL-8 > 
LTB4, PAF.  IL-8-mediated cross-desensitization is regulated via inhibition of 
phosholipase C (PLC) activation downstream of other groups of chemoattractant receptors 
(Ali, Richardson et al. 1999).  Evidence suggests that this may be due to differences in 
signaling pathways whereby neutrophil responses to IL-8, PAF, and LTB4 are dependent 
on phosphoinositide-3-kinase (PI3K)/Akt pathway, whereas p38 mitogen-ativated kinase 
(p38 MAPK)-dependent signaling mainly mediates neutrophhil responses to fMLP and 
C5a.  There is a hierarchy between the two pathways in which the former can be inhibited 
by the latter (Haribabu, Zhelev et al. 1999; Heit, Tavener et al. 2002).  This inhibition may 
be necessary and important for neutrophils to reach the inflammation sites.  During an 
infection, multiple chemoattractants are released in varied locations by resident cells such 
as endothelial cells, epithelial cells, and macrophages. Neutrophils from vasculature need 
to decide which chemoattractant to follow. Foreign bacterial peptide (e.g., fMLP) and the 
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 bacterial product (e.g., LPS)-induced complement (e.g., C5a) may be more dangerous 
singals for the innate immunity.  Therefore, neutrophils may have evolved such that the 
(fMLP- and C5a- activated) MAPK pathway dominates when faced with multiple 
chemoattractants. This decision-signaling process of neutrophils is crucial for the innate 
immunity to focus on the most dangerous targets, foreign pathogens.  In addition, IL-8-
CXCR1 signaling can heterologuous desensitization of C5aR and FPR may be because (1) 
IL-8 activated CXCR1 can  phosphorylate FPR and C5aR with limited level resulting in 
decreased activation of PLC, (2) IL-8 activated CXCR1 downstream signaling, PI3K/Akt, 
may also interfere p38-MAPK phosphorylation activated by C5a and fMLP (see Fig 1.3.). 
 
1.2.3.6. Roles of CXCL8, CXCR1 and CXCR2 in inflammation 
CXCL8 was first purified as a chemotactic factor for neutrophils (Yoshimura, 
Matsushima et al. 1987).  However, subsequent studies demonstrated that IL-8 exhibits 
multiple effects on neutrophils, including induction of shape change, release of lysosomal 
enzymes (Peveri, Walz et al. 1988), induction of a respiratory burst (Peveri, Walz et al. 
1988), generation of superoxide, hydrogen peroxide (Thelen, Peveri et al. 1988), and 
bioactive lipids (Schroder 1989), and increases in the expression of adhesion molecules 
(Detmers, Lo et al. 1990).  Moreover, IL-8 enhances transendothelial migration of these 
cells by inducing rapid shedding of L-selectin (CD62L) (Huber, Kunkel et al. 1991).  
CXCR1 and CXCR2 have functionally distinct roles in inflammation.  For instance, 
they are both important in mediating neutrophil chemotaxis, MPO and elastase release, and 
cell calcium mobilization (Jones, Wolf et al. 1996; Gonsiorek, Fan et al. 2007), but it is the 
CXCR1, and not the CXCR2, that mediates neutrophil respiratory burst and activation of 
phospholipase D (Jones, Wolf et al. 1996).  On the other hand only the CXCR2 is 
important in mediating MMP-9 release from neutrophils (Chakrabarti and Patel 2005). 
 
1.2.3.7. ELR-CXC chemokines in inflammatory diseases 
The ELR-CXC chemokines are often expressed redundantly during inflammatory 
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Figure 1.3. Cross-desensitization of neutrophil chemoattractant receptors. 
 
Peptide chemoattractants (fMLP, C5a, IL-8) activate signaling pathways through 
Gαi and βγ subunits to activate phosholipase C (PLC). PLC can further activate protein 
kinase C (PKC) and provide signals to cross-phosphorylate other chemoattractant receptors.  
FPR and C5aR are more resistant to the phosphorylation driven by CXCR1 signaling, 
while they are better able to phosphorylate thereby desensitize the CXCR1.  ERK and 
PI3K are the down-stream signaling intermediates of CXCR1 signaling, while MAPK is 
the down-stream intermediate of FPR and C5aR.  
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 responses (Miller, Cohen et al. 1992; Caswell, Middleton et al. 2001; Remick, Green et al. 
2001), and often exacerbate the pathology of inflammatory diseases.  Studies have 
demonstrated that ELR-CXC chemokines play an important role in mediating the 
pathology of ARDS (Strieter, Keane et al. 2005), wherein they mediate neutrophil 
recruitment and activation, a hallmark of ARDS (Abraham 2003).  Elevated levels of IL-8 
correlate highly with pulmonary neutrophilia and the mortality of ARDS (Miller, Cohen et 
al. 1992; Aggarwal, Baker et al. 2000).  ELR-CXC chemokine-mediated neutrophilia in 
the respiratory system also greatly contributes to the severity of COPD pathology. High 
expression of IL-8, ENA-78 and their common receptor, CXCR2 has been demonstrated to 
be critical to the exacerbation of COPD (Qiu, Zhu et al. 2003).  Ischemia and reperfusion 
of a local organ often causes remote organ injury, resulting in multiple organ dysfunction 
syndrome (MODS), and neutrophil activation is thought to be a primary reason of MODS. 
The severe pulmonary injury associated with MODS often results in ARDS (Carden and 
Granger 2000).  ELR-CXC chemokines, e.g., IL-8, ENA-78, and CINC-1, are strongly 
upregulated in pulmonary, hepatic, skeletal, and intestinal ischemia and reperfusion injury 
models (Sekido, Mukaida et al. 1993; Colletti, Kunkel et al. 1995; Bless, Warner et al. 
1999; Ishii, Ishibashi et al. 2000).  By use of antibody neutralization approaches, it has 
been demonstrated that ELR-CXC chemokines have an important role in mediating 
neutrophil-induced injury (Sekido, Mukaida et al. 1993; Bless, Warner et al. 1999). IL-8 
plays a crucial role in attracting neutrophils into synovial fluid and joint tissues in 
RA,where MMP-9 released by activated neutrophils contribute significantly to cartilage 
destruction (Van den Steen, Proost et al. 2002).  Taken together, these results strongly 
suggest that strategies should be taken to block ELR-CXC chemokine-induced excessive 
neutrophil responses.  
 
1.2.3.8. ELR-CXC chemokine antagonism and other anti-inflammatory therapies 
1.2.3.8.1. Neutrophil antibody 
As discussed above, ELR-CXC chemokines are often redundantly expressed during 
inflammatory responses, which results in excessive activation of neutrophils and 
exacerbation of pathology.  The development of a means to effectively antagonize their 
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 actions has been a clinical priority for some time (Harada, Mukaida et al. 1996; Baggiolini 
and Moser 1997).  Since neutrophils are important effector cells in acute lung injury, anti-
neutrophil antibodies have been used to improve the pathologies induced by hemorrhage, 
endotoxemia, and myocardial ischemia.  These studies indicated that anti-neutrophil 
antibody treatments could decrease inflammatory cytokine (e.g., MIP-2, IL-1β, and/or 
TNFα) expression and the extent of lung edema in hemorrhage- or endotoxemia-induced 
lung injury models (Abraham, Carmody et al. 2000).  In a myocardial ischemia/reperfusion 
(I/R) model, it has also been shown to improve survival rates of I/R animals, lower 
expression of IL-6 and IL-8, reduce myocardial neutrophil infiltration, and produce smaller 
myocardial infarcts as compared to the untreated control animals (Kohtani, Abe et al. 
2002). 
 
1.2.3.8.2. ELR-CXC chemokine antibodies and glucocorticoids   
Anti-ELR-CXC chemokine antibodies, such as anti-IL-8, -MIP-2, -KC, and -CINC 
were developed to treat inflammatory diseases, especially I/R injury.  They have been 
shown to be effective in ameliorating lung, intestinal, skeletal and renal I/R injury (Sekido, 
Mukaida et al. 1993; Bless, Warner et al. 1999; Miura, Fu et al. 2001; Souza, Bertini et al. 
2004).  Since different ELR-CXC chemokines, e.g., ENA-78 in COPD (Qiu, Zhu et al. 
2003), may play redundant roles in inflammation, it would be ideal to simultaneously 
block all ELR-CXC chemokine functions.  It has been demonstrated that administration of 
antisera for both MIP-2 and KC before reperfusion of ischemic kidneys yields more 
effective inhibition of the pathology than either antiserum alone (Miura, Fu et al. 2001), 
which also support the notion that these chemokines have redundant functions. 
Glucocorticoids have been used as anti-inflammatory agents to reduce the exacerbation of 
diseases characterized by airway inflammation, such as asthma.  The main effect of this 
drug is to inhibit cytokine (e.g., IL-8) gene transcription and expression (Mukaida, 
Okamoto et al. 1994; Zhang, Truong-Tran et al. 2007).  It may also enhance innate 
immune responses in airway mucosa, especially epithelial cells (Zhang, Truong-Tran et al. 
2007).  Glucocorticoids have many side effects, such as immunosuppression, which 
impacts our abilities to use them extensively.   
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 1.2.3.8.3. ELR-CXC chemokine receptor antibody and antagonists 
As noted, the ELR-CXC chemokines activate neutrophils through binding to the 
CXCR2 or the CXCR1 and CXCR2.  It is obvious that blockade of both receptors (as 
opposed to only one) could be a more effective approach to inhibiting target cell function.  
There are a couple of studies that have addressed a hexapeptide antileukinate (Ac-
RRWWCR-NH2) CXCR2 antagonist which has been used to treat inflammatory diseases.  
The data from these two studies indicated that antileukinate has potent abilities to inhibit 
neutrophil influx and cytokine and chemokine expression in lung tissues during 
hemorrhage-primed, cecal ligation and puncture-induced, acute lung injury (Lomas-Neira, 
Chung et al. 2004).  This CXCR2 antagonist is also effective in protecting mice against 
acute pancreatitis and associated lung injury, which is believed to be mediated by ELR-
CXC chemokines (Bhatia and Hegde 2007).  Another type of CXCR2 angonist is a series 
of non-peptide antagonists including SB225002 and SB256610.  SB225002 is a synthetic 
chemical that competitively binds CXCR2 on neutrophils and blocks IL-8-induced 
neutrophil chemotaxis in vitro and neutrophil margination in vivo (White, Lee et al. 1998). 
SB265610 can antagonize neutrophil calcium mobilization and chemotaxis-induced by 
CINC-1, and block pulmonary neutrophil accumulation induced by hyperoxia (Auten, 
Richardson et al. 2001).  Another synthetic chemical, Sch527123, is able to block CXCR2-
mediated neutrophil chemotaxis and to antagonize neutrophil infiltration and goblet cell 
hyperplasis in LPS-challenged rat lungs.  These drugs are mainly focused on CXCR2-
mediated inflammatory responses.  As discussed previously, neutrophil release of ROI and 
elastase are mainly mediated via the CXCR1 (Jones, Wolf et al. 1996; Jones, Dewald et al. 
1997), such that it would be ideal to incorporate blockade of both CXCR1 and CXCR2 in 
anti-inflammatory therapies.  A class of derivatives of 2-arylphenylpropionic acid, 
including repertaxin and DF2162, are reported to be effective, non-competitive, allosteric 
inhibitors of the chemokine receptors CXCR1 and CXCR2. These two molecules are able 
to block neutrophil chemotaxis, calcium mobilization-induced by IL-8, CINC-1, or/and 
GROα.  They are also able to prevent intestinal I/R injury and adjuvant-induced arthritis in 
rats (Souza, Bertini et al. 2004; Barsante, Cunha et al. 2008).  But in these studies, there is 
no unequivocal evidence to show that these two drugs target CXCR1-mediated functions,  
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 e.g., neutrophil ROI release, so it is hard to conclude that they antagonize both the CXCR1 
and CXCR2. 
Early studies have shown that minimal amino-terminal truncation of CXCL5 
(Nufer, Corbett et al. 1999), CXCL6 (Wuyts, D'Haese et al. 1999) or CXCL8 (Clark Lewis, 
Dewald et al. 1994) significantly increases their respective  receptor affinities.  Natural 
amino truncation of CXCL8 potentiates its CXCR1-, but not CXCR2-, dependent activities 
by 10- to 27-fold (Van den Steen, Proost et al. 2000).  Truncation into, but not beyond, the 
receptor-signaling ELR motif of some CXC chemokines can transform them into receptor 
antagonists (Moser, Dewald et al. 1993).  But truncated CXCR2 ligands do not fully block 
CXCL8 signaling and ELR-truncated CXCL8 displays a relatively low receptor affinity 
(Moser, Dewald et al. 1993; McColl and Clark Lewis 1999).  Truncation of the 5’ terminal 
two amino acids of bovine CXCL8, combined with a lysine to arginine substitution at 
amino acid 11 (i.e., CXCL8 (3-73) K11R), is associated with significantly higher affinities 
for both CXCR1 and CXCR2, thus creating a CXCL8 analogue that possesses remarkably 
strong neutrophil agonist activities (Li and Gordon 2001).  By use of two additional amino 
acid substitutions, G31P or P32G (Li and Gordon 2002), both shown by Clark-Lewis and 
colleagues to be important for CXCL8 activity (Clark Lewis, Dewald et al. 1994), our lab 
developed another two mutants, CXCL8(3-73)K11R/G31P and CXCL8(3-73)K11R/ P32G, 
which both had strong antagonist activities.  Additional substitutions within these two 
candidate antagonists were all within the reported receptor recognition region of the 
molecule (i.e., R11, T12, H13, K17 ) (Li and Gordon 2002), such that we had generated 
two antagonist families (i.e. G31P- and P32G- based).  Among them, bovine CXCL8(3-
73)K11R/G31P (bG31P) was superior to all others (Li and Gordon 2002).  bG31P blocks 
binding of monospecific anti-CXCR1 and anti-CXCR2 antibodies to neutrophils (Li and 
Gordon 2002) and, when titrated against its parent chemokine, 0.5 nM bG31P 50% blocks 
neutrophil responses to 129 nM (1 µg/ml) CXCL8 (Li, Zhang et al. 2002).  At ≤10 ng/ml, 
it also 93-97% blocks responses to the neutrophil chemoattractants present in wash fluids 
from the lungs of animals with clinical pneumonic pasteurellosis (Li, Zhang et al. 2002).  
Our lab has also confirmed the efficacy (i.e., up to 98%) of bG31P in blocking neutrophil 
infiltration of endotoxin challenge sites in cattle and it does so for 2-3 dy following a 
single injection (Li, Zhang et al. 2002).  So, bG31P is a potent ELR-CXC chemokine 
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 antagonist.  Furthermore, we have evidence that bG31P can strongly antagonize agonist 
activity of human CXCL8 for human neutrophils.  
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CHAPTER 2 : RATIONALE, HYPOTHESIS, AND OBJECTIVES 
 
Rationale 
In developing CXCL8(3-74)K11R/G31P ( bG31P), our lab had first generated an 
exceptionally high binding affinity analogue of bovine CXCL8 analogue, CXCL8(3-
74)K11R.  This analogue had ~ 450 fold greater binding affinity for neutrophils than did 
wild-type bovine CXCL8 (Li and Gordon 2001).  We used this high affinity analogue to 
subsequently generate bG31P, which was shown to be highly effective in blocking ELR-
CXC chemokine-induced neutrophil responses in vitro and neutrophilic pathology in vivo 
(Li and Gordon 2002; Li, Zhang et al. 2002; Gordon, Li et al. 2005).  When we began to 
examine the issue of generating a fully human orthologue of bG31P, we looked at the 
human CXCL8 structure-function studies by Ian Clark-Lewis’ lab, wherein it was reported 
that human CXCL8(3-72)K11R has an only 4-fold greater binding affinity for neutrophils 
than its parent molecule, human CXCL8(3-72),.  This raised a question in our minds as to 
whether a human CXCL8(2-72)K11R-based form of a human G31P would be of sufficiently 
high affinity to be a clinically useful competitive antagonist.  In addition, Clark-Lewis had 
reported that human CXCL8(4-72)G31P/P32G had a 20-fold reduced binding affinity for 
neutrophils relative to wild-type CXCL8 (Clark Lewis, Dewald et al. 1994), and this raised 
further questions in our minds regarding a purely human form of G31P.  As a result, we 
elected to take a two-pronged approach to generating a human(ized) G31P, including 
humanization of the bovine molecule, as described in detail below, and simply making and 
testing a fully human form.  My part of this included generating and characterizing 
humanized forms of the drug, and characterizing the human G31P that had been generated 
by others in the lab.  Therefore, based on the following information: 
• bG31P is a potent bovine ELR-CXC chemokine antagonist; 
• bG31P can strongly antagonize human CXCL8 agonist activity for human 
neutrophils;  
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 • bovine and human CXCL8 share relatively high amino acid sequence identity; and 
• Most of discrepant amino acids between bovine and human CXCL8 are located in 
the carboxyl-terminal half of the molecule and knowledge that several amino-
terminal residues (e.g., amino acids 4-6, 10-22, and 30-35) are critical for receptor 
binding and activation, 
 
My hypothesis is that: 
A humanized form of bG31P, or human G31P, can also block the actions of 
ELR-CXC chemokines on neutrophils. This novel antagonist should provide an 
effective anti-inflammatory therapy for ELR-CXC chemokine-driven neutrophil-
mediated pathology. 
 
My objectives were to: 
1) Develop a humanized form of the ELR-CXC chemokine antagonist, bovine 
CXCL8(3-74)K11R/G31P and assess its antagonist activities in vitro and in vivo. 
2) Characterize a fully human form of the ELR-CXC chemokine antagonist, bovine 
CXCL8(3-74)K11R/G31P (generated by others in the lab) using in vitro assays and a 
guinea pig airway endotoxemia model. 
3) Test the role of human CXCL8(3-72)K11R/G31P (hG31P) in blocking aspiration of 
gastric content-induced bacterial (i.e., aspration) pneumonia. 
4) Examine the effect of hG31P on intestinal ischemia and reperfusion-induced 
neutrophilic pathology. 
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CHAPTER 3 : HUMANIZED FORMS OF THE CXCR1/CXCR2 ANTAGONIST, 
BOVINE CXCL8(3–74)K11R/G31P, EFFECTIVELY BLOCK ELR–CXC 
CHEMOKINES ACTIVITY AND AIRWAY ENDOTOXEMIA PATHOLOGY 1 
 
Chapter 3 overview 
Based on a review of the theoretical literature regarding the structure-activity 
relationships within the ELR-CXC chemokine CXCL8, we had anticipated that a human 
analogue of bG31P, CXCL8(3-72)K11R/G31P (i.e., hG31P), may not be a potent antagonist 
for ELR-CXC chemokines, as noted above (Chapter 2 Rationale). So, the first step of my 
dissertation research was to humanize bG31P. The manuscript comprising this chapter 
describes the rationale and approaches for generating and characterizing a chimeric 
humanized form of bG31P, human-bovine (hb) G31P, and its analogues. Since human 
CXCL8 and bovine CXCL8 share high homology and the structure and function study 
showed that NH2-terminus is biologically and structurally important, I developed a 
chimeric protein, bCXCL8(3-44)K11R/G31P-hCXCL8(45-72) ( i.e., hbG31P). I subsequently 
used the vector for this hbG31P as a target for site-directed mutagenesis and generated 
T3K, H13Y, T15K, E35A, and S37T substitutions within hbG31P. I assessed the 
antagonist activities of these proteins using neutrophil chemotaxis, calcium flux and WBC 
ROI release assays.  I also examined the abilities of hbG31P to block neutrophil infiltration 
in a guinea pig airway endotoxemia model.  In this study, I designed and carried out all the 
experiments, although I had assistance from other co-authors in the in vitro and in vivo 
experiments.  I analyzed the data and co-wrote the manuscript with Dr. Gordon.   
 
                                                 
1 Zhao Xixing, F. Li, J. R. Town, X. Zhang, W. Wang, and J.R. Gordon  2007. Humanized 
forms of the CXCR1/CXCR2 antagonist, bovine CXCL8(3–74)K11R/G31P, effectively 
block ELR–CXC chemokine activity and airway endotoxemia pathology. International 
Immunopharmacology 7: 1723–1731 
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 3.1. INTRODUCTION 
The ELR-CXC chemokines, so named because of their amino sub-terminal 
Glu-Leu-Arg (ELR) and Cys-X-Cys motifs, are important for neutrophil recruitment.  
CXCL8 (i.e., IL-8), the prototypical ELR-CXC chemokine, binds to the CXCR1 and 
CXCR2 receptors with high affinity, whereas all others, including GRO-α, -β, and -γ, 
ENA-78, GCP-2, and NAP-2 (i.e., CXCL1-3 and 5-7, respectively) have lower 
affinities, primarily for the CXCR2 (Baggiolini 1998).  Their expression is up-
regulated during inflammatory events (e.g., acute respiratory distress syndrome, 
inflammatory bowel disease; (Baggiolini, Dewald et al. 1994; Baggiolini, Dewald et al. 
1997)), so that they have been broadly implicated in the pathology of many 
inflammatory diseases (Cummings, Martin et al. 1999; Mehrad, Strieter et al. 1999).  
Numerous other mediators (e.g., C5a, LTB4) are also relevant to such diseases of 
course (Tsai, Strieter et al. 2000; Woodruff, Arumugam et al. 2003; Chen, Lam et al. 
2006), but because of their pathogenic roles in multiple settings, the development of 
specific ELR-CXC chemokine inhibitors has become an important research goal 
(Carvalho, Wakabayashi et al. 1997; Ramos, Fernandes et al. 2006). 
We previously generated a very high affinity analogue of bovine CXCL8, 
CXCL8(3–74)K11R (Li and Gordon 2001), which we used to generate a similarly high 
affinity, broad-spectrum ELR-CXC chemokine antagonist, bovine CXCL8(3–
74)K11R/G31P (bG31P).  This antagonist blocks the abilities of ELR-CXC chemokines 
to activate or chemoattract neutrophils in vitro (Li, Zhang et al. 2002) and  in vivo (Li, 
Zhang et al. 2002).  A single treatment with bG31P ≈ 97% blocks neutrophil 
infiltration into intradermal endotoxin challenge sites for 2-3 days (Li, Zhang et al. 
2002), and dramatically reduces pulmonary pathology and pyrexia in endotoxemic 
animals (Gordon, Li et al. 2005).  While bG31P could perhaps be useful in the humans, 
it goes without saying that a human equivalent thereof would be of significantly more 
use.  However, prior structure-function data has indicated that human CXCL8(3-
72)K11R is not a particularly high affinity neutrophil agonist, and that a G31P 
substitution within human CXCL8(3-72) only marginally reduces its neutrophil agonist 
activities (Clark Lewis, Dewald et al. 1994), suggesting that human CXCL8(3-
72)K11R/G31P (i.e., the human counterpart of bG31P) would not be a particularly 
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 effective chemokine antagonist.  Thus, we began a systematic humanization of bG31P 
to determine whether partially humanized bG31P isoforms might still be effective 
ELR-CXC chemokine antagonists. 
Bovine and human CXCL8 share the homology of 78% at amino acid level.  
Most of the discrepant amino acids reside in the carboxy-terminal half of the molecule 
(Table 3.1.), while the amino-terminal residues (e.g., amino acids 4-6, 10-22, and 30-
35) are essential for receptor binding and activation (Clark-Lewis, Schumacher et al. 
1991; Clark Lewis, Dewald et al. 1994; Hammond, Shyamala et al. 1996).  Thus, we 
first ligated the amino and carboxy portions of bG31P and human CXCL8, respectively, 
to generate bCXCL8 (3-44) K11R/G31P-hCXCL8 (45-72) (i.e., hbG31P), and found that it 
fully retained the antagonist activity of bG31P for human neutrophils.  We then one-
by-one substituted the remaining human-bovine discrepant amino acids (i.e., T3/K, 
H13/Y, H15/K, E35/A, and S37/T), and expressed and characterized each of these 
further humanized hbG31P analogues. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Reagents and supplies 
We have reported most reagents employed (Li and Gordon 2001; Li and 
Gordon 2002; Li, Zhang et al. 2002; Gordon, Li et al. 2005), but in addition we 
purchased: fluo-4 AM (Invitrogen Inc, Burlington, ON); QIAprep Spin Miniprep 
(QIAGEN Inc., Mississauga, ON); QuickChangeTM Site-Directed Mutagenesis kit 
(Stratagene Cloning Systems, La Jolla, CA); hexadecyltrimethylammonium bromide 
(HTAB), tetramethylbenzidine (TMB), luminol, (Sigma Chemical Co, Mississauga, 
ON); biotinylated anti-human CXCL8 antibody (R & D Systems, Minneapolis, MN); 
and rabbit anti-human lactoferrin antibody, recombinant (r) lactoferrin and biotinylated 
anti-lactoferrin Ab  (ICN Biomedicals Inc., Irvine, CA).  Hartley guinea pigs (5 week-
old females) were purchased from Charles River Laboratories (Charles River, MA); all 
experiments were carried out in accord with the guidelines of the Canada Council on 
Animal Care.  
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 Table 3.1. The amino acid sequences of bovine and human CXCL8/IL-8 
 
                   1   2    3   4   5    6    7   8    9  10  11  12  13 14  15 16 17  18 19  20  21  22  23  24  25   
bovine    M  S  T  E  L  R  C  Q  C  I  K  T  H  S  T  P  F  H  P  K  F   I   K  E  L  
human    S  A   K  E  L  R  C  Q  C  I  K  T  Y  S  K  P  F  H  P  K  F   I   K  E  L   
             26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  
bovine    R   V  I   E   S  G  P  H  C  E  N  S   E   I    I  V  K  L  T  N  G  N  E  V  C   
human   R   V  I   E   S  G  P  H  C  A  N  T   E   I    I   V  K  L  S  D  G  R  E  L  C   
              51  52  53  54  55  5 6  57  58  59   60   61  62  63   64  65  66  67  68  69  70  71  72  73  74 
bovine     L   N  P  K  E   K  W  V  Q  K  V  V  Q   V  F  V  K  R  A   E  K  Q  D  P   
human    L   D  P  K  E   N  W  V  Q  R  V  V  E    K  F  L  K  R  A   E  N  S         
 
Bovine and human CXCL8/IL-8 share 78% amino acid sequence homology, 
with most of the discrepant amino acids residing in the carboxy half of the molecule. 
The target residues for this study (i.e., amino acids, 3, 13, 15, 35, and 37) are bold and 
italicized. 
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 3.2.2. Generation of recombinant analogues of bCXCL8(3-74)K11R/G31P 
A human CXCL8(3-72) cDNA was synthesized commercially (Takara Biotech, 
Dalian, China), such that the coding sequence was flanked by a 5’BamH I site and a 3’ 
stop codon (TAA) followed by an EcoR I site, and ligated into the plasmid pGEX-2T 
to generate pGEX- hCXCL8(3-72). We previously reported the expression vector for 
bG31P, pGEX-bCXCL8(3-74)K11R/G31P (Li, Zhang et al. 2002).  To generate a 
chimeric human-bovine form of bG31P, we digested the bovine and human plasmids 
pGEX-bCXCL8(3-74)K11R/G31P and pGEX-hCXCL8(3-72), respectively, with Hind III 
and Pst I.  We ligated the 1049 base pair Hind III/PstI fragment from pGEX-
hCXCL8(3-72) (i.e., encoding hCXCL8 amino acids 44-72) into the 4100 base pair 
fragment from the digested pGEX-bCXCL8(3-74)K11R/G31P (i.e., the bulk of the 
pGEX vector and the coding sequence for bG31P amino acids 3-43) to generate 
bCXCL8(3-44)K11R/G31P-hCXCL8(45-72), or hbG31P.  We used this chimeric vector as 
a target for site-directed mutagenesis (primers listed in Table 3.2.) to make T3K, H13Y, 
T15K, E35A, and S37T substitutions within the hbG31P vector.  We verified all 
sequences commercially (Plant Biotechnology Institute, Saskatoon), then expressed 
and characterized each analogue by SDS-PAGE and Western blotting, as noted (Li and 
Gordon 2001; Li and Gordon 2002).  All were the correct molecular weight (i.e., one 
band of ≈8 kD) and reacted with anti-human IL-8 antibodies. 
 
3.2.3. Neutrophil chemotaxis assay 
Our neutrophil isolation and modified Boyden chamber microchemotaxis 
assays have been described previously (Li and Gordon 2001; Li and Gordon 2002; Li, 
Zhang et al. 2002).  Purified neutrophils were suspended in PBS+ (phosphate-buffered 
saline [PBS; pH 7.4], 1.2 mM MgCl2, 5 mM KCl, 0.5 mM CaCl2, 5 mM glucose, and 
0.1% bovine serum albumin).  The chemoattractants (e.g., CXCL8) and putative 
antagonists were mixed together for the assays, which were quantified by direct  
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 Table 3.2. Site-directed mutagenesis PCR primers employed for the generation of 
hbG31P’s mutants 
 
 
Analogue 
Upstream primers 
 (5’-3’ orientation) 
Downstream primers 
 (5’-3’ orientation) 
hIL-8(3-72) 
C GGA TCC AAA GAA CTT AGA 
TGT CAG 
G GAA TTC TTA TGA ATT TTC 
AGC CCT CTTC 
hbG31P/T3K 
CTG GTT CCG CGT GGA TCC 
AAA GAA CTT CGA TGC C 
G GCA TCG AAG TTC TTT GGA 
TCC ACG CGG AAC CAG 
hbG31P/H13Y 
C CAA TGC ATA AGA ACA TAT 
TCC ACA CCT TTC C 
G GAA AGG TGT GGA ATA TGT 
TCT TAT GCA TTG G 
hbG31P/T15K 
TGC ATA AGA ACA CAT TCC 
AAA CCT TTC CAC CCC 
GGG GTG GAA AGG TTT GGA ATG 
TGT TCT TAT GCA 
hbG31P/E35A 
GT CCG CCA CAC TGT GCC AAT 
TCA GAA ATC 
GAT TTC TGA ATT GGC ACA GTG 
TGG CGG AC 
hbG31P/S37T 
CCG CCA CAC TGT GAA AAT 
ACA GAA ATC ATT G 
C AAT GAT TTC TGT ATT TTC ACA 
GTG TGG CGG 
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 counting of at least five 40× objective fields within the stained chemotaxis assay 
membranes.  In preliminary experiments optimal chemotaxis was induced with 10 
ng/ml CXCL8.  The results are expressed as the mean number of cells per 40× field ± 
SEM. 
 
3.2.4. Reactive Oxygen Intermediate (ROI) release assay 
To generate total white blood cells (WBC), heparin-anticoagulated human 
blood was mixed at a 1:1 ratio with 6% dextran (75 kDa) in PBS and allowed to stand 
undisturbed at room temperature until the red blood cells had sedimented.  The WBC 
in the upper phase were washed and resuspended at 2.5×106 cells/ml in HBSS.  For the 
assays, we mixed 50 µl of WBC, 25 µl of human CXCL8 (100 ng/ml) or HBSS, 25 µl 
of antagonist (containing 10, 50, 100 ng/ml hbG31P, final concentration) or HBSS, and 
50 µl of Luminol (0.3 mM).  In preliminary dose-response experiments, we had 
determined that optimal ROI release was induced with 100 ng/ml CXCL8.  The ROI 
release was assessed by chemiluminescence using a microplate spectrofluorometer 
(NovoStar, BMG LABTECH Inc., Durham, NC).  The data are expressed as the 
maximum sample luminescence of the experimental sample, minus the HBSS control 
values, in luminescence units. 
   
3.2.5. Intracellular Ca2+ flux assay 
Neutrophils (5×106 cells/ml in Ca2+-free PBS+) were stained for 30 min at 37˚C 
with 2 µM fluo-4 AM, washed twice with Ca2+-free PBS+ medium, resuspended at 
4×106 cells/ml in PBS+ containing 3.3 nM Ca2+, and then kept at room temperature.  
For the assays, 50 µl of cells were preincubated for 15 min with 50 µl of medium or 
antagonist, and then challenged with 50 µl of medium or agonist (CXCL8 or CXCL1).  
Intracellular Ca2+ mobilization was assessed using a microplate spectrofluorometer 
(emission and excitation wavelengths, 520 nm and 488 nm, respectively) and based on 
so-generated ‘area under the curve’ readouts.  Preliminary experiments showed that  
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 100 ng/ml CXCL8 induced optimal PMN intracellular Ca2+ mobilization.  For technical 
reasons associated with the high inter-experiment variance of spectrofluorimeter 
readouts, the data are expressed as the mean percent inhibition (± SEM) of agonist-
induced Ca2+ flux across at least three independent experiments. 
  
3.2.6. Guinea pig acute lung endotoxemia 
Our guinea pig airway endotoxemia model has been noted previously (Gordon, 
Li et al. 2005).  Briefly, 30 min before airway challenge with 200 µl of Escherichia 
coli LPS (serotype 0127B8; 5 µg/kg in PBS), the animals (n = 5) were given 250 µg/kg 
hbG31P or saline (0.5ml) s.c., then euthanized 15 h later with halothane.  We had run 
preliminary hbG31P dose-response experiments using hbG31P doses of 50, 100 and 
250 µg/kg and found that at the lower two doses we achieved only 20-40% inhibition 
of airway neutrophilia (data not shown).  Bronchoalveolar lavage (BAL) fluid 
collection, BAL WBC (and RBC) enumeration and differentials were performed as 
noted (Gordon, Li et al. 2005); the results are expressed as the mean number of cells 
per BAL sample. Peripheral blood total WBC counts were also assessed.  All samples 
were assessed independently. 
 
3.2.7. Myeloperoxidase assay (MPO) 
BAL fluids (10 µl) were diluted 10-fold with 0.5% HTAB, and then 10 µl of 
these diluted samples were incubated at room temperature for 10 min with 100 µl TMB, 
before stopping the reactions with 100 µl of 1M phosphoric acid. The reactions were 
quantified by spectroscopy (OD, 450 nm) and the data expressed as OD450 ± SEM. 
 
3.2.8. Lactoferrin (LF) ELISA 
We employed a standard capture ELISA format, with optimized concentrations 
of capture (2.45 µg/ml) and detection (0.85µg/ml) antibodies, as noted (Schneider, Li 
et al. 2001).  The standards comprised lactoferrin (6.25- 400 ng/ml) and the samples 
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  were diluted 1:10 for the assay. The results were expressed as the mean concentration 
(ng/ml) of each group ± SEM. 
 
3.2.9. Lung Pathology 
We euthanized the animals with halothane, then did bronchalveolar lavages 
(BAL) on each, after which we removed, photographed, and assessed the 
cardiopulmonary tree for pleural hemorrhagic consolidation. The caudal left lung lobe 
of each animal was fixed for 3 h in acid-alcohol formaldehyde and routinely processed 
to paraffin sections in our institutional pathology department.  For routine 
histopathology, the tissue sections were stained with a standard hemotoxylin and eosin 
(H&E) protocol and examined in a blinded manner at 400× magnification.  The 
histologic sections were photographed at 400× or 1000× magnification. 
 
3.2.10. Statistical analysis 
Two-group comparisons were made using student’s t-tests (two-tailed). The 
results are expressed as the mean ± SEM. 
 
3.3. RESULTS 
3.3.1. hbG31P antagonizes human neutrophil chemotaxis, ROI release, and 
intracellular Ca2+ flux in response to CXCL8 and CXCL1 signaling. 
The agonist activity of hbG31P for human neutrophils was tested using 
chemotaxis and WBC ROI release assays.  CXCL8 was a strong agonist for both 
chemotaxis (Fig. 3.1A) and ROI release (Fig. 3.1B). Neither hbG31P nor bG31P 
displayed discernible agonist activity when used at 10, 50 (Fig. 3.1), or 100 (data not 
shown) ng/ml.  On the other hand, 10 or 50 ng/ml hbG31P effectively blocked 
neutrophil chemotaxis induced by 10ng/ml CXCL8 or WBC ROI release stimulated by 
100 ng/ml CXCL8 (Fig. 3.2A & B, respectively), as well as intracellular Ca2+ flux 
induced by CXCL1 or CXCL8 (each at 100 ng/ml; Fig.3.2C).  
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Figure 3.1. The human-bovine chimeric protein hbG31P is not a neutrophil agonist. 
 
The agonist activities of hbG31P were compared with those of bG31P using 
chemotaxis and reactive oxygen intermediate (ROI) release assays (see material and 
methods). (A) The ability of hbG31P to chemoattract human neutrophils was compared to 
that of medium (Med.) alone, human CXCL8, and bG31P (each, 10 ng/ml).  The results 
are expressed as the mean (±SEM) number of cells/40× objective microscope field. Neither 
hbG31P nor bG31P displayed discernible agonist activity relative to the medium control. 
(B) Similarly, the ability of hbG31P to induce ROI release from human WBC was 
compared to that of HBSS (med.), bG31P (each, 50 ng/ml) or human CXCL8 (100 ng/ml).  
Luminol-amplified luminescence was detected using a microplate spectrofluorimeter, and 
the data expressed as the maximum luminescence for each sample (± SEM).  Neither 
bG31P nor hbG31P possessed significant neutrophil agonist activity when compared with 
medium alone.  These results are representative of three independent experiments. 
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Figure 3.2.  hbG31P is an effective ELR-CXC chemokine antagonist.  
 
The antagonist activities of the hbG31P were compared with those of bG31P using 
chemotaxis and ROI release assays, as in Fig 3.1., as well as chemokine-induced 
intracellular Ca2+ flux, as noted in the methods.  (A) Both bG31P and hbG31P (each, 10 
ng/ml) inhibited human neutrophil chemotactic responses to CXCL8 (10 ng/ml; *, p≤0.05 
versus CXCL8 alone) as well as (B) CXCL8-induced ROI release from human WBC 
(CXCL8, 100 ng/ml; bG31P or hbG31P, each 50 ng/ml, *, p≤0.05 versus CXCL8 alone).  
(C)  Both antagonists (100 ng/ml) also blocked equimolar CXCL8- and CXCL1-induced 
neutrophil intracellular Ca2+ flux in human neutrophils; in 3 of 3 experiments hbG31P 
treatment led to ≈20% greater antagonism than did bG31P treatments.  The percent 
inhibition by (h)bG31P of intracellular Ca2+ flux induced by CXCL1 and CXCL8 were 
calculated from the ‘area under the curve’ data of three independent experiments, as 
determined using Fluo-4 AM-loaded cells. 
 
 
 
 
 
 
 60
 3.3.2. Further humanization of hbG31P does not reduce its antagonist activities. 
Within hbG31P there remained five human-bovine discrepant amino acids (i.e., 
T3, H13, T15, E35, and S37; Table 3.1).  Thus, we generated further hbG31P 
analogues in which each of these were replaced one-by-one (i.e., T3K, H13Y, T15K, 
E35A, and S37T) and confirmed that none of these were neutrophil agonists (p>0.05 
versus medium alone; Fig. 3.3A).  Furthermore, all except T15K strongly inhibited 
CXCL8-driven chemotaxis (Fig. 3.3B) and dose-dependently antagonized CXCL8-
induced ROI release (i.e., versus 100 ng/ml CXCL8; Fig.3.3C).  Furthermore, all were 
equally antagonistic for CXCL1- or CXCL8-induced intracellular Ca2+ flux except 
H13Y, whether tested at 10 (for each, ≈20% effective; data not shown) or 100 ng/ml 
(Fig. 3.3D).  These results were representative of three experiments.  
  
3.3.3. hbG31P is an effective antagonist of endotoxin-induced acute lung 
inflammation 
Since hbG31P was confirmed to be a good antagonist in vitro and none of other 
analogues displayed markedly better antagonist activity (and some tended to be 
inferior), we confined our in vivo assessments to hbG31P, testing its activity in a 
standard guinea pig acute airway endotoxemia model, as described (Gordon, Li et al. 
2005).  As noted, at 15 h after induction, animals suffering from airway endotoxemia 
develop intense pulmonary inflammatory responses (Gordon, Li et al. 2005).  The 
hbG31P treatments had protective effects as observed either grossly or histologically 
(Fig. 3.4A).  At the gross pathology level, we observed marked hemorrhagic 
consolidation in the anterior right lung lobes of the saline-treated, LPS-challenged 
animals (LPS control), and treatment with 250 µg/kg hbG31P reduced this to near 
background (Fig. 3.4A, upper panels).  When observed histologically, the 
inflammatory cell congestion in the lung tissues of the saline-treated LPS-challenged 
animals was very marked (Fig. 3.4A, lower LPS control panel), and most of these cells 
were neutrophils as determined by morphology and staining with H&E stains (inset).  
The hbG31P treatments dramatically reduced the inflammatory congestion in the lungs 
(Fig. 3.4A, lower right panel) 
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Figure 3.3.  Further humanization of hbG31P does not markedly augment its 
antagonist activities.   
 
We generated analogues of hbG31P in which each of the remaining human/bovine-
discrepant amino acids were one-by-one replaced with their human equivalent residue, and 
then we compared each of these with hbG31P, as in Fig.3.1 and 3.2.  (A) Neither hbG31P 
nor any of the analogues (10 ng/ml) displayed significant chemotactic activity relative to 
medium controls. These results are from one experiment that is representative of three 
independent experiments. (B) With the exception of T15K, each of the tested analogues 
(10 ng/ml) equally blocked CXCL8- (10 ng/ml) induced chemotactic responses (*, p≤0.05, 
**, p≤0.01, each compared to CXCL8 alone). (C) 1-100 ng/ml of each antagonist was used 
to characterize their activities in WBC ROI release assays.  With the exception of H13Y, 
each analogue dose-dependently inhibited CXCL8-induced ROI release from stimulated 
WBC.  At 100 ng/ml, each analogue equally blocked ROI release.  (D) At 100 ng/ml, each 
analogue blocked intracellular Ca2+ flux in CXCL8- or CXCL1-stimulated neutrophils.  
None of these analogues displayed more potent antagonist activity than hbG31P.   
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Figure 3.4.  hbG31P displays potent anti-inflammatory activity in endotoxemic 
animals.  
  
Airway endotoxemia was induced in guinea pigs by intranasal instillation of 
bacterial endotoxin (LPS; 5 µg/kg), while saline control animals were administered an 
equal volume of saline.  The animals were treated 30 min before LPS challenge either 
with saline (LPS control) or hbG31P (LPS+hbG31P; 250 µg/kg), and euthanized at 15 
h post-challenge.  (A) The cardiopulmonary tree of each animal, including the heart (H) 
and lungs, was removed and photographed using a dorsal approach (upper panel), then 
processed to paraffin sections for H& E staining (lower panel).  The lungs of the saline 
control animals were normal in gross and histological appearance (left panels), while 
the lungs of the LPS control animals, and particularly the cranial right lung lobe 
(circled) of each animal, were markedly hemorrhagic (middle panels) and congested 
with red blood cells RBC) and neutrophils (PMN; inset, LPS control histology). The 
lungs of the hbG31P-treated LPS-challenged animals were largely free of hemorrhagic 
consolidation and displayed greatly reduced pulmonary inflammation (right panels). (B) 
We performed bronchalveolar lavages (BAL) on each animal and the total neutrophil, 
WBC and RBC counts within the airways as noted in the materials and methods 
section.  We also assessed the BAL fluid levels of myeloperoxidase (MPO) and 
lactoferrin (LF) by colorimetric assays and ELISA, respectively.  The data indicate that 
hbG31P was highly effective in reducing PMN (p≤0.05 compared to saline therapy), 
white blood cell (WBC; p≤0.05), and RBC (p≤0.01) infiltration of the airways, and 
also in reducing the release of LF (p<0.01) and MPO (p<0.01) into this compartment. 
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 As expected based on our histological assessments, treatment with hbG31P 
reduced the numbers of neutrophils and total white blood cells (WBC) recoverable 
from the airways to near background (p ≤ 0.01, versus saline-treated animals; Fig. 
3.4B). Furthermore, the levels of the neutrophil degranulation markers MPO and LF in 
the BAL fluid of the hbG31P-treated animals were also dramatically lower than those 
in the saline-treated group.  Thus, hbG31P was a highly effective antagonist of 
pulmonary neutrophil infiltration in endotoxemic animals.  Furthermore, the numbers 
of red blood cells entering the airways following hbG31P-treatment were also 
dramatically reduced.  This clearly confirmed that ELR-CXC chemokine antagonism 
can ameliorate loss of vascular integrity in endotoxemia, as noted previously (Gordon, 
Li et al. 2005).   Thus, our data confirmed that overall the human-bovine chaemeric 
protein, hbG31P, has very potent anti-inflammatory activity, as determined in a robust 
model of acute lung inflammation. 
 
3.4. DISCUSSION 
We showed that the human-bovine chimeric protein bCXCL8(3-44)K11R/G31P-
hCXCL8(45-72) (i.e., hbG31P) fully retained the antagonist activity of bG31P.  Among 
the ELR-CXC chemokines, the ‘ELR’ and the “11-17” loop (i.e., amino acids 11-17) 
motifs are critical for receptor signaling and recognition (Clark-Lewis, Dewald et al. 
1994), respectively, while the COOH-terminal α-helix (e.g.,, amino acids 59-72) is 
important structurally, rather than for receptor binding (Clark-Lewis, Schumacher et al. 
1991).  Nevertheless, both the amino and carboxyl termini reportedly may be critical 
for CXCR2 binding (Schraufstatter, Barritt et al. 1993), while the hydrophobic pocket 
formed in part by Lys49, Tyr13, Ser14, and Phe21, also participates in CXCL8 
receptor binding (Hammond, Shyamala et al. 1996).   Our evidence indicates that the 
human-bovine discrepant amino acids within the carboxy half of bG31P (i.e., between 
T44 and P74) did not markedly influence its antagonist activities.  It has been reported 
that neutrophil intracellular Ca2+ flux is mediated by both CXCR1 and CXCR2 
signaling , while superoxide release is CXCR1-dependent (Jones, Wolf et al. 1996).   
Inasmuch as hbG31P impaired intracellular Ca2+ flux induced by CXCL1 (a CXCR2 
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 ligand) and ROI release, our data suggests that hbG31P acts through both the CXCR1 
and CXCR2, as was reported previously for bG31P (Gordon, Li et al. 2005). 
Our data indicated that none of the human-bovine discrepant amino acids 
within hbG31P that we tested (i.e., T3, H13, T15, E35, and S37) markedly affected its 
antagonist activities.  Thr3, the first amino acid within hbG31P, is proximal to both the 
receptor-signaling (i.e., the ELR) motif.  Others have shown that residues proximal to 
the ELR motif are dispensable for activity among the ELR-CXC chemokines (Clark-
Lewis, Schumacher et al. 1991).  On the other hand, amino acids H13 and T15 both 
reside within the ‘receptor recognition loop’ of the molecule, a key region for binding 
to the CXCR1 (Schraufstatter, Ma et al. 1995), but we did not observe marked 
alterations in antagonist activities as a result of either H13Y or T15K substitutions.  We 
knew that a non-conserved H13F substitution within the receptor recognition loop of 
bovine CXCL8(3-73)K11R/G31P (i.e., bG31P) has little effect on the molecule’s 
antagonist activity (Li, Zhang et al. 2002), although the conserved K11R substitution 
within bovine CXCL8 had a dramatic effect on receptor affinity (Li and Gordon 2001).  
Residues E35 and S37 reside just proximal to cysteine 34 (which sulfhydryl bonds 
directly into the ELR-CXC motif), and close to the junction of two β-pleated sheet 
regions of the molecule.  Thus, perturbations in this region, with their potential to be 
translated across the C7-C34 cysteine bond into the vicinity of the ELR motif or to 
significantly affect the orientation of these β-pleated sheets, could potentially have had 
significant effects on the activity of hbG31P.  But the non-conserved E35A substitution 
also did not significantly affect the molecule’s antagonist activity in vitro, and this is in 
accord with the previous report that Ala35 of human CXCL8 is not an important 
functional determinant (Clark-Lewis, Dewald et al. 1994).  The S37T substitution did 
yield a hbG31P analogue with slightly better antagonist activity against CXCL8-
induced neutrophil chemotaxis and ROI release, although it did not seem to 
differentially affect intracellular Ca2+ flux in CXCL8-stimulated cells.  Thus, it is 
possible that Thr37 of human CXCL8 may contribute modestly to the molecule’s 
affinity for the CXCR1.   
 Acute endotoxin-induced lung injury is characterized by an accumulation of 
neutrophils in the airways (Togbe, Schnyder-Candrian et al. 2006), largely driven by 
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 ELR-CXC chemokines (Cummings, Martin et al. 1999).  Our data confirmed that 
hbG31P blocked total and neutrophilic leukocyte infiltration of the airways, as well as 
the pulmonary hemorrhagic response in this condition.  The pulmonary neutrophil 
recruitment we observed would be related to ELR-CXC chemokine expression, but it 
could potentially also be affected by other mediators including, for example, LTB4, 
C5a (Tsai, Strieter et al. 2000; Woodruff, Arumugam et al. 2003; Chen, Lam et al. 
2006), or PAF (Lad, Olson et al. 1985).  Our antagonist blocked the ELR-CXC 
chemokines, but it is unlikely to directly affect the activities of such alternate agonists.  
The fact that hbG31P blocked ≈94% of the neutrophil infiltration of these endotoxemic 
airways raises the question of whether such alternate neutrophil chemoattractants are 
involved in this response and, if so, whether ELR-CXC chemokine antagonism in some 
way blocks these as well.  This suggests that ELR-CXC chemokine antagonism has 
effects above and beyond blockade of high-level neutrophil infiltration of the tissues.  
For example, it could block the activities of the CXCR1 and/or CXCR2 expressed on 
resident lung cells (e.g., epithelial cells; (Farkas, Hahn et al. 2005)) and thereby the 
initiation of the ELR-CXC chemokine responses in the tissues.  Since all neutrophil 
chemoattractants operate through G-protein coupled receptors (Murphy 1994), it 
remains to be seen whether G31P signaling has effects that go beyond simple blockade 
of the CXCR1 and CXCR2. 
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CHAPTER 4 : ELR-CXC CHEMOKINE RECEPTOR ANTAGONISM TARGETS 
INFLAMMATORY RESPONSES AT MULTIPLE LEVELS 2 
 
Chapter 4 overview 
In Chapter 3, we reported that hbG31P and its analogues fully retained the 
antagonist activities of bG31P.  To reach the final goal of developing a fully human form 
of CXCR1 and CXCR2 antagonist, recently, Ms Jennifer Town, Dr. Fang Li, and I 
generated a fully human form of bG31P from human CXCL8 (i.e., hG31P).  Jennifer and I 
characterized the antagonist activities of this human protein in in vitro bioassays and in 
vivo models.  They will be described in this chapter and also in Chapters -5,-6.  In this 
chapter, we mainly assessed the antagonist activities of hG31P for ELR-CXC chemokine-
induced neutrophil chemotaxis, ROI release, intracellular calcium flux, and apotosis.  We 
also tested the antagonist activities of hG31P in blocking cystic fibrosis patient sputum-
induced human neutrophil chemotaxis, and endotoxin-induced airway epithelial cell ELR-
CXC chemokine and cytokine release.  Moreover, we assessed the ability of hG31P to 
heterologously desensitize other GPCRs (e.g., C5aR, BLT1, FPR).  Jennifer characterized 
several important effects of hG31P, e.g., heterologous desensitization of GPCR, the 
neutrophil apoptosis experiments, and epithelial cell cytokine and chemokine release.  I 
was involved in setting up the neutrophil calcium flux and ROI release assays and 
examining the effects of the hG31P on neutrophil chemotaxis, calcium flux, and ROI 
release induced by ELR-CXC chemokines.  I also undertook in vivo model system, guinea 
pig airway endotoxemia, to examine the antagonist activities of hG31P in acute lung injury. 
Finally, Jennifer and I were responsible for analyzing the data. Dr. Gordon and I co-wrote 
the manuscript with contributions from the other co-authors.   
                                                 
2 Zhao Xixing, J.R. Town, F. Li, X. Zhang, D.Cockcroft, and J.R. Gordon.  ELR-CXC 
chemokine receptor antagonism targets inflammatory responses at multiple levels. 2009.  J 
Immunol. Mar 1; 182(5):3213-22. 
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 4.1. INTRODUCTION 
Neutrophil responses are a critical element in host defense during bacterial 
infections, but can also be overtly pathogenic.  Thus, during many inflammatory diseases 
neutrophils contribute more to the pathology than do the microbes themselves (Nathan 
2002).  Neutrophil recruitment is a complex process involving activation of local structural 
cells (e.g., epithelial cells) via pathogen-associated molecular pattern receptors, 
complement cascade products or arachidonic acid metabolites, such that the structural cells 
express inflammatory mediators (e.g., IL-1, CXCL8) (Smith, Fedyk et al. 2001).  These 
can in turn activate regional endothelial cells, which actively foster intravascular neutrophil 
retention via the now classical paradigm of chemokine- (e.g., CXCL8) and adhesion 
molecule-mediated rolling-arrest-diapedesis (Springer 1994; Baggiolini 1998).   
The ELR-CXC chemokines are a subgroup of the CXC chemokine family in which 
the amino sub-terminal two cysteine residues, which are separated by an alternate amino 
acid, are immediately preceded by a Glu-Leu-Arg motif.  They include CXCL1-3 and 5-8 
(growth-related oncogene α, β, and γ [GRO α, β, and γ], epithelial cell neutrophil-
activating peptide-78 [ENA-78], granulocyte chemotactic protein-2 [GCP-2], neutrophil 
activating peptide-2 [NAP-2], and interleukin-8 [IL-8], respectively) (Baggiolini 1998), 
which chemoattract and activate neutrophils via two closely related G protein-coupled 
receptors (GPCR), the CXCR1 and CXCR2.  CXCL8 binds both receptors with high 
affinity, while CXCL6 binds both receptors with lower affinity (Wolf, Delgado et al. 1998; 
Wuyts, Proost et al. 1998).  The other ELR-CXC chemokines bind to the CXCR2, also 
with relatively lower affinities (Ahuja and Murphy 1996; Wuyts, Proost et al. 1998).  Both 
the CXCR1 and CXCR2 can trigger chemotactic responses and intracellular Ca2+ flux in 
neutrophils and contribute to elastase release (Chuntharapai and Kim 1995; Wuyts, Proost 
et al. 1998), but activation of the respiratory burst and phospholipase D release responses 
are reportedly CXCR1-dependent (Jones, Wolf et al. 1996), whereas CXCR2 signaling is 
critical to MMP-9 release (Chakrabarti and Patel 2005).  Moreover, these two receptors 
may be differentially involved in neutrophilic pathology in vivo.  For example, the CXCR1 
is reportedly of more importance in inflammatory bowel diseases (Gijsbers, Van Assche et 
al. 2004), sepsis and acute respiratory distress syndrome (Cummings, Martin et al. 1999; 
Goodman, Cummings et al. 1999), while both it and the CXCR2 play roles in synovial 
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 infiltration by neutrophils in arthritic joints (Podolin, Bolognese et al. 2002).  However, 
numerous alternate GPCR are involved in neutrophilic inflammation, including those for 
LTB4, C5a, and fMLP, such that antagonism of either LTB4 or C5a has been shown to be 
of significant benefit in various inflammatory settings (Wollert, Menconi et al. 1993; 
Crooks, Bayley et al. 2000; Park, Tofukuji et al. 2000).  The precise interrelationships of 
these mediators in inflammatory responses have not been formally determined, but it has 
been reported that signaling through the C5a or fMLP receptors can effectively desensitize 
the ELR-CXC chemokine receptors (Blackwood, Hartiala et al. 1996).  On the other hand, 
CXCL8 reportedly poorly desensitizes some events (e.g., intracellular Ca2+ flux) associated 
with C5a and fMLP receptor signaling (Tomhave, Richardson et al. 1994; Richardson, Ali 
et al. 1995), although it can desensitize chemotactic responses driven by these ligands 
(Blackwood, Hartiala et al. 1996). 
Some time ago we developed a very high affinity broad-spectrum ELR-CXC 
chemokine antagonist, bovine CXCL8(3–74)K11R/G31P (bG31P) (Li, Zhang et al. 2002; Li, 
Zhang et al. 2002) based on a high affinity bovine CXCL8 analogue, CXCL8(3–74)K11R (Li 
and Gordon 2001).  This antagonist could block CXCL8 binding to neutrophils, as well as 
neutrophil activation by agonists present in wash fluids from the lungs of cattle with 
bacterial pneumonia.  Bovine G31P fully antagonizes neutrophil responses to endotoxin 
challenge of cattle for more than two days after a single low-dose treatment (Li, Zhang et 
al. 2002), and blocks pyrexia, hemorrhagic consolidation, and pulmonary neutrophilia in 
airway endotoxemia in guinea pigs even if delivered after the onset of symptoms (Gordon, 
Li et al. 2005).  We also subsequently developed numerous human-bovine chimeric forms 
of bovine G31P that were as effective as bG31P in blocking ELR-CXC chemokine-
mediated pathology (Zhao, Li et al. 2007), and then developed a fully human form of 
G31P (hG31P).  However, some of the protective effects of bovine G31P in airway 
endotoxemia (Gordon, Li et al. 2005), for example, seemed to be somewhat tangentially 
related to its putative neutrophil-centered effects. For example, G31P treatment reduces 
endogenous pyrogen expression and pyrexia prior to the time when neutrophils were 
appreciably present in the airways, suggesting that it may have effects on structural (e.g., 
epithelial) cells.  Moreover, data from a study of its effects in aspiration pneumonia, 
wherein high level bacterial colonization of the lungs occurs, confirmed its effectiveness in 
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 this environment as well (Chapter 5).  In such cases the bacteria would release formyl 
peptides (e.g., fMLP) among other products and activate the complement cascade, leading 
to the generation of C5a.  Thus, we wished to explore further the mechanisms by which 
G31P might interact with airway epithelial cells, but also its effect on neutrophil responses 
to ligands for heterologous GPCR. 
 
4.2. MATERIALS AND METHODS 
4.2.1. Reagents and supplies    
The following reagents were purchased commercially: restriction endonucleases 
BamHI and EcoRI, T4 DNA ligase, DNA polymerase, fluo-4 AM, MEM [with L-
glutamine], HEPES, lipofectamine 2000, MEM non-essential amino acid solution 
(Invitrogen Canada Inc, Burlington, ON); QIAprep Spin Miniprep, QIAquick Gel 
Extraction Kits, QIA shredder and RNeasy Mini Kit (QIAGEN Inc, Mississauga, ON); 
QuickChangeTM Site-Directed Mutagenesis kit and Brilliant® qRT-PCR Master Mix Kit 
(Stratagene Cloning Systems, La Jolla, CA); glutathione-Sepharose, the expression vector 
pGEX-2T, benzamidine-Sepharose (Amersham-Pharmacia Biotech, Piscataway, NJ); 
aprotinin, dextran, endotoxin (Escherichia coli LPS, serotype 0127:B8), 
hexadecyltrimethylammonium bromide (HTAB), gelatin, isopropyl-thio-D-
galactopyranoside (IPTG), luminol, phenol red-free Hank´s Balanced Salt Solution 
(HBSS), phenylmethysufonyl fluoride (PMSF), tetramethylbenzidine (TMB), Triton X-
100, and dithiothreitol (DTT) (Sigma Chemical Co, Mississauga, ON); paired anti-CXCL8 
capture and detection antibodies and recombinant CXCL8 (R & D Systems, Minneapolis, 
MN); rabbit anti-human lactoferrin antibody, recombinant lactoferrin and biotinylated anti-
lactoferrin antibody (ICN Biomedicals, Inc, Irvine, CA); Lymphocyte Separation Medium 
density gradient medium (MP Biomedicals LLC, Aurora, ON); Diff-Quick stain kit 
(American Scientific Products, McGraw Park, IL); annexin V/PI staining kit (BD 
Biosciences, Rockville, MD); and five-week old female Hartley guinea pigs (Charles River 
Laboratories, Charles River, MA).  All the experiments were carried out according to the 
guidelines established by the Canada Council on Animal Care and were approved by 
University of Saskatchewan animal ethics review panel.   
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 4.2.2. Generation of hG31P   
A full-length human CXCL8 cDNA was synthesized commercially (Takara 
Biotech, Dalian, China).  From this we generated a glutathione-S-transferase (GST) fusion 
protein construct encoding amino acids 3-72 of human CXCL8, then introduced a Lys11-
to-Arg substitution (we reported previously that bovine CXCL8(3-72)K11R is a very high 
affinity CXCR1/CXCR2 agonist; ref (Li and Gordon 2001).  We next introduced a Gly31 
to Pro substitution, to generate human CXCL8(3-72) K11R/G31P (hG31P). Each plasmid 
was transformed into competent HB101 cells and their sequences were verified 
commercially (Plant Biotechnology Institute, Saskatoon, SK). The methods for expressing 
the constructs, cleaving the target proteins from their GST fusion partners, and purifying 
these have been described in detail (Li, Zhang et al. 2002; Li, Zhang et al. 2002).  Briefly, 
the recombinant bacteria were sonicated in the presence of the protease inhibitors aprotinin 
(2 mg/ml) and PMSF (50 mM), then the recombinant GST fusion proteins present in the 
sonicates were purified by affinity chromatography using glutathione-sepharose columns. 
The recombinant CXCL8 analogues were cleaved from their GST fusion partners by 
thrombin digestion and then further purified using benzamidine-sepharose columns.  The 
relative molecular mass and purity of each protein was verified by SDS-PAGE and 
Western blotting with biotinylated anti-human CXCL8 antibody (Li and Gordon 2001; Li, 
Zhang et al. 2002). 
 
4.2.3 Generation of CXCR1-transfected HEK293 cells.   
HEK293 cells (CRL-1573; American Type Culture Collection [ATCC], Manassas, 
VA) were transfected with the gene for the CXCR1 in the vector pCDNA3.1+ (Missouri 
S&T cDNA resource center; www.cdna.org) using lipofectamine.  The CXCR1-expressing 
cells were selected using gentamicin (800 µg/ml) and their expression of the CXCR1 gene 
was confirmed by FACS and qRT-PCR. 
 
 
 
 73
 4.2.4. Neutrophil chemotaxis assay   
Chemotaxis was assessed using modified Boyden chamber microchemotaxis assays 
(Li and Gordon 2001; Li, Zhang et al. 2002; Li, Zhang et al. 2002) with either purified 
neutrophils or CXCR1-transfected HEK cells.  For the former, human peripheral blood 
leukocytes were fractioned on standard density gradients, and the neutrophils harvested 
from the bottom of the gradients and cleared of contaminating red blood cells by hypotonic 
lysis.  The purified neutrophils (or HEK cells) were suspended at 2×106/ml in PBS+ 
(phosphate-buffered saline [PBS; pH 7.4], 1.2 mM MgCl2, 5 mM KCl, 0.5 mM CaCl2, 5 
mM glucose, and 0.1% bovine serum albumin).  The chemoattractants (e.g., CXCL8), 
either alone or together with hG31P, were placed in the lower compartment of the Boyden 
chamber wells and cells in the upper compartment, with the two compartments separated 
by polyvinylpyrrolidone-free, 5 (neutrophils) or 10 (CXCR1-HEK cells) µm pore-size 
polycarbonate filters. After incubation for 20 min (neutrophils) or 5 h (CXCR1-HEK cells) 
at 37°C in a 5% CO2 atmosphere, the cells that had migrated into the filters were fixed and 
stained using a Diff-Quick kit. The numbers of cells responding in each well were 
enumerated by direct counting of at least five 40× objective fields, and the results 
expressed as the mean number of cells per 40x field ± SEM. 
In a series of preliminary experiments we confirmed that CXCL1, CXCL5, and 
CXCL8 induced maximal neutrophil chemotactic responses at concentrations of 100, 100, 
and 10 ng/ml, respectively, while CXCL8 induced maximal CXCR1-HEK cell responses at 
100 ng/ml.  We also optimized the dilution of each sputum sample (i.e., 1:1 to 1:100) 
required to maximize its neutrophil chemotactic activity.  We tested the effects on sputum-
induced chemotactic responses by using hG31P at 0.1-100 ng/ml, and found that the 
antagonistic effects observed at 10 ng/ml were not altered by increasing the dose of hG31P 
(data not shown). 
 
4.2.5. Reactive oxygen intermediate release assay  
We used total white blood cell (WBC) preparations for the reactive oxygen 
intermediate (ROI) release assays.   To generate WBC, heparin-anticoagulated human 
blood was mixed with an equal volume of 6% (w/v) dextran (75 kD) in PBS, and then the 
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 tubes were allowed to stand upright and undisturbed for ≈1 h at room temperature. When 
the red blood cells had sedimented, the upper phase, comprising plasma, platelets and 
WBC, was centrifuged and the cell pellet resuspended at 2.5×106 cells/ml HBSS.  For the 
assays, we mixed 50 µl of WBC, 25 µl of human CXCL8 (final concentration, 100 ng/ml) 
or HBSS, 25 µl of HBSS or the indicated concentrations of hG31P, and 50 µl of luminol 
(0.3 mM).  We had confirmed in preliminary experiments that 100 ng/ml CXCL8 was 
optimal for induction of WBC ROI release, as determined by chemiluminescence using a 
microplate spectrofluorimeter (NovoStar, BMG LABTECH Inc. Durham, NC). The data 
are expressed as the maximum sample luminescence minus that of cells exposed to HBSS 
alone. 
 
4.2.6. Assay of intracellular Ca2+ flux 
Cells were purified as described above, and then washed twice with Ca2+-free PBS+ 
medium and suspended at 5×106 cells/ml in the same medium.  The cells were stained for 
30 min at 37˚C with 2 µM fluo-4 AM, then washed twice with Ca2+-free PBS+, 
resuspended at 4×106 cells/ml in PBS+ containing 3.3 nM Ca2+, and kept at room 
temperature until used for testing.  Prior to challenge, the cells were incubated for 15 min 
with medium or hG31P (100 ng/ml), then challenged with medium or human CXCL1, 
CXCL5, or CXCL8 (each, 100 ng/ml).  In preliminary experiments we had confirmed that 
100 ng/ml induced optimal intracellular Ca2+ flux in these cells, as determined using a 
microplate spectrofluorimeter (emission wavelength, 520 nm; excitation wavelength, 488 
nm). 
 
4.2.7 Heterologous desensitization of GPCR.   
Neutrophils were purified as above and resuspended in PBS+ medium at 2×106 
cells/ml, then stimulated with 0.1 nM C5a, 1 nM fMLP, or 1 ng/ml LTB4 in the presence 
of 0, 10 or 50 ng/ml hG31P.  The impact of the hG31P on the agonist-induced intracellular 
Ca2+ flux and chemotactic responses were measured as noted above.  These experiments 
were repeated three times. 
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 4.2.8. Sputum samples 
Sputum samples were collected for diagnostic purposes from 12 cystic fibrosis or 
bronchiectasis patients with bacterial pneumonia.  As controls for samples not associated 
with bacterial infections, sputa from two subjects with COPD or asthma were also obtained.  
For processing, the sputum mucus plugs were dispersed by treatment with 1% DTT/HBSS, 
then the cells were sedimented and the supernatants dialysed extensively against multiple 
changes of PBS, as noted previously (Swystun, Gordon et al. 2000; Gordon and Li 2002; 
Gordon, Swystun et al. 2003).  The levels of CXCL8 in each sample were determined by 
ELISA, as noted (Gordon, Swystun et al. 2003).  The supernatants were aliquoted and 
stored at -80˚C.  Sputum from healthy donors did not induce any significant neutrophil 
chemotactic responses (data not shown). 
 
4.2.9. Effects of hG31P on responses of A549 bronchial epithelial cells 
Human A549 bronchial epithelial cells (ATCC No.CCL185) were grown to a 
maximum of 90% confluence in 24-well plates in MEM (with L-glutamine) supplemented 
with 10% FBS, 0.01 M HEPES, and non-essential amino acids. Prior to stimulation, the 
cell monolayers were washed and provided with fresh medium, then exposed for 15 min at 
room temperature to 1-100 ng/ml of hG31P.  The indicated doses of LPS or 0 – 1.28×106 
unstimulated purified neutrophils from healthy donors were added to the cells, which were 
incubated for 16 h at 37 °C before the supernatants were collected.  Total RNA was 
collected from the cells using commercial extraction kits and standard approaches.  ELISA 
assays were used to quantify cytokine levels in the supernatant fluids, while qRT-PCR was 
used to quantify the relative mRNA levels. 
 
4.2.10. ELISA assay of lactoferrin and chemokines 
Our ELISA protocols have been reported in detail previously (Gordon, Swystun et 
al. 2003).   Culture supernatants were not diluted before the assays, while BAL fluids for 
lactoferrin assays were diluted 1:10.  The data are presented as pg/ml (IL-8) or ng/ml 
(lactoferrin), based on recombinant protein standard curves.  The cytokine ELISAs were 
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 sensitive to 5–10 pg/ml, while the lactoferrin assay was sensitive to 5 ng/ml.  Our CXCL8 
ELISA does not detect hG31P, as the capture antibody does not recognize this molecule 
(JRG, unpublished observation). 
 
4.2.11. Quantitative real time PCR (qRT-PCR)    
Total cellular RNA was quantified spectrophotometrically and stored at -80°C.  For 
the qRT-PCR, we used a commercial one-step master mix kit, with the thermal profile 
programmed as: first segment, 50°C for 30 min, and 95°C for 10 min (1 cycle); second 
segment, 95°C for 30 sec, 62°C for 30 sec, and 72°C for 30 sec (40 cycles); and third 
segment, the reading was taken at 72°C during the 30-sec plateau.  The sequences of the 
qRT-PCR primers were: GAPDH forward, 5’- TGC CTC CTG CAC CAC CAA C-3’ and 
reverse, 5’- GGC CAT CCA CAG TCT TCT GG-3’; CXCL1 forward, 5’- CCC AAG 
AAC ATC CAA AGT GTG A-3’ and CXCL1 reverse, 5’- GTC ACT GTT CAG CAT 
CTT TTC G -3’.  
 
4.2.12. Neutrophil apoptosis 
Human neutrophils were isolated as described above and resuspended at 5×106 
cells/ml in PBS+, then aliquoted into 96-well plates at 100 μl per well.  Medium (PBS+) 
alone or containing hG31P (100 ng/ml) was added to the cells and incubated for 15 min at 
room temperature, before addition of CXCL1 or CXCL8 (100 ng/ml) or carrier medium 
alone.  After 24 h at 37°C the cells were stained as per the manufacturer's instructions 
using FITC-labeled annexin V and propidium iodide for FACS detection of apoptotic and 
necrotic cells, respectively, then analyzed within one hour using FACScan flow cytometer. 
 
4.2.13. In vivo confirmation of the anti-inflammatory activities of G31P 
The assessment of hG31P’s effect on 15 h airway endotoxemia pathology in guinea 
pigs has been described previously for the bovine and human-bovine chimeric forms of 
G31P (Gordon, Li et al. 2005; Zhao, Li et al. 2007).  Briefly, for challenge the animals (n = 
5) were challenged with a 200 µl bolus of LPS (5 µg/kg) in sterile saline by intranasal 
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 intubation. At 30 min before challenge, 250 µg/kg hG31P or an equivalent volume (1 ml) 
of saline was given s.c. and at 4, 8, or 16 h post-challenge the animals were euthanized 
with halothane. Bronchoalveolar lavage fluid (BAL) was collected using 2.0 ml volumes of 
sterile saline.  BAL total WBC and red blood cells were enumerated by direct counting, 
and the results expressed as the mean number of cells per BAL sample (± SEM).  BAL cell 
differentials were determined using Wright’s solution-stained BAL cell cytospin 
preparations and the total numbers of neutrophils were calculated using these data.  All the 
data are expressed as means ± SEM.  All BAL fluids were assessed independently (either 
immediately or after storage at –80°C) for myloperoxidase (MPO), matrix 
metalloproteinase-9 (MMP-9), MMP-2, and lactoferrin (LF). This experiment as repeated 
twice. 
 
4.2.14. Myeloperoxidase assay 
BAL fluids (10 µl) were diluted 10-fold with 0.5% HTAB and incubated at 
room temperature for 10 min with 10 volumes of TMB, before stopping the reactions 
with 10 volumes of 1M phosphoric acid. The reactions were quantified by 
spectroscopy (OD, 450 nm) and the data expressed as the mean OD450 ± SEM.  Each 
sample was assayed in triplicate. 
 
4.2.15. Assessment of BAL fluid MMP-9 levels   
BALF levels of MMP-2 and -9 were measured by gel zymography, as previously 
described (Chakrabarti and Patel 2005).  Briefly, 20 μl samples of BAL sample were run 
on 7.5% SDS-PAGE gels containing 1 mg/ml gelatin. The gels were incubated overnight at 
room temperature in 2.5% Triton X-100, 50 mM Tris-HCl, 10 mM calcium chloride, 1 
mM zinc chloride, rinsed in deionized water for 30 min, and then incubated overnight at 
37°C in 50 mM Tris-HCl, 10 mM calcium chloride, 1 mM zinc chloride, before staining 
with Coomassie brilliant blue. The identities of the gelatinolytic MMP-2 and -9 bands were 
determined based on their molecular weights and comparison with standards prepared from 
homogenates of untreated HT1080 fibrosarcoma cells (ATCC CCL21)(Sariahmetoglu, 
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 Crawford et al. 2007).  The results are expressed as relative densitometry units for each 
gelatinase band. 
 
4.2.16. Statistical analysis 
Two-group comparisons were made using student’s t-tests (two-tailed).  We used 
Spearman Rank correlation analyses to assess the correlations between the sputum 
cytokine levels and their associated responses.  All results are expressed as the mean ± 
SEM. 
 
4.3. RESULTS 
4.3.1. Human CXCL8(3-72)K11R/G31P effectively antagonizes both CXCR1- and 
CXCR2-dependent activation of neutrophils.    
To confirm unequivocally whether human CXCL8(3-72)K11R/G31P (hG31P) acts at 
least in part through the CXCR1 we employed CXCR1-transfected HEK293 cells.  We 
confirmed by FACS (data not shown) and qRT-PCR (Fig. 4.1A) that these cells express this 
receptor but not the CXCR2 (data not shown) and that 100 ng/ml CXCL8 induced 
chemotactic and intracellular Ca2+ flux responses.  At 10 ng/ml hG31P blocked CXCL8-
induced chemotactic responses by ≈80%, while at 100 ng/ml (but not 10 ng/ml; data not 
shown) it dramatically reduced intracellular Ca2+ flux (Fig. 4.1A).  Given that the biological 
differences between CXCR1-transfected HEK cells and neutrophils, we also confirmed with 
freshly purified human neutrophils that hG31P blocked CXCL8 (10 ng/ml)-induced 
chemotaxis and reactive oxygen intermediate (ROI) release (Fig. 4.1B).  It is noteworthy that 
neutrophil superoxide release is reportedly attributable exclusively to CXCR1 signaling (15).  
We also found that 10 ng/ml hG31P markedly attenuated intracellular Ca2+ flux induced by 
100 ng/ml CXCL8 (Fig. 4.1B).  We then assessed hG31P’s ability to block activation of 
neutrophils induced by CXCR2-exclusive ligands.  As with CXCL8, hG31P dose-
dependently blocked chemotactic responses of neutrophils to CXCL1 and CXCL5 (both 100 
ng/ml), while 10 ng/ml hG31P ≥95% reduced intracellular Ca2+ flux induced by an optimal 
dose (100 ng/ml) of either ligand (Fig.4.1C).  It is noteworthy that, overall, CXCL8 was a 
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 substantially stronger agonist than either CXCL1 or CXCL5 in terms of inducing this 
intracellular Ca2+ response. 
 
4.3.2. Human G31P induces heterologous desensitization of alternate G protein-
coupled receptors. 
Numerous neutrophil agonists, including C5a, LTB4, ELR-CXC chemokines, and 
fMLP, signal into these cells via distinct G protein-coupled receptors (GPCR).  It has been 
shown previously that signaling through C5a, fMLP, or CXCL8 can reciprocally 
desensitize neutrophil chemotactic responses to subsequently introduced heterologous 
ligands (Blackwood, Hartiala et al. 1996).  On the other hand, CXCL8 reportedly does not 
effectively desensitize C5a- or fMLP-induced neutrophil activation as assessed by 
intracellular Ca2+ flux (Tomhave, Richardson et al. 1994; Richardson, Ali et al. 1995).  In 
assessing G31P’s relative capacity to affect heterologous GPCR signaling, it is important 
to recognize that G31P has a much higher affinity for its receptors than do the ELR-CXC 
chemokines.  Thus, bovine G31P inhibits by 50% the chemotactic responses of neutrophils 
to a ≈250-fold higher concentration of native ligand (i.e., CXCL8) (Li, Zhang et al. 2002).  
We wished to assess then the extent to which hG31P would desensitize neutrophil 
responses to ligands such as C5a, fMLP, and LTB4, each of which are relevant neutrophil 
agonists in inflammatory conditions.  Thus we examined hG31P’s impact on intracellular 
Ca2+ flux and chemotactic responses induced by each of these (Fig.4.2.). We found that 0.1 
nM C5a induced marked Ca2+ flux in neutrophils, as well as chemotactic responses, and 
that the addition of hG31P reduced C5a-mediated chemotaxis by ≥50%, although its 
impact on intracellular Ca2+ flux was substantially more modest.  The bacterial tripeptide 
fMLP induced a much more robust Ca2+ flux response than did C5a, but an essentially 
equivalent chemotactic response.  The hG31P treatment very substantially reduced both the 
Ca2+ and chemotactic (85% reduced) responses.  LTB4 was a strong neutrophil agonist in 
both assays and, as with fMLP, hG31P substantially reduced LTB4-induced Ca2+ flux and 
chemotactic (≈67% reduction) responses.  Taken together, these data show that hG31P did 
dampen neutrophil responses to each of these heterologous GCPR ligands. 
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Figure 4.1. The ELR-CXC chemokine antagonist CXCL8(3-72)K11R/G31P operates by 
targeting the CXCR1 and CXCR2 on neutrophils.  
 
 
  (A) We generated CXCR1-transfected HEK293 cells and used these to determine 
whether human (h) G31P acts via the CXCR1.  We used qRT-PCR to assess CXCR1 
expression by control and CXCR1-transfected HEK cells and compared this expression 
with that of peripheral blood neutrophils (left panel).   For the chemotaxis assays, 
responses to an optimized concentration of CXCL8 (10 ng/ml) were assessed using 
modified Boyden chamber microchemotaxis assays, as noted in the Materials and Methods. 
The ability of hG31P (10 ng/ml) to antagonize this response was assessed by 
simultaneously exposing the cells to the agonist and antagonist.  The results are expressed 
as the mean (±SEM) number of cells/40x objective microscope field (middle panel).  For 
the Ca2+ flux assays, neutrophils were labeled with the Ca2+ indicator dye fluo-4AM and 
assayed in the presence (100 ng/ml) or absence of hG31P for chemokine (100 ng/ml) -
induced intracellular Ca2+ flux as described in the Materials and Methods (right panel).   (B) 
We also assessed whether hG31P could antagonize CXCL8-dependent chemotaxis, 
reactive oxygen intermediate (ROI) release, and intracellular Ca2+ flux responses by 
purified human neutrophils using the same approaches as in panel A.  (C) In order to 
confirm that hG31P also acted via the CXCR2 we tested its ability to antagonize neutrophil 
chemotactic and intracellular Ca2+ flux responses induced by the CXCR2-exclusive ligands 
CXCL1 and CXCL5 (both 100 ng/ml).  Our data confirm that hG31P did effectively 
antagonize both CXCR1- and CXCR2-dependent responses.  * and **, p < 0.05 and 0.01, 
respectively, relative to the chemokine treatments alone.  The data shown are 
representative of at least three experiments performed with similar results.  The dashed 
lines across graphs in panels A, B, and C represent the mean background response in the 
indicated assays. 
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Figure 4.2.  Human G31P engagement of neutrophils induces heterologous 
desensitization of their G protein-coupled receptors for C5a, LTB4, and fMLP.  
 
Purified Purified human neutrophils were stimulated with 0.1 nM C5a, 1 nM fMLP, 
or 1 ng/ml LTB4, in the absence or presence of 10 or 50 ng/ml of hG31P, as described in 
the Material and Methods. (A) The ability of hG31P (10 ng/ml) to interfere with the 
agonist-induced intracellular Ca2+ flux was assessed as in Fig. 1.  (B) The abilities of 
varying doses of hG31P to block the cells’ chemotactic responses were also assessed as 
above.  G31P very substantially reduced Ca2+ flux induced by fMLP and LTB4, but was 
less effective in blocking C5a-dependent Ca2+ flux, and this relative efficacy was observed 
also in the chemotaxis assays.   * and **, p < 0.05 and 0.01, respectively, relative to the 
agonist treatments alone.  The data shown are representative of at least three experiments 
performed with similar results. The dashed lines across graph in panel B represents the 
mean background response in the assay.  
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 4.3.3. Human G31P effectively antagonizes the inflammatory mediators present in 
sputum from bacterial pneumonia patients   
As suggested above, inflammatory diseases are marked by the simultaneous 
expression of numerous neutrophil agonists.  Sputum from cystic fibrosis (CF) patients, for 
example, can contain CXCL8 and other CXC chemokines, LTB4, formyl peptides (e.g.,, 
fMLP), and perhaps C5a (Mackerness, Jenkins et al. 2008).  Thus, given that our data 
documenting that hG31P can variably desensitize these receptors we wished to know just 
how effective it would be in blocking the agonists present in inflammatory samples.  Thus, 
we obtained a bank of sputa from 12 CF and bronchiectasis patients being treated for 
bacterial pneumonia and directly tested the impact of hG31P on their neutrophil chemotactic 
activities (Fig. 4.2.).   The disease status of the CF donors was classified as advanced, severe, 
moderate or mild, and that of the bronchiectasis donors as severe or moderate, or frank 
bacterial pneumonia, based on clinical criteria.  We included sputum from one asthmatic and 
one chronic obstructive pulmonary disease (COPD) subject as controls.  We assessed the 
levels of CXCL8 in each sputum sample (Fig. 4.3.; values above the sample bars) and found 
that these correlated positively with the samples’ ability to induce neutrophil chemotaxis 
(r=0.63 [14 DF], p=0.013).  At 10 ng/ml hG31P ≈60-95% inhibited the chemotactic 
responses of neutrophils from healthy blood donors to the sputum from 10 of the 12 cystic 
fibrosis and bronchiectasis donors.  Only sputum from the two donors classified as having 
advanced cystic fibrosis (donors 1 and 2) appeared more or less resistant to the antagonistic 
effects of hG31P in this assay.  Interestingly, the relative ability of hG31P to block sputum-
induced neutrophil chemotactic activities (i.e., percent inhibition) was not significantly 
correlated with the levels of CXCL8 in the samples (r=0.369 [14 DF], p=0.15).  For example, 
sample 1 contained 3.09 ng/ml of CXCL8 and was only modestly affected by hG31P, while 
sample 10 contained 3.32 ng/ml CXCL8 and its activity was almost ablated by the hG31P 
treatment. The sputum from the asthmatic and COPD subjects also induced marked 
neutrophil responses and hG31P largely blocked these too; we have reported previously that 
sputum from asthmatic subjects contains high levels of CXCL8 (Gordon and Li 2002). 
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Figure 4.3.  Human G31P antagonizes the neutrophil chemotactic activities present in 
sputum from cystic fibrosis (CF) and bronchiectasis patients with bacterial 
pneumonia. 
 
Sputum samples were collected from 12 CF or bronchiectasis patients with 
bacterial pneumonia as well as two control subjects with COPD or asthma, and assayed for 
their CXCL8 content (values above the black bars).  The abilities of hG31P (10 ng/ml) to 
antagonize chemotactic responses of neutrophils from healthy donors to optimized 
dilutions of the sputa were assessed as in Fig. 4.1.  The data are expressed as the mean 
(±SEM) number of cells/40x objective microscope field.  The assays were repeated twice 
and gave essentially the same results each time. Sputum from healthy donors did not 
induce any significant neutrophil chemotactic responses (data not shown).  With the 
exception of samples 1 and 2, G31P significantly reduced the cells chemotactic responses.  
**, p≤0.01 versus no G31P treatment.  The chemotaxis assays were repeated twice. The 
dashed line across the graph represents the mean background response in the assay. 
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 4.3.4. Human G31P blocks ELR-CXC chemokine-mediated anti-apoptotic effects in 
neutrophils. 
As neutrophils leave the vasculature or become effete they rapidly undergo 
programmed cell death or apoptosis as a means of preventing adventitious host pathology.  
However, during inflammatory events it is in the best interest of the host to maintain these 
cells in a viable state such that they can effectively engage microbial targets.  An array of 
inflammatory mediators, including the ELR-CXC chemokines, have anti-apoptotic effects on 
neutrophils (Glynn, Henney et al. 2002).  We wished to know then whether hG31P’s anti-
inflammatory effects would extend to reversing chemokine-induced anti-apoptotic processes, 
thereby allowing neutrophils to quickly progress into apoptosis.  We used FITC-annexin V 
binding as our assay of apoptosis.  We stained freshly purified neutrophils with this marker 
as a negative control (shaded signal, Fig. 4.4.) and cells that had been cultured for 18 h in 
medium alone as an apoptosis positive control (Fig. 4.4., upper panel).  The freshly purified 
cells appeared to have two levels of annexin binding, with most cells being more or less 
negative and a smaller proportion binding moderate levels of this apoptosis marker.  When 
we added CXCL8 to the cells (Fig. 4.4., middle panel, dashed line) there was a marked 
diminution of the numbers of cells that strongly bound annexin V and the addition of hG31P 
to these cultures fully reversed this CXCL8-induced anti-apoptotic activity.  CXCL1 also 
had protective effects on neutrophils, but they were subtly different than those of CXCL8 
(Fig. 4.4, bottom panel, dashed line).  The CXCL8-protected cells had largely bound 
intermediate levels of annexin V, while those incubated with CXCL1 bound either very low 
or intermediate levels of annexin.  The addition of hG31P to the CXCL1 cultures induced a 
substantial proportion of the cells to upregulate their apoptotic processes, but nevertheless 
there remained a significant population of cells that bound intermediate levels of annexin. 
 
4.3.5. Human G31P antagonizes the inflammatory cycle in endotoxin-challenged 
bronchial epithelial cells   
Exposure of the airway epithelium to bacterial endotoxin triggers a pulmonary 
inflammatory response, wherein these cells secrete CXCL8, for example, which directly 
fosters neutrophil recruitment into this tissue compartment.  While we have shown that  
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Figure 4.4.  Human G31P reverses the anti-apoptotic influence of CXCL1 and 
CXCL8 on neutrophils. 
 
Purified human neutrophils were cultured for 18 h in medium alone (apoptosis 
positive control; top panel) or in the presence of 100 ng/ml CXCL1 or CXCL8, either with 
(solid lines) or without (dashed lines) hG31P (100 ng/ml), and stained with fluorochrome-
labeled annexin V.  The proportions of apoptotic (annexin V-binding) cells were 
determined by FACS.  Negative control results obtained using freshly purified annexin V-
stained neutrophils (shaded tracing) are included in each graph.  Necrotic cell death was 
also assessed by propidium iodide uptake; we found ≤3% propidium iodide-positive cells 
in all samples. The data indicate that cells incubated in medium alone were largely 
apoptotic.  Exposure to CXCL8 or CXCL1 reduced apoptosis very substantially, but 
addition of hG31P to these cultures largely reversed the ELR-CXC chemokine-induced 
anti-apoptotic effects.  These assays were repeated three times. 
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 hG31P antagonizes the impact of the ELR-CXC chemokines on neutrophil responses, little 
attention is paid to whether epithelial cells themselves respond to the ELR-CXC chemokines 
they elaborate in airway endotoxemia, or to the neutrophils they recruit.  We thus decided to 
investigate this using human type II alveolar A549 epithelial cells that we challenged with 
bacterial endotoxin (Fig 4.5.) in the presence or absence of hG31P.  The quiescent A549 
cells secreted very little CXCL8, but LPS dose-dependently up-regulated their expression of 
this chemokine.  Reports of CXCR1 and CXCR2 expression by epithelial cells vary, so we 
wished first to determine whether our A549 cells expressed either of these receptors.  We 
used qRT-PCR and did indeed detect significant levels of the CXCR1 (Fig. 4.5A, right panel) 
but little in the way of CXCR2.  When we challenged our A549 cells with 10 ng/ml LPS in 
the presence of increasing doses of hG31P, the cells produced progressively less CXCL8 
(Fig. 4.5B).  This effect extended also to their expression of CXCL1, wherein hG31P 
reduced LPS-induced CXCL1 expression by ≈98%, as determined by qRT-PCR.   
Neutrophils release a variety of mediators that are potential epithelial cell agonists 
(e.g., elastase; (Chen, Lin et al. 2004), while epithelial cells similarly secrete neutrophil 
agonists.  This suggests the possibility that these cells could through a putative mutual 
stimulatory mechanism drive an escalating inflammatory process.  We tested this by co-
culturing purified otherwise quiescent neutrophils with monolayers of resting A549 cells.   
While the neutrophils were largely unstimulated, there was a significant background 
release of CXCL8 by these cells over 16 h in culture (Fig. 4.6).  Nevertheless, simple co-
culture of these neutrophils with A549 cells induced a synergistic expression of CXCL8 in 
the cultures, and this effect was dependent on the numbers of neutrophils added to the 
cultures (Fig. 4.6).  The A549 cells did not secrete significant amounts of CXCL8 when 
cultured on their own.  The addition of hG31P to these co-cultures dramatically (up to 98%) 
reduced the expression of CXCL8 (p≤0.01; Fig. 4.6.). 
 
4.3.6. Human G31P blocks airway endotoxemia-induced acute lung inflammation   
The observations that a fully human form of G31P blocked inflammatory responses 
at multiple levels (e.g., heterologous desensitization of GCPR, pro-apoptotic effects, 
blockade of the autocrine epithelial inflammatory cycle) suggested that it could be effective  
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Figure 4.5.  Human G31P antagonizes the endotoxin-induced inflammatory cycle in 
human bronchial epithelial cells.    
 
Monolayers of A549 bronchial epithelial cells were exposed to (A) varying doses of 
endotoxin, and the culture supernatant collected 16 h later and assayed by ELISA for 
CXCL8 (left panel).  Expression of the CXCR1 or CXCR2 by the A549 cells and human 
neutrophils was assessed by qRT-PCR using specific primers (right panel). Our data indicate 
that peak CXCL8 expression was found in the A549 cultures that were challenged with 10 
µg/ml LPS, and that our A549 cells expressed significant levels of CXCR1, though certainly 
much less than that found in neutrophils.  (B)  A549 cell monolayers were challenged with 
10 µg/ml of LPS in the presence of the indicated concentrations of hG31P, and 16 h later the 
culture supernatants and cellular RNA was isolated and assayed for CXCL8 protein (ELISA) 
and CXCL1 mRNA (qRT-PCR).   Addition of hG31P to the A549 cells dose-dependently 
suppressed expression of both chemokines by the LPS-challenged cells. * and **, p < 0.05 
and 0.01, respectively, relative to the baseline treatments alone.  The data shown are from 
one experiment that is representative of at least three experiments performed. 
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Figure 4.6.  Co-culture of quiescent A549 cells with unstimulated peripheral blood 
neutrophils leads to syngergistic CXCL8 expression. 
 
The indicated numbers of quiescent, purified human peripheral blood neutrophils 
from healthy donors were either cultured alone (PMN alone) or added to monolayers of 
unstimulated A549 cells (A549+PMN).  G31P (100 ng/ml) was added to half of these 
cultures and 16 h later the culture supernatants were harvested assayed for CXCL8 by 
ELISA.  The addition of neutrophils to the A549 cells synergistically enhanced expression 
of CXCL8 in a cell concentration-dependent fashion, and hG31P antagonized this cytokine 
response. * and **, p < 0.05 and 0.01, respectively, relative to the no hG31P treatments 
alone.  The data shown are from one blood donor that is representative of the responses of 
three such donors. 
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 also in blocking inflammatory responses in vivo.  We have shown that bovine and bovine-
human chimeric orthologues of human G31P can block an array of inflammatory pathologies, 
including airway endotoxemia (Gordon, Li et al. 2005; Zhao, Li et al. 2007), aspiration 
pneumonia (footnote 3), ischemia-reperfusion injury (Zhao et al, manuscript in preparation), 
and environmental pollutant-induced lung injury (Podechard, Lecureur et al. 2008).  While 
we know in airway endotoxemia that bovine G31P treatments reduce neutrophil infiltration 
of the airways, it remains possible that neutrophils marginate in the pulmonary vasculature 
under the influence of the inflammatory mediators expressed in this compartment and are 
activated in situ.  For this reason we wished to determine whether we could detect markers of 
the individual neutrophil granules or of activated structural cells in the lungs of endotoxemic 
animals.  We induced airway endotoxemia in guinea pigs as reported previously (Gordon, Li 
et al. 2005; Zhao, Li et al. 2007) and assessed the levels of myeloperoxidase (MPO; 1˚ 
granules), lactoferrin (LF; 2˚ granules), and matrix metalloproteinase-9 (MMP-9; 3˚ granules) 
at 4, 8, and 16 h after endotoxin challenge.  We confirmed that hG31P did indeed reduce 
airway neutrophilia (90-99% reduced at 4, 8 and 16 h; p≤0.01 versus saline-treated animals).  
In concert with this there were significant reductions in the BAL levels of myeloperoxidase 
(MPO; p≤0.05, 8 h time-point only), lactoferrin (LF; p≤0.05, all times), and matrix 
metalloproteinase-9 (MMP-9; p≤0.05, 4 and 8 h time-points), which suggested that few 
neutrophils that did achieve the lungs were not sufficiently activated to degranulate.  We 
coincidentally observed a strong signal from a 68 kD gelatinase (Fig. 4.7.) that co-migrated 
with MMP-2 expressed in positive control HT1080 fibrosarcoma cells (data not shown), 
suggesting that we had indeed strongly activated the lung epithelium and other structural 
cells that express this metalloproteinase (D'Ortho, Jarreau et al. 1994; Fligiel, Standiford et al. 
2006).   G31P treatment also essentially abrogated this response at each time suggesting that, 
as we had observed with our A549 cells, structural cells were also influenced by ELR-CXC 
chemokine antagonism in vivo. 
 
4.4. DISCUSSION 
We have generated a human orthologue of bovine CXCL8(3–74)K11R/G31P (bG31P; 
ref.(Li and Gordon 2002; Li, Zhang et al. 2002).  We show in this study that this human  
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Figure 4.7.  Human G31P treatments of airway endotoxemic animals reduce neutrophil 
recruitment and activation within the airways. 
 
Airway endotoxemia was induced in guinea pigs by i.n. instillation of bacterial 
endotoxin (5µg/kg).  The animals (n=5) were treated 30 min prior to challenge with either 
saline (black bars) or G31P (grey bars; 250 µg/kg) and euthanized 4, 8, or 16 h later.  
Differential counts were done on the cells recovered by bronchoalveolar lavage (BAL) and 
the BAL fluids were assessed for the levels of myeloperoxidase (MPO), lactoferrin (LF), 
and matrix metalloproteinase-9 (MMP-9), as specific markers of neutrophil primary, 
secondary, and tertiary granules, respectively, as noted in the materials and methods. The 
MMP-9 graphical data are drawn from the zymogram (lower panel) by gel scanning 
densitometry.  The zymogram shows  the BAL levels of MMP-9 (92 kD) and MMP-2 (68 
kD), an activation marker of lung structural cells.  The G31P treatments dramatically 
reduced neutrophil activation in the airways as well as structural cell activation. *, p<0.05 
and **, p<0.01 as compared with LPS plus saline treatment only.  Data are expressed as 
the mean ± SEM, and are representative of two repeat experiments. 
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 G31P specifically blocks activation of neutrophils through the CXCR1 and CXCR2, and 
thereby their chemoattraction into inflammatory foci and expression of reactive oxygen 
intermediates (ROI).  In engineering bovine G31P from its parent molecule, CXCL8, our 
first step was to introduce high affinity into the molecule, which we did by amino terminal 
truncation and substitution of a lysine in place of Arg11 to generate CXCL8(3-74)K11R (Li 
and Gordon 2001).  These arguments were in part based on prior work with human 
CXCL8 by Ian Clark-Lewis (Clark-Lewis, Schumacher et al. 1991; Clark-Lewis, Dewald 
et al. 1994), although the bovine form of CXCL8(3-74)K11R appeared to have unexpectedly 
high agonist activity relative to its closest human counterpart (Li and Gordon 2001).  We 
next reduced the receptor signaling activity of this agonist by introducing a Gly residue in 
place of Pro31 to generate an antagonist that fortuitously had exceptionally high affinity 
relative to CXCL8 (Li, Zhang et al. 2002).  We hypothesize that it is this augmented 
receptor affinity that allows hG31P to so effectively compete with native ELR-CXC 
chemokines for their receptors on neutrophils.  It makes sense that G31P would operate via 
both the CXCR1 and CXCR2 because its parent molecule was CXCL8, a high affinity 
ligand of both receptors (Jones, Wolf et al. 1996; Jones, Dewald et al. 1997).  Our data 
showing that hG31P blocks CXCL8-dependent intracellular Ca2+ flux and chemotaxis in 
CXCR1-transfected HEK cells confirms unequivocally that hG31P targets the CXCR1, 
and the fact that it blocks the activities of CXCL1 and CXCL5, which are exclusive 
CXCR2 agonists (Jones, Wolf et al. 1996; Jones, Dewald et al. 1997), similarly confirms 
its interactions with these receptors. 
We also documented herein that hG31P desensitizes heterologous GPCR in a 
quantitatively better fashion than CXCL8 (Blackwood, Hartiala et al. 1996), likely in part 
because of its high affinity interactions with the CXCR1 and CXCR2 (Li, Zhang et al. 
2002).  Thus, hG31P blocked both intracellular Ca2+ flux and chemotactic responses of 
neutrophils to signaling via CD88/C5aR (the C5a receptor), BLT1 (the LTB4 receptor), 
and FPR (the fMLP receptor), although it was not as effective in desensitizing C5a-
dependent Ca2+ flux as that associated with LTB4 or fMLP signaling.  It has been reported 
that in responding to signals generated in inflammatory settings, neutrophils adopt a 
hierarchical response pattern, with responsiveness to agonists immediately responsible for 
recruitment from the vasculature (e.g., CXCL8, LTB4) being superceded as the cells 
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 traverse the blood vessel wall by responsiveness to those that would draw the cell to the 
pathogen itself (e.g., C5a, fMLP) (Heit, Tavener et al. 2002).  This effect is reportedly 
brought about by C5a- and fMLP-driven activation of MAPK in neutrophils, which 
dampens Akt activation, a critical event in responses to CXCL8 and LTB4 (Heit, Tavener 
et al. 2002).  In the context of a bacterial infection, for example, this process would make a 
great deal of sense, since as the neutrophil moves into the tissues and towards the pathogen 
it must necessarily concentrate its resources on that target.  In support of this, it had also 
been reported that while the fMLP and C5a receptors can cross-desensitize one another and 
the CXCL8 receptor, CXCL8 signaling cannot reciprocally desensitize Ca2+ flux or a 
number of other intracellular events downstream of the fMLP or C5a receptors (Tomhave, 
Richardson et al. 1994; Richardson, Ali et al. 1995).  At odds with this, however, is the 
report that while the CXCR2 cannot desensitize the CD88 or FPR, CXCR1 signaling can 
do so, albeit at significantly lower levels that that seen with C5a or fMLP-induced CXCL8 
receptor desensitization (Richardson, Pridgen et al. 1998).  Also at odds is the report that 
CXCL8 signaling desensitizes neutrophil chemotactic responses to subsequent C5a or 
fMLP exposures (Blackwood, Hartiala et al. 1996).  Our own data clearly indicated that 
hG31P desensitizes neutrophil responses to fMLP, C5a, and LTB4, as noted likely related 
to high affinity interactions with its receptors.  This could in part explain its effectiveness 
in dampening the pathology associated with airway endotoxemia in our model.  It is known 
that endotoxin activates C5 to generate C5a (Smedegard, Cui et al. 1989), and it seems 
reasonable to suggest that commercial endotoxin preparations such as we used would 
likely be contaminated with bacterial tripeptides (e.g., fMLP).  Furthermore, given that 
LTB4 antagonism is of significant benefit in airway endotoxemia (Fink, O'Sullivan et al. 
1993; Wollert, Menconi et al. 1993), it is also reasonable to suggest that this agonist would 
also have been present in our endotoxemic animals, although we did not assess this.  This 
suggests that the neutrophilic pathology we observed could well be related to the combined 
effects of multiple agonists, including ELR-CXC chemokines, C5a, LTB4, and perhaps 
fMLP.  We hypothesize that hG31P’s ability to ameliorate this pathology is attributable to 
its ability to not only block the CXCR1 and CXCR2, but also desensitize these other 
GPCR. 
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 Another important finding in this study was that hG31P also antagonized the 
responses of airway epithelial cells to bacterial endotoxin.  Our data shows that A549 cells 
express the CXCR1, although epithelial expression of the CXCR1 or CXCR2 is not 
uniform. While unstimulated BEAS2B or colonic epithelial cells don’t express the CXCR-
1 or -2 (Dwinell, Eckmann et al. 1999; Farkas, Hahn et al. 2005), epithelial cell lines from 
cystic fibrosis patients (IB3-1 and CFBE41o-) do express these receptors (Boncoeur, Criq 
et al. 2008).  On the other hand, hypoxic Caco-2 and HT-29 bronchial epithelial cells 
express the CXCR1 (but not the CXCR2) and undergo chemotactic responses to CXCL8 
signaling (Sturm, Baumgart et al. 2005).  This could suggest that inflammatory signals 
upregulate expression of these receptors, but in A549 cells, at least, LPS stimulation does 
not alter their expression of the CXCR1 or CXCR2 (J. Town, unpublished observation).  
The blockade of CXCL8 expression in LPS-stimulated epithelial cells by hG31P leads us 
to speculate that CXCR1 ligands are autocrine inflammatory mediators for these cells.  It 
had been reported previously that CXCL8 is an autocrine growth factor for pancreatic 
tumour (Takamori, Oades et al. 2000) and melanoma (Schadendorf, Moller et al. 1994; 
Norgauer, Metzner et al. 1996) cells but, as far as we are aware, this is the first 
demonstration that ELR-CXC chemokine expression can be a self-perpetuating event for 
epithelial cells.  We also found that simple co-culture of quiescent human neutrophils with 
A549 cells strongly induced CXCL8 expression in these cultures and that G31P interrupts 
this response, dramatically reducing chemokine production. We did not determine which 
population of cells was activated in these co-cultures and therefore responsible for the 
cytokine expression.  A number of mediators released from activated neutrophils (e.g., 
cathepsin G, elastase, defensins) can induce the release of CXCL8 from respiratory 
epithelial cells and, reciprocally, a number of epithelial products are neutrophil agonists 
(Khair, Davies et al. 1996; Skerrett, Liggitt et al. 2004).  Although neutrophils can be 
readily activated by the procedures used in their isolation (Venaille, Misso et al. 1994; 
Link, Hummel et al. 1997), when cultured alone neither the epithelial cells or neutrophils 
secreted substantial amounts of CXCL8, indicating that the interactions between these two 
cells were instrumental in their induction, and that endotoxin contamination of our culture 
medium by itself would not explain our observations.  More importantly, G31P was able to 
interfere with these intercellular interactions sufficiently to ameliorate their influence on 
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 one another.  The remarkable degree to which G31P dampened neutrophilic inflammation 
in our airway endotoxemic animals suggests that its ability to block the interactions 
between bronchial epithelial cells and those neutrophils that did find their way into the 
airways could be another integral component of its therapeutic effects.   
Neutrophils are continuously generated in the bone marrow and released into the 
circulation at exceptionally high rates, which means of course that they need to be equally 
quickly disposed of if a homeostatic balance is to be maintained.  Thus, neutrophils are 
pre-programmed to undergo apoptotic death quite rapidly, and this is only offset if 
inflammatory events dictate that there is an extended need for increased numbers of viable 
cells.  A number of inflammatory mediators have anti-apoptotic effects on neutrophils, 
including the ELR-CXC chemokines (Glynn, Henney et al. 2002; Kobayashi, Voyich et al. 
2005), such that cells exposed to these mediators remain viable for extended periods of 
time and thereby can potentially contribute to the regional anti-microbial activities.  This 
translates also into potential contributions to adventitious pathogenic processes, such that 
the ability of hG31P to countermand ELR-CXC chemokine-driven anti-apoptotic effects 
would be of significant benefit to the host by virtue of encouraging functional removal of 
these cells from the inflammatory environment.  
We had previously shown that bovine and a human-bovine chimeric form of G31P 
are effective in blocking neutrophilic pathology associated with airway endotoxemia 
(Gordon, Li et al. 2005; Zhao, Li et al. 2007), and we confirmed here for the first time that 
the human orthologue G31P was similarly effective.  Herein we assessed the kinetics of 
neutrophil infiltration of the airways as well as their activation in situ in the lungs.  Our 
data showed that G31P can dramatically reduce neutrophil recruitment and activation, 
inasmuch as we found high levels of the primary, secondary and tertiary granule markers 
myeloperoxidase (MPO), lactoferrin (LF), and matrix metalloproteinase-9 (MMP-9), 
respectively, in lungs of the saline-treated endotoxemic animals, but not in the G31P-
treated animals.  Previous studies have shown that a number of matrix metalloproteinases 
are present in the airways during experimental or clinical acute lung injuries or respiratory 
distress (D'Ortho, Jarreau et al. 1994; Fligiel, Standiford et al. 2006), and we found both 
MMP-2 and MMP-9 in our BAL samples.  While one might argue that the multiple 
gelatinases detected in our zymograms (i.e., 92 and 68 kD) could have been attributable to 
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 processing of high molecular weight MMP-9 to smaller forms, such processing of MMP-9 
reportedly leads to generation of 86 and 82 kD gelatinases (i.e., not a 68 kD activity) 
(Ramos-DeSimone, Hahn-Dantona et al. 1999).  MMP-2 is expressed as a 72 kD zymogen 
that is processed to a 68 kD gelatinase (Growcott, Spink et al. 2006).  MMP-2 is mainly 
produced by resident cells during acute lung injury, including for example type II epithelial 
cells or endothelial cells (Fligiel, Standiford et al. 2006), such that the observation that 
G31P blocked its expression further supports our hypothesis that this antagonist acts not 
only on the neutrophil, but also on epithelial or other resident cells.  Endothelial cells, 
another source of MMP-2 (Fligiel, Standiford et al. 2006), also express the CXCR2 
(Reutershan, Morris et al. 2006), so could potentially also fall under the influence of G31P. 
In conclusion, our data indicate that G31P is a potent antagonist of neutrophil 
activation induced by ELR-CXC chemokines.  It targets not only the CXCR1 and CXCR2, 
but also heterologous GPCR (e.g., CD88/C5aR, BLT1, and FPR) expressed on CXCR1- or 
CXCR2-positive cells, and it interrupts the autocrine epithelial cell inflammatory cascade 
triggered by bacterial endotoxins.  Thus, the beneficial effects of G31P flow from its 
ability to simultaneously target multiple inflammatory processes.  We speculate that the 
ability of G31P to antagonize heterologous GPCR may be a very important part of its anti-
inflammatory activities, such that ELR-CXC chemokine antagonism in the absence of such 
activities (e.g., by anti-chemokine antibodies) may provide somewhat less effective 
protection.  An obvious question to ask when one wishes to block neutrophil participation 
in biological responses is whether there are deleterious effects.  For example, in bacterial 
pneumonia one might expect that these cells may be required for successful elimination of 
the pathogen(s).  However, we have found that G31P very significantly attenuates 
pathology in aspiration pneumonia but at the same time does not reduce control of the 
microbial populations that enter the airways (Chapter 5).  Blocking neutrophil recruitment 
in bovine pneumonic pasteurellosis similarly improves outcomes very significantly 
(Slocombe, Malark et al. 1985).  We would predict based on our cumulative results that a 
broad array of inflammatory diseases would thus benefit from such ELR-CXC chemokine 
antagonism, as might other processes in which inflammation per se is not necessarily 
prevalent, but in which the ELR-CXC chemokines have nevertheless been implicated. 
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CHAPTER 5 : BLOCKADE OF NEUTROPHIL RESPONSES IN ASPIRATION 
PNEUMONIA VIA ELR-CXC CHEMOKINE ANTAGONISM DOES NOT 
PREDISPOSE TO AIRWAY BACTERIAL OUTGROWTH 3 
 
Chapter 5 overview 
As we showed in the last chapter, hG31P effectively antagonized neutrophilic 
inflammatory responses to bacterial LPS challenge by virtue of its abilities to block ELR-
CXC chemokine signaling through both the CXCR1 and CXCR2 receptors.  hG31P also 
antagonized human airway epithelial cell responses to LPS challenge as well as ligand-
induced activation of heterologous GPCRs (e.g., C5aR, BLT1, and FRP), which raise the  
question of whether hG31P would also inhibit bacterial clearance in the airway.  In this 
chapter we addressed this question.  Basically, I set up a guinea pig model of aspiration 
pneumonia and examined the abilities of hG31P to block neutrophil activation and 
infiltration into the airway, pulmonary hemorrhagic consolidation, lung tissue chemokine 
expression, and the airway bacterial burden.  Assisted by my co-authors, I designed and 
finished all the experiments, analyzed the data, and wrote the manuscript.  
 
5.1. INTRODUCTION 
Aspiration pneumonia is a condition brought on by aspiration of foreign materials, 
most often gastric contents.  It occurs primarily in unconscious or semiconscious patients, 
and is relatively common during general surgical anaesthesia (incidence, 1 in 3000) 
(Olsson, Hallen et al. 1986; Warner, Warner et al. 1993).  The local inflammatory sequelae 
vary from sub-clinical pneumonitis to severe acute lung injury (ALI) and acute respiratory 
                                                 
3 Zhao Xixing, J. R.Town, F. Li, W. Li, X. Zhang, and J.R. Gordon.  Blockade of 
neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does 
not predispose to airway bacterial outgrowth. Submitted to Pulmonary pharmacology and 
therapeutics 
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 distress syndrome (ARDS) (Pepe, Potkin et al. 1982; Fowler, Hamman et al. 1983), 
depending on the volume and the pH of the gastric contents (Marik 2001).  However, 
ALI/ARDS associated with aspiration pneumonia carries a mortality rate of 10-30% 
(Olsson, Hallen et al. 1986; Warner, Warner et al. 1993).   
Neutrophils are the primary drivers of this inflammatory response in aspiration 
pneumonia (Folkesson, Matthay et al. 1995; Beck-Schimmer, Rosenberger et al. 2005; 
Davidson, Knight et al. 2005; Raghavendran, Davidson et al. 2005).  When activated, 
neutrophils release an array of microbicidal factors, including reactive oxygen 
intermediates (ROI), defensins, and proteolytic enzymes, but they also foster the 
inflammatory responses through elaboration of proinflammatory cytokines (e.g., TNF, IL-1) 
and chemokines (e.g., CXCL8/IL-8, CXCL1/GROα).  The ELR-CXC motif-containing 
chemokines (e.g., CXCL8, macrophage inflammatory protein-2 [MIP-2]) are central to the 
recruitment and activation of neutrophils in such inflammatory settings, including 
aspiration pneumonia (Folkesson, Matthay et al. 1995; Baggiolini 1998; Rotta, Shiley et al. 
2004; Beck-Schimmer, Rosenberger et al. 2005).  This suggests that ELR-CXC chemokine 
antagonism, and thereby amelioration of the neutrophil responses, could potentially offer 
an adjunct therapeutic approach in aspiration pneumonia.  However, an important caveat to 
such an approach would be that neutrophils are thought to be a critical component of the 
innate anti-bacterial response.  This raises the question of whether blockade of neutrophil 
recruitment during bacterial infections would be patently detrimental.     
The ELR-CXC chemokines chemoattract and activate neutrophils via two closely 
related G protein-coupled receptors (GPCR), the CXCR1 and CXCR2 (Wolf, Delgado et al. 
1998).  We have reported that bovine CXCL8(3–73)K11R/G31P and human CXCL8(3-
72)K11R/G31P (hG31P), and human-bovine chimeras thereof, effectively antagonize 
neutrophilic inflammatory responses to bacterial lipopolysaccharide (LPS) challenge by 
virtue of their abilities to block ELR-CXC chemokine signaling through both of these 
receptors (Li and Gordon 2002; Li, Zhang et al. 2002; Gordon, Li et al. 2005; Zhao, Li et 
al. 2007; Zhao, Town et al. 2009).  hG31P also antagonizes human airway epithelial cell 
responses to LPS challenge as well as ligand-induced activation of heterologous GPCR 
(i.e., C5a, LTB4, and fMLP) (Zhao, Town et al. 2009) .  In the present study, we assessed 
whether hG31P-dependent blockade of neutrophil participation in the innate immune 
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 response following aspiration of acidified gastric contents would foster bacterial 
survival/growth in the airway.  Our data have shown that the hG31P treatments did not do 
so and, moreover, they significantly ameliorated pulmonary pathology. 
 
5.2. MATERIALS AND METHODS 
5.2.1. Animal and reagents 
Most commercial reagents have been described previously (Li and Gordon 2001; Li 
and Gordon 2002; Zhao, Li et al. 2007)  but we also purchased: RNAlater, QIAprep Spin 
Miniprep, QIAquick Gel Extraction, QIA shredder and RNeasy Mini Kits (QIAGEN Inc, 
Mississauga, ON); Brilliant qRT-PCR Master Mix Kit (Stratagene Cloning Systems, La 
Jolla, CA); and blood agar plates (Becton Dickinson). Human G31P was generated and 
characterized as noted (Zhao, Town et al. 2009).  Female Hartley guinea pigs (4-week old, 
250-300g) were purchased from Charles River Laboratories (Charles River, MA); all 
experiments were carried out according to the guidelines established by the Canada 
Council on Animal Care and were approved by our institutional animal ethics review panel.  
 
5.2.2. Preparation of gastric contents   
The protocol used for preparing gastric contents was as described previously 
(Knight, Davidson et al. 2004; Davidson, Knight et al. 2005) with minor changes.  In brief, 
stomach contents were collected from healthy guinea pig donors, dispersed in normal 
sterile saline, and filtered through sterile gauze.  A stock solution of gastric contents was 
prepared in normal saline at 100 mg/ml (w/v), aliquoted and stored in -80 ºC.  This stock 
was further diluted to 40 mg/ml and adjusted to pH 2.0 immediately before use. 
 
5.2.3. Guinea pig aspiration pneumonia model 
  In preliminary experiments we optimized dosing of gastric contents to be used for 
the challenges, instilling the gastric contents at 0, 5, 10, 20, 35, 50, or 75 mg/kg into the 
airways of each animal.  At 20 h after challenge we harvested the animals and assessed 
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 their pulmonary hemorrhagic consolidation and airway leukocyte responses.  The gastric 
contents dose-dependently induced pulmonary neutrophilic inflammation and hemorrhagic 
consolidation within the 5-35 mg/kg dose range (data not shown).  We similarly assessed 
the effects of using gastric contents of differing pH and found that a pH of <2.0 was often 
lethal for the guinea pigs, as were volumes of gastric contents greater than 250 µl.  The 
timing for induction of pulmonary pathology and the G31P treatment doses in this model 
were also optimized (data not shown).   
For the experiments reported herein, we infused 250 µl of acidified gastric contents 
(35 mg/kg; pH 2.0) into the nares of each experimental animal, and at the same time 
treated them s.c. with 1 ml of saline alone or containing 250 μg/ml of human G31P.  All 
animals were euthanized at 20 h post-challenge using halothane.  The animals were 
assigned to four treatment groups (n=5/group), as follows:  Group 1, pH 7.2 saline i.n. 
(saline control group); Group 2, pH 2.0 saline i.n. (acidified saline control group); Group 3, 
acidified gastric contents i.n. and saline treatment s.c.; and Group 4, acidified gastric 
contents i.n. and G31P treatment s.c..  For the intranasal challenges the animals were 
anesthetized by i.p. injection of 40 mg/kg ketamine and 5μg/kg xylazine.  The experiments 
were repeated three times, and the depicted data are representative of each experiment.    
The respiratory tree of each animal was removed from each animal on euthanasia, 
gently washed and blotted, and then the dorsal and ventral aspects of each were 
photographed.  The photographic images were scored for the proportion of the surface area 
that was grossly hemorrhagic using image analysis software.  Bronchoalveolar lavage 
(BAL) fluid collection, BAL WBC (and RBC) enumeration and differentials were then 
performed as noted (Gordon, Li et al. 2005) and the results expressed as the mean number 
of cells per ml BAL sample.  Peripheral blood total WBC counts and differentials were 
performed as well.  BAL fluids and serum were aliquoted and stored at -80˚C, while 
samples of lung tissue for analysis of chemokine mRNA levels were stored at -20˚C 
inRNAlater solution until processed for RNA extraction.  All samples from each animal 
were assayed independently. 
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 5.2.4. Myeloperoxidase assay  
BAL fluids were diluted 10-fold with 0.5% hexadecyltrimethylammonium bromide 
(HTAB), and 10 µl of the diluted samples were incubated at room temperature for 10 min 
with 100 µl tetramethylbenzidine (TMB).  The reactions were stopped by addition of 100 
µl of 1M phosphoric acid and the MPO levels quantified by spectroscopy (OD, 450 nm).  
The data expressed as OD450 ± SEM. 
 
5.2.5. Lactoferrin ELISA   
We employed a standard capture ELISA, with optimized concentrations of capture 
(2.45 µg/ml) and detection (0.85 µg/ml) antibodies, as noted (Zhao, Li et al. 2007).  The 
standards comprised purified lactoferrin (0 - 400 ng/ml).  The BAL samples were diluted 
1:10 for the assay, which had a sensitivity of 6.25 ng/ml.  The results are expressed as the 
mean concentration (ng/ml) of each group ± SEM. 
 
5.2.6. Assessment of lung tissue neutrophilia   
After bronchoalveolar lavage, the caudal left lung lobe of each animal was fixed on 
ice for 3 h in acid-alcohol formaldehyde (Gordon, Li et al. 2005), and routinely processed 
to 7 µm paraffin sections.  The tissues were stained with hematoxylin and eosin and 
examined in a blinded manner at 400x power.  The results were expressed as the mean of 
neutrophils/40× field for each group (n = 5) ± SEM. 
 
5.2.7. Peripheral blood neutrophil chemotaxis   
We assessed whether the G31P treatments would block the abilities of the 
peripheral blood neutrophils to respond to ELR-CXC chemokines.  To do so, neutrophils 
were purified from the peripheral blood of each animal and used for modified Boyden 
chamber microchemotaxis assays, as reported previously (Li and Gordon 2002; Li, Zhang 
et al. 2002; Zhao, Li et al. 2007).  The purified cells were suspended in phosphate-buffered 
saline [PBS; pH 7.4] supplemented with 1.2 mM MgCl2, 5 mM KCl, 0.5 mM CaCl2, 5 mM 
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 glucose, and 0.1% bovine serum albumin.  Human CXCL8 (10 ng/ml) or PBS were used 
as chemoattractants for each sample.  The assays were quantified by direct counting of at 
least five 40× objective fields per well.  The results are presented as the experimental 
minus control well values (i.e., CXCL8 minus PBS responses), and expressed as the mean 
number of cells per 40× field ± SEM.  
 
5.2.8. Isolation of lung tissue total RNA and quantitative real time PCR (qRT-PCR)   
RNA from the lung tissue samples was isolated and purified using Qiagen RNeasy 
Mini Kits, according to the supplier’s protocol. The total RNA was quantified 
spectrophotometrically and stored at -80 °C.  The levels of β-actin, CXCL1 and CXCL8 
mRNA in each sample were determined by qRT-PCR.  The guinea pig gene-specific 
primers were: β-actin forward: 5’-CGT AAG GAC CTC TAT GCC AAC AC-3’ and β-
actin reverse: 5’-GAC TCA TCG TAC TCC TGC TTG CT-3’; CXCL1 forward: 5’- CCC 
AAG AAC ATC CAG AGC GTA G-3’ and CXCL1 reverse: 5’- TGG CTT TGC TTC 
CTT TCA GC-3’; CXCL8 forward: 5’- TGC GAT GCC AGT GTA TTA AGA TT-3’ and 
CXCL8 reverse: 5’- CTC TTC AAG AAC ATG CTC ACC AC-3’.  We used a one-step 
master mix protocol for the qRT-PCR, with a thermal profile of: first segment, 50°C for 30 
min and 95°C for 10 min (1cycle); second segment, 95°C for 30 sec, 62°C for 30 sec, and 
72°C for 30 sec (40 cycles), followed by a dissociation curve. 
 
5.2.9. BAL fluid bacteriology   
BAL fluids were diluted 1:250 after collection and 100µl aliquots were applied to 
blood agar plates using standard approaches. After overnight incubation at 37°C, the 
bacterial colonies on each plate were counted, and the colony morphology assessed by 
microscopic observation.  The bacteria from each colony type were also subjected to Gram 
staining, all by our professional bacteriology service, Prairie Diagnostic Services. The 
results were expressed as the mean number of Gram-negative or –positive enterobacilli, or 
Gram-positive corynebacterium-like organisms for the BAL samples from each group (± 
SEM). 
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 5.2.10. Statistical analyses   
The results are expressed as the mean ± SEM. Multiple group comparisons were 
made using one-way analysis-of-variance (ANOVA), while two-group comparisons were 
made using student’s t-tests (two-tailed).  
 
5.3. RESULTS 
5.3.1. Neutrophil blockade in aspiration pneumonia ameliorates pulmonary 
pathology.   
Much of the pathology associated with aspiration pneumonia is attributable to 
overly aggressive neutrophil responses to the aspirated materials.  These can contain acidic 
particulate matter from the gut in cases of aspirated regurgitate as well as resident upper 
airway microbes that the aspirate may incidentally wash into the lower airway.  While 
antagonism of the neutrophilic inflammation could potentially be beneficial on one hand, 
neutrophils are thought to be important for successful clearance of bacteria.  Thus, herein 
we tested the abilities of guinea pigs to successfully handle aspiration of acidified gastric 
contents when their neutrophil responses to the pulmonary insult were blocked.  We used 
four groups of guinea pigs (n=5/group), including normal saline and acidified saline 
controls and animals that received the acidified gastric contents with or without treatment 
with 250 µg/kg recombinant human G31P, as noted in the Materials and Methods.  The 
experiments were repeated three times, with low experiment-to-experiment variance (Table 
5.1.); all depicted data are from one experiment that is representative of each experiment.  
It is clear that the acidified gastric contents induced strong pulmonary 
inflammatory responses, including robust airway and tissue neutrophil responses (Fig. 
5.1A, B).  The challenges also had a significant impact on vascular integrity within the 
lungs, as there was grossly evident hemorrhagic consolidation across the pleural surfaces 
(Fig. 5.1C), and we inevitably found substantial numbers of red blood cells (RBC) within 
the BAL fluids (Fig. 5.1D).  The acidified saline control animals displayed pulmonary 
responses that were indistinguishable from those of pH 7.2 saline-infused controls (p>0.5, 
for each parameter).  The airway and tissue neutrophil responses of the aspiration  
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 Table 5.1. Total BAL WBC and PMN data of three independent experiments. 
 
Total WBC     Total PMN 
                        ( 105 cells/ml)                           ( 105 cells/ml)   
                 Exp 1       Exp 2         Exp 3         Exp 1  Exp 2          Exp 3 
Saline        5.1           8.7     7.0                      0.7            1.9             2.0 
GC      19.1         32.9     39.9                      11.7         18.7           25.7 
GC/G31P  5.2*        17.5     9.5**                     1.5*          4.3*            2.4** 
* and **, p ≤ 0.05 and 0.01, respectively, relative to the GC group 
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Figure 5.1. Human CXCL8(3-72)K11R/G31P can effectively block neutrophil 
infiltration and loss of vascular integrity in aspiration pneumonia animals. 
 
  (A) Bronchoalveolar lavage (BAL) white blood cells were enumerated and 
differential counts were performed for each animal. The neutrophil (PMN) numbers were 
calculated from this data (Airway PMN), which are expressed as the mean number of cells 
(× 105)/ml (+/- SEM). (B) The tissue neutrophil response was assessed by direct counting 
of  haematoxylin & eosin-stained lung tissue sections (Tissue PMN) and the data expressed 
as the mean number of cells in each 40× object fields (+/- SEM). (C) In addition, the BAL 
red blood cell (RBC) was enumerated as above, and the data were expressed in the same 
way as airway PMN. The results demonstrated that 250µg/kg G31P significantly reduced 
the 20 h airway and tissue neutrophil responses (p<0.01, and p<0.05), and reduced the 
appearance of red blood cells in the airways (p<0.01). Data shown in these figures are from 
one experiment that is representative of three independent experiments. *, p<0.05 or **, 
p<0.01, versus the saline-treated, GC-challenged animal values.  
 
 107
 pneumonia animals treated with 250 μg/kg G31P were 90% and 85% reduced, respectively, 
relative to the saline-treated aspiration pneumonia animals (Fig. 5.1A, B).  The G31P 
treatment also ameliorated that impact of the gastric aspirates on pulmonary vascular 
integrity, markedly reducing both the pleural hemorrhagic consolidation and appearance of 
RBC in the airways (Fig. 5.1C, D).  Thus, the G31P treatment did effectively block 
pulmonary neutrophilia and local vascular complications induced by the aspiration of 
acidic gastric contents. 
 
5.3.2. ELR-CXC chemokine antagonism significantly decreased airway neutrophil 
degranulation in aspiration pneumonia 
While the G31P treatments markedly reduced the pulmonary neutrophil responses, 
they were not abrogated.  Thus we also assessed BAL fluids (BALF) for markers of 
neutrophil activation within the airways.  Degranulation is considered as a hallmark feature 
of neutrophil activation, such that the levels of neutrophil granule markers in tissue 
samples are often used as surrogate measures of neutrophilic inflammation.  Thus we 
measured the levels of myeloperoxidase (MPO) and lactoferrin (LF), as indicators of 
neutrophil primary and secondary granule release, respectively, in the BALF of our 
experimental animals.  G31P treatment of aspiration pneumonia animals reduced the 
BALF MPO levels to background (p<0.005, versus the saline-treated gastic content-
challenged group; Fig. 5.2A) and reduced the BALF LF levels by 68% relative to the 
saline-challenged controls (p≤0.05; Fig. 5.2B). These results demonstrated that the G31P 
treatments had dramatically reduced neutrophil migration and activation, as determined by 
direct counting and assessment of activation markers. 
 
5.3.3. Human G31P effectively blocked lung tissue ELR-CXC chemokine mRNA 
expression 
We have shown that G31P treatment inhibited neutrophil activation and migration 
into lung tissue and airway caused by aspiration of gastric contents.  One would predict 
that while the primary (GC) challenge would upregulate ELR-CXC chemokine expression  
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Figure 5.2. CXCL8(3-72)K11R/G31P also significantly decreased the appearance of 
neutrophil primary and secondary granules products in the airway. 
 
Neutrophil primary and secondary granules were assessed by measuring 
myloperoxidase (MPO) and lactoferrin (LF) using colorimetric assay and ELISA, 
respectively. (A) BAL from each animal was diluted and reacted with the colorimetric 
substrate TMB, and the developing reaction product was assessed spectrophotometrically, 
OD450.  The data were expressed as the mean OD450 (± SEM). (B) Diluted BAL was also 
used to measure the secondary granule, LF using an ELISA assay. The data were expressed 
as ng/ml (± SEM). The data indicated that G31P significantly decreased MPO production 
(p<0.01) and also LF (p<0.05), though to a substantially lesser extent. Data shown in these 
figures are from one experiment that is representative of four experiments (n=5 
animals/group). *, p<0.05 or **, p<0.01, versus the saline-treated, GC-challenged animal 
values. 
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 by airway epithelial cells, for example, neutrophil influx into the lungs would both bring 
additional sources of these chemokines and exacerbate the epithelial response.   We have 
recently found that G31P can partially block ELR-CXC chemokine induction in LPS-
challenged human bronchial epithelial cells (footnote 2).  We wished therefore to know 
whether G31P treatments of aspiration pneumonia animals would reduce pulmonary 
expression of ELR-CXC chemokines and other inflammatory mediators, in addition to 
blocking neutrophil influx.  Thus, we used quantitative real time PCR (qRT-PCR) to probe 
the lung tissues from our aspiration pneumonia and control animals for expression of 
CXCL8 and CXCL1 and the cytokines TNFα and IL-1β.  We found that even at 20 h after 
the gastric content challenge, CXCL8 and CXCL1 mRNA levels were still expressed at 
levels two-fold greater than  in saline-challenged (i.e., normal control) animal (Fig. 5.3 A, 
B).  The G31P treatments reduced lung expression of CXCL8 at this time to near 
background and CXCL1 expression by 50%, relative to the saline control animals (Fig. 
5.3A, B).  However, at this time TNFα and IL-1β levels were at background in the saline-
treated aspiration pneumonia animals, such that the G31P treatment had no discernible 
effect on their expression (data not shown).  These results indicate that G31P treatment did 
reduce ELR-CXC chemokine expression in the inflamed lung tissues following aspiration 
of acidified gastric contents.            
            
5.3.4. Neutrophils from G31P-treated animals are hyporesponsive to CXCL8 
stimulation in vitro   
While G31P blocked ELR-CXC chemokine expression in the lungs of our 
experimental animals, we would predict based on earlier study (Gordon, Li et al. 2005) that, 
even if exposed to these chemokines in vivo, the circulating neutrophils of the G31P-
treated animals would be incapable of responding and moving into the tissues.  To test this, 
we purified peripheral blood neutrophils from each animal and assessed their ability to 
respond in vitro to CXCL8 in chemotaxis assays.  As shown in our airway endotoxemia 
model (Gordon, Li et al. 2005), the cells from the G31P-treated aspiration pneumonia 
animals were indeed hyporesponsive to CXCL8 (Fig. 5.4A; p<0.01, relative to either the 
normal control or saline-treated aspiration pneumonia animals).  This suggested that G31P  
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Figure 5.3.  CXCL8(3–72)K11R/G31P can block ELR-CXC chemokine expression in 
aspiration pneumonia  animals. 
 
Total RNA was purified from lung tissue of each animal and expression of the 
ELR-CXC chemokines, CXCL8 and CXCL1, was measured using quantitative real-time 
PCR (qRT-PCR), as described in the Materials and Methods. The data were expressed as 
the relative quantities of mRNA relative to a calibrator sample (a representative saline 
control group sample). (A, B) The result indicate that the aspiration pneumonia animals 
expressed two-fold more CXCL8 and CXCL1 mRNA relative to saline-challenged 
aspiration pneumonia animals at 20  after GC challenge, and the G31P can block CXCL8 
and CXCL1 mRNA expression by 90% and 50%, respectively. 
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Figure 5.4.  CXCL8(3–74)K11R/G31P blocks chemotactic responses of guinea pig 
neutrophils to CXCL8.   
 
As described above, guinea pigs were challenged with saline or GC (+/- G31P) and 
sacrificed 20 h later, as in Fig5.1. (A) Neutrophils were purified from the peripheral blood 
of each animal and used in modified Boyden chamber microchemotaxis assays in which 
saline or 10ng/ml human CXCL8 was the chemoattractant.  Each sample was assessed in 
duplicate, and the responses assessed by counting the number of cells within five 40x 
objective microscope fields of the stained chemotaxis membranes. The data were 
expressed as the number of cells (experimental minus control) per 40x field (± SEM).  The 
neutrophils from the G31P-treated animals (GC/G31P) were significantly less able to 
respond to CXCL8 than those from the saline-treated (GC/Sal.) or normal (Sal. p<0.01) 
animals.  (B) Differential counts were performed on the blood WBC from each group of 
animals and the proportions of neutrophils enumerated. The data were expressed as the 
mean percentage of WBC that was neutrophils (± SEM). The data indicate that hG31P 
treatment modestly increased the proportion of circulating neutrophils in the blood.  The 
data presented are from one experiment that is representative of four experiments (n=5 
animals/group). *, p<0.05 or **, p<0.01, versus the saline-treated, GC-challenged animal 
values. 
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 had occupied the CXCL8 receptors (i.e., CXCR1 and CXCR2) on the circulating 
neutrophils in these animals, preventing them from responding to CXCL8 after purification.  
In addition, we assessed the impact of the various treatments on the circulating neutrophil 
in our animals, and found that G31P-treatments significantly increased the numbers of 
neutrophils trafficking in the blood (Fig. 5.4B) relative to the saline-treated aspiration 
pneumonia animals, which were slightly neutropenic relative to the normal control animals.  
Others have reported though that surgical anaesthesia can induce a mild neutropenia in 
healthy control animals (Morisaki, Aoyama et al. 1998). 
 
5.3.5. Neutrophil blockade did not increase bacterial growth in the lungs of animals 
with aspiration pneumonia  
Given the roles of neutrophils in anti-bacterial defenses, a critical element of this 
investigation was whether neutralization of the pulmonary neutrophil response with G31P 
would predispose the animals to development of runaway airway bacterial growth.  Thus, 
we assessed the bacterial loads in the BAL fluids of our experimental animals, grossly 
differentiating the BAL flora as gram-negative or -positive enterobacilli (gr- or gr+-entero., 
respectively), or gram-positive corynebacterium-like (coryne-like) organisms.  For each of 
these bacterial designations, the mean value of bacterial CFU was higher in the saline-
treated aspiration pneumonia animals than the G31P-treated animals, although not 
significantly so (Fig. 5.5.).  This data indicates that neutrophil blockade did not negatively 
affect bacterial clearance in this model. 
 
5.4. DISCUSSION 
We have previously generated multiple forms of ELR-CXC chemokine antagonists, 
including bovine, human, and human-bovine chimeric orthologues (Li and Gordon 2002; 
Li, Zhang et al. 2002; Gordon, Li et al. 2005; Zhao, Li et al. 2007).  Each of these takes on 
the form of an amino-truncated CXCL8 molecule with arginine and proline substitutions at 
amino acids K11 and G31, respectively.  In vitro, each inhibits the responses of normal 
resting human neutrophils to human CXCR1 and CXCR2 ligands (e.g., CXCL1, CXCL5,  
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Figure 5.5.  Neutrophil blockade did not increase bacterial growth after CXCL8(3–
72)K11R/G31P treatment. 
 
Aspiration pneumonia was induced in guinea pigs as in Figure 5.1.  BAL fluids 
from each animal were diluted 1:250 and cultured overnight on blood agar plates. The 
bacteria colonies that developed were differentiated and counted. The data are expressed as 
the number of colonies (×106) per ml BAL. The result show that three primary groups of 
organisms, including, gram-negative enterobacilli (gr- enter rod), gram-positive 
enterobacilli (gr+ non-enter rod), and gram-positive corynebacterium-like (gr+ 
corynebacterium) were cultured from the BAL.  The G31P treatment did not increase the 
bacterial load in the aspiration pneumonia animal (p>0.05). This data is from one 
experiment that is representative of four experiments (n=5 animals/group) performed. 
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 and CXCL8), including intracellular Ca2+ flux, ROI production, and chemotaxis (Li and 
Gordon 2002; Zhao, Li et al. 2007), as well as their anti-apoptotic activities (Zhao, Town 
et al. 2009).  In addition, we have found that human CXCL8(3-72)K11R/G31P (hG31P) 
antagonizes intracellular Ca2+ flux and chemotaxis induced in neutrophils by ligands for 
heterlogous GPCRs, including LTB4, C5a, and bacterial tripeptide fMLP (Zhao, Town et 
al. 2009).  In vivo, each of these antagonists can dramatically reduce pulmonary 
neutrophilic inflammation, hemorrhagic consolidation and pyrexia in guinea pigs suffering 
from airway endotoxemia (Gordon, Li et al. 2005; Zhao, Li et al. 2007) including, in the 
case of the bovine antagonist at least, when administered after the onset of symptoms 
(Gordon, Li et al. 2005).  
In the present study, we examined the ability of human G31P to inhibit pulmonary 
inflammatory responses when guinea pigs were challenged via the airway with acidified 
stomach contents, as opposed to purified bacterial endotoxin alone.  It is apparent that 
either the gastric contents themselves contained bacteria or that intranasal infusion of these 
contents washed upper airway microorganisms into the lower airways.  Thus, the insult 
included bacterial challenge in a highly acidic (pH 2.0) environment.  This combination 
has been used by others as a model of aspiration pneumonia (Marik 2001).  We observed 
inhibition by G31P of pulmonary neutrophil recruitment, hemorrhagic consolidation and 
ELR-CXC chemokine expression in response to the aspiration of these gastric contents, 
and found that this G31P treatment did not negatively affect bacterial clearance by the 
innate immune system.  Indeed, if anything, there was a trend towards augmented bacterial 
clearance in the G31P-treated animals.  The residual anti-bacterial defenses that could have 
provided protection against the gastric content challenges include both physical and 
adaptive responses (e.g., the mucociliary clearance escalator and epithelial defensin 
production), although we did not experimentally address these systems in this report. 
Neutrophils are major contributors to defensin expression in inflamed airways, 
wherein they secrete human neutrophil peptides-1, -2, and -3 (Ashitani, Mukae et al. 1998).  
Indeed, in patients with diffuse panbronchiolitis, BAL neutrophil defensin levels correlate 
significantly with IL-8 expression and neutrophil numbers (Ashitani, Mukae et al. 1998).  
Neutrophil serine proteases and defensins also directly affect the airway epithelium, 
decreasing ciliary beat and increasing mucus production and expression of IL-8 by the 
 115
 epithelial cells, which would serve to further augment the neutrophil responses (Hiemstra, 
van Wetering et al. 1998).  Thus, G31P would have had protective effects derived directly 
from blockade of primary neutrophil influx, but also at the level of the epithelial cell by 
virtue of preventing the neutrophil-dependent activation of these cells.  
The accidental aspiration of gastric content is associated clinically with serious 
illness, including acute lung inflammation (ALI) and/or acute respiratory distress 
syndrome (ARDS), often with lethal outcomes even for individuals under intensive care 
(Fowler, Hamman et al. 1983; Olsson, Hallen et al. 1986).  Acute lung injury induced by 
acidic gastric contents is characterized by enhanced chemokine expression and neutrophil 
sequestration (Raghavendran, Davidson et al. 2005), and others have reported that even 
sterile acidic solutions can induce lung injury associated with dramatic increases in IL-8 
expression and neutrophil activation (Folkesson, Matthay et al. 1995). It was interesting 
then that, in our model, instillation of 250µl of pH 2.0 saline did not lead to significant 
neutrophil sequestration or other pathology discernible using our approaches (Folkesson, 
Matthay et al. 1995; Raghavendran, Davidson et al. 2005).  This may have been because 
our challenge medium was not as acidic as that used by some others or that we used 
smaller volumes.  Others have reported that solutions of pH < 2.5 and gastric content 
volumes of ≤0.3 ml/kg body weight are required to develop lung injury (Exarhos, Logan et 
al. 1965; James, Modell et al. 1984).  We chose a pH of 2.0 and a gastric content dose of 
35 mg/kg because, when combined, these parameters had led to very significant pathology 
in our preliminary experiments.   As our data shows, this included elevated pulmonary 
neutrophil infiltration and hemorrhagic consolidation, which confirms that these 
parameters were sufficient to adequately model aspiration pneumonia. 
We have assessed the kinetics with which different neutrophil granule markers 
appear in the airways in endotoxemic animals, and found that the levels of primary (MPO) 
and secondary (LF) granule markers peaked at different times.  Nevertheless, G31P 
effectively inhibited both in these animals (Zhao, Town et al. 2009).  Herein we found that 
high levels of MPO could still be detected at 20 h after challenge with acidified gastric 
contents, while LF levels were not markedly different in the pneumonic animals compared 
with the normal controls.  However, both markers were significantly affected by the G31P 
treatment.  It should be noted that myeloperoxidase is also a product of monocytes (Lau 
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 and Baldus 2006).  The LF result could reflect the fact that LF is primarily an acute phase 
reaction product in aspiration pneumonia.  In addressing the mechanisms by which G31P 
inhibited neutrophilic inflammation in this model, we also assessed the pulmonary 
expression of the ELR-CXC chemokines CXCL1 and CXCL8.  It has been reported that in 
a mouse model of aspiration pneumonia expression of macrophage inflammatory protein 
(MIP)-2 and keratinocyte-derived cytokine (KC) peaked at 6 h, though both were still 
elevated relative to normal controls at 24 h after challenge (Raghavendran, Davidson et al. 
2005).  In our study, we detected elevated levels of CXCL1 and CXCL8 expression in our 
animals at 20 h, and G31P inhibited expression of both chemokines.  This confirms that 
G31P had local effects on chemokine expression in the lungs, perhaps as noted above by 
simply reducing neutrophil-dependent exacerbation of the epithelial cell responses. When 
we addressed the more systemic outcomes of the G31P treatments, we found apparently 
increased numbers of circulating neutrophils in the G31P-treated aspiration pneumonia 
animals relative to the saline-treated ones.  This is likely attributable to G31P’s blockade of 
the ELR-CXC chemokine receptors on these cells, prevent them from marginating in the 
pulmonary capillary bed under the influence of the locally expressed chemokines (e.g., 
CXCL8).  The circulating neutrophils of our G31P-treated animals were hyporesponsive to 
CXCL8, as noted previously in airway endotoxemia (Gordon, Li et al. 2005).  
In clinical settings, it is common to find gram-positive cocci and gram-negative 
bacilli in transtracheal samplings from aspiration pneumonia patients (Marik 2001).  These 
bacteria arise mainly from the nasopharynx or oropharynx, and enter the lung with the 
aspirated regurgitate (Marik 2001). The aspirate volume and bacterial burden, and the 
general condition of the individual’s innate immune system correlate strongly with 
aspiration pneumonia pathology (Marik 2001).  In our model we instilled gastric contents 
intranasally, which would have effectively flushed the nasopharyngeal and tracheal flora 
directly into the lungs.  We found that the G31P treatments did not increase the bacterial 
loads in the lungs of our animal.  It had been reported that the inhibition of MIP-2 
bioactivity in vivo impairs Klebsiella pneumoniae clearance in a mouse model, although 
the kinetics of the inflammatory response in that model and ours were quite different (e.g., 
they observed maximal MIP-2 expression at 48 h) (Standiford, Kunkel et al. 1996).  In our 
system, bacterial clearance was not affected by the inhibition of neutrophil function, which 
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 may be because the bacteria in the airways of our animals were mostly likely normal 
commensals from the nasopharynx or oropharynx, as opposed to pathogenic organisms 
(e.g., K. pneumoniae).  Respiratory commensals may normally become pathogenic only 
adventitiously (e.g., when confronting a compromised immunoinflammatory system). 
It has been reported that aspiration of acidic regurgitates can damage both ciliated 
and non-ciliated tracheal cells, which would be anticipated to affect mucociliary clearance 
(Gaynor 1988).  It may also decrease airway epithelial expression of β-defensin-1, but not 
β-defensin-2 (Nakayama, Jia et al. 2002).  On the other hand, the abilities of alveolar 
macrophage to phagocytose tracer particles is significantly enhanced when they were 
exposed to acid environments in vitro or in vivo (Naumann and Schlesinger 1986).  In our 
system, bacterial clearance was not affected by antagonism of neutrophil function, 
suggesting that alternate pulmonary microbicidal functions (e.g., macrophage phagocytosis, 
β-defensin expression) were sufficient to deal with the insult. 
In summary, our data indicate that our ELR-CXC antagonist, G31P, can effectively 
reduce aspiration pneumonia pathology in a guinea pig model of disease, and thereby 
suggest that broad spectrum ELR-CXC chemokine antagonism may be useful approach in 
treating patients who have aspired regurgitates.  
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CHAPTER 6 : REDUCTION IN LOCAL AND REMOTE ORGAN INJURY BY 
ELR-CXC CHEMOKINE BLOCKADE IN SUPERIOR MESENTERIC ARTERY 
ISCHEMIA/REPERFUSION INJURY 4 
 
Chapter 6 overview 
To extend our knowledge of the effects of hG31P on other neutrophil-mediated 
inflammatory diseases, in this chapter I set up a rat superior mesenteric artery (SMA) 
ischemia and reperfusion (I/R) injury model and assessed the roles of neutrophil and ELR-
CXC chemokines in local (i.e., gut) and remote (e.g., lung) organ pathology.  I also 
examined the effects of G31P on pulmonary neutrophil sequestration, pulmonary vascular 
permeability, and gut pathology.  This manuscript mainly describes the process of my 
setting up the intestinal I/R injury model and the characterization of the antagonist 
activities of G31P in reducing local and remote organ injury.  I set up this model with 
assistance of Ms Jennifer Town, Xiaobei Zhang, and Aimei Yang, designed and finished 
all the experiments. Finally, I analyzed the results and wrote the manuscripts with the 
assistance from my co-authors. 
 
6.1. INTRODUCTION 
It has been widely accepted that intestinal ischemia/reperfusion (I/R) injury is 
associated with severe multiple organ failure (MOF), including the lung (Schmeling, Caty 
et al. 1989; Caty, Guice et al. 1990; He, Han et al. 2008).  A number of proinflammatory 
cytokines and chemokines are critically involved in this pathology (Caty, Guice et al. 
                                                 
4 Zhao Xixing, J. R. Town, A. Yang, X. Zhang, G. Sawicki, and J.R. Gordon.  Reduction 
in local and remote organ injury by ELR-CXC chemokine blockade in superior mesenteric 
artery ischemia/reperfusion injury.  Submitted to Journal of Surgical Research 
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 1990), although the pathogenesis of intestinal I/R-induced gut pathology and MOF is 
complex and not completely understood. Nonetheless, reactive oxygen intermediate (ROI) 
generation and neutrophil sequestration are believed to be two fundamental causative 
factors (Schmeling, Caty et al. 1989; Souza, Bertini et al. 2004; Cerqueira, Hussni et al. 
2005).  The pivotal role of neutrophils in these processes (Schmeling, Caty et al. 1989; 
Bless, Warner et al. 1999; Cerqueira, Hussni et al. 2005) suggests that blockade of their 
recruitment could be an important therapeutic approach to intestinal I/R injury.  The list of 
neutrophil agonists potentially involved in I/R injury includes TNFα and IL-1β (Caty, 
Guice et al. 1990) and the ELR-CXC chemokines (e.g., CXCL1, CXCL8, MIP-2) 
(Schmeling, Caty et al. 1989; Sekido, Mukaida et al. 1993; Bless, Warner et al. 1999), but 
also C5a (Bless, Warner et al. 1999; Wada, Montalto et al. 2001), LTB4 (Souza, Coutinho 
et al. 2000), ROI (Koike, Moore et al. 1993), and adhesion molecules (Bless, Warner et al. 
1999).  Multiple reports have implicated individual ELR-CXC chemokines as primary 
effectors and shown that their neutralization ameliorates I/R-induced local and remote 
organ pathology (Bless, Warner et al. 1999; Miura, Fu et al. 2001; Souza, Bertini et al. 
2004; Kaneko, Tamura et al. 2007), making these mediators attractive therapeutic targets.   
In humans, the ELR-CXC chemokines include growth-related oncogene-α, -β, and 
-γ (GRO-α, -β, -γ; CXCL-1, -2, and -3, respectively), epithelial neutrophil-activating 
peptide-78 (ENA-78; CXCL5), granulocyte chemotactic protein-2 (GCP-2; CXCL6), 
neutrophil-activating peptide 2 (NAP-2; CXCL7), and IL-8 (CXCL8) (Baggiolini 1998).  
Each of these chemokines binds to either the CXCR1 and/or CXCR2; CXCL6, CXCL7, 
and CXCL8 bind both receptors, while the others bind only the CXCR2 (Ludwig, Petersen 
et al. 1997; Wolf, Delgado et al. 1998).  Rat ELR-CXC chemokines aren’t strictly 
comparable to the human chemokines, but include CINC-1 (GRO), -2α, -2β, and -3 (MIP-
2).  Each binds to target cells only via CXCR2, even though homologues of both the 
CXCR1 and CXCR2 have been discovered in rats (Dunstan, Salafranca et al. 1996; Shibata, 
Konishi et al. 2000).  CXCR1 and CXCR2 belong to the class of receptors called the G 
protein-coupled receptors (GPCR), as do the receptors for multiple other important 
inflammatory neutrophil agonists (e.g., C5a, LTB4, platelet activating factor [PAF], and 
the bacterial tripeptide formyl-Met-Leu-Phe [fMLP]) (Zhelev, Alteraifi et al. 2004). 
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 We recently developed an ELR-CXC chemokine antagonist, human CXCL8(3-
72)K11R/G31P (hG31P).  This CXCL8 analogue can dramatically reduce pulmonary 
pathology related to airway challenge with bacterial endotoxin (Zhao, Town et al. 2009), 
but also pathology subsequent to aspiration of bacterial-laden gastric contents (i.e., in 
aspiration pneumonia) (Chapter 5).  We have shown that hG31P antagonizes CXCR1-
dependent responses as well as those related to CXCR2-exclusive ligands but, importantly, 
it also antagonizes heterologous GPCRs (i.e., C5a, LTB4, and fMLP) that are involved in 
neutrophilic inflammation (Zhao, Town et al. 2009). We hypothesize that hG31P’s ability 
to antagonize both ELR-CXC chemokine receptors as well as these alternate GPCR could 
potentially provide it with a strong therapeutic advantage during neutrophilic inflammatory 
events.  In this study, we employed a rat model of superior mesenteric artery (SMA) 
ischemia and reperfusion (I/R) injury and characterized the effects of hG31P on local and 
remote organ pathology in this model system.   
 
6.2. MATERIALS AND METHODS: 
6.2.1. Reagents and Animals   
CXCL8(3-72)K11R/G31P (G31P) was prepared as described (Zhao, Town et al. 
2009).  Reagents included buprenorphine analgesic (Reckitt Benckiser Pharmaceuticals Inc, 
Richmond, VA), ketamine (Bioniche, Bellville, ON), xylazine (Bayer Healthcare, Toronto, 
ON), isofluorane (Baxter, Mississauga, ON), iodine surgical detergent (0.75% iodine), 
ocular lubricant (Allergan Inc, Markham, ON), RNAlater, QIA shredder and RNeasy Mini 
Kits (QIAGEN Inc, Mississauga, ON), and a qRT-PCR one-step master mix kit (Brilliant 
SYBR® Green qRT-PCR Master Mix Kit; Stratagene, LaJolla, CA).  Other reagents that 
were purchased commercially have been described previously (Li and Gordon 2001; Li, 
Zhang et al. 2002; Zhao, Li et al. 2007).  Male Sprague-Dawley rats (250-300g, 5-week 
old) were purchased from Charles River Laboratories (Charles River, MA).  All the 
experiments were carried out according to the guidelines established by the Canada 
Council on Animal Care and were approved by our institutional animal ethics review panel. 
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 6.2.2. Animal model of intestinal I/R-induced injury  
Rats were fasted 20 hours before the experiments but allowed free access to water. 
On the day of the experiment, the animals were anaesthetized using ketamine/xylazine (40 
μg/kg/ 5 μg/kg, i.p.) and maintained under anaesthesia with 1% isoflurane and 1% oxygen.  
The animals were given 0.05 mg/kg buprenorphine i.m. for pain management.  A 
laparotomy was performed and the superior mesenteric artery (SMA) was isolated and 
totally occlusion for 1 hour using a plastic loop and tubing.  After removal of the ligature, 
the abdominal incision was closed using 4-0 monofilament suture thread.  The animals 
were allowed to recover for 2 hours as the reperfusion injury developed, and then they 
were euthanized with halothane. Sham-operated animals underwent identical surgical 
procedures with the exception that the plastic loop and tubing were not closed to occlude 
the SMA.  We ran multiple preliminary experiments in order to optimize ischemia and 
reperfusion times, including 0.5, 1, 1.5, and 2 h ischemia and 0.5, 1, 2, 4, 8, 16 h 
reperfusion time.  Based on a minimization of mortality with maintenance of discernible 
pathology, 1 and 2 h were chosen as our ischemia and reperfusion times, respectively, for 
all subsequent experiments.  For these the animals were assigned to three groups:  sham, 
I/R with saline, and I/R with 500 μg/kg G31P s.c. (n=5).  The dose of G31P was chosen 
based on preliminary experiments.  All experiments were repeated three times. 
 
6.2.3. Determination of circulating leukocytes and neutrophils   
Blood smears were made and stained with Wright’s solution and differential counts 
performed on 200 cells per sample. Total white blood cells (WBC) were enumerated by 
hemocytometer counting after lysis of the red blood cell (RBC) with 2% acetic acid in 
water.  The total neutrophil numbers were calculated from these values.  
 
6.2.4. Examination of bronchoalveolar lavage (BAL) fluid protein levels, neutrophil 
and RBC numbers.   
Bronchoalveolar lavage (BAL) fluid was collected as noted previously using 2 ml 
volumes of sterile saline (10).  BAL total WBC and RBC were enumerated by direct 
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 counting, and the results expressed as the mean number of cells per BAL sample (± SEM).  
BAL WBC cell differentials were determined using Wright’s solution-stained BAL cell 
cytospin preparations and the total numbers of neutrophils were calculated using these data.  
All the data are expressed as means ± SEM.  The total protein level was determined using 
duplicate replicates in a Bradford microassay according to the suppliers protocols (Bio-Rad 
Laboratories), with bovine serum albumin protein standards.  The data was expressed as μg 
protein/ml BAL fluid (± SEM). 
 
6.2.5. Measurement of MMP-2 and MMP-9 by zymography  
Lung and gut tissue homogenates were prepared and MMP-2 and -9 levels were 
assessed as described previously (Sawicki, Leon et al. 2005; Yu, Yang et al. 2006).  
Briefly, equal weights (100 mg wet wt) of right lung and jejunum from each animal were 
suspended in 1 ml of 0.5% hexadecyltrimethylammonium bromide (HTAB) in 50 mM 
phosphate buffer (pH 6.0) and homogenized for 20 seconds, then sonicated three times for 
30 seconds each, all on ice.  The homogenates were centrifuged at 12,000 rpm at 4°C and 
the supernatants harvested and stored at –80°C.  Next, 40 μg equivalents of homogenate 
were applied to 8% polyacrylamide gels containing 2 mg/mL gelatin.  After electrophoresis, 
the gels were first rinsed 3 times for 20 minutes each in 2.5% Triton X-100, then twice for 
20 min each in incubation buffer (50 mmol/L Tris-HCl, 5 mmol/L CaCl2, 150 mmol/L 
NaCl, and 0.05% NaN3), and finally soaked overnight at 37°C in incubation buffer.  The 
soaked gels were stained for 2 h (2% Coomassie Brilliant blue G in 25% methanol/10% 
acetic acid [w/v]) before destaining with 2% methanol/4% acetic acid.  The gelatinase 
activities of the samples were discerned as transparent bands against the Coomassie blue-
stained gelatin background.  To quantify the activities of enzymes, these zymograms were 
imaged using a GS-800 Calibrated Densitometer (Bio-Rad). The intensities of the 
individual bands were analyzed using Quantity1 software (Bio-Rad) and reported as such. 
Conditioned medium from untreated HT1080 cells was used as MMP-2 and MMP-9 
reference standard (Tanaka, Iwamoto et al. 1995).  
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 6.2.6. Measurements of tissue cytokine and chemokine mRNA levels using 
quantitative real-time PCR (qRT-PCR).   
Lung and jejunum tissues were harvested and stored in 600 μl RNAlater at -20°C.  
The sample RNA was later purified using commercial RNA preparation kits, according to 
the supplier’s protocol.  The total RNA was quantified spectrophotometrically and stored 
at -80 °C.  The levels of β-actin, TNFα, IL-1β, IL-6, IL-10, GRO, CINC-2a, and MIP-2 
mRNA in each group were determined by qRT-PCR, using the rat gene-specific primers 
(Table 6.1.).  We used a one-step qRT-PCR master mix kit with a thermal profile of: first 
segment, 50°C for 30 min and 95°C for 10 min (1 cycle); and second segment, 95°C for 30 
sec, 62°C for 30sec, and 72°C for 30 sec (40 cycles), followed by a dissociation curve. 
 
6.2.7. Evaluation of lung tissue neutrophil sequestration 
After bronchoalveolar lavage, the caudal left lung lobe of each animal was fixed for 
3 h in acid-alcohol formaldehyde (Gordon, Li et al. 2005), and routinely processed to 6 µm 
paraffin sections, which were stained with hematoxylin and eosin. Neutrophils were 
enumerated by microscopy in a blinded manner under a 40× objective.  The results were 
expressed as the mean of neutrophils/40× field for each group (n = 5) ± SEM. 
 
6.2.8. Assessment of jejunal and pulmonary pathology.     
After euthanasia, the intestinal track of each animal was examined and grossly 
graded for signs of edema and discolouration.  In addition, the contents of the gut were 
gently extruded and examined.  We established a five-point scoring system to assess gross 
lung pathology, as follows: 0, no discernible edema, discolouration of gut wall or jejunal 
contents; 1, no discernible edema or discolouration, but jejunum contains yellow fluid; 2, 
10% of jejunum edematous, discoloured, and contained bloody-looking fluid; 3, 25% of 
jejunum edematous, discoloured, and contained bloody-looking fluid; 4, 50% of jejunum 
edematous, discoloured, and contained bloody-looking fluid; 5, 100% of jejunum 
edematous, discoloured, and contained bloody-looking fluid.  To assess histopathology, the 
caudal left lung lobe of each animal and jejunum wall were fixed and processed as  
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 Table 6.1. Rat qRT-PCR primers employed for assessing tissue cytokine and 
chemokine expression. 
 
 
 
Target 
genes 
 
Upstream primers (5’-3’ 
orientation) 
 
Downstream primers (5’-3’ 
orientation) 
β-actin AGAGGGAAATCGTGCGTGAC CGATAGTGATGACCTGACCGT 
TNFα TCGAGTGACAAGCCCGTAGC GAAGAGAACCTGGGAGTAGATAA 
IL-1β GATGATGACGACCTGCTAGTGTG TGGCTTATGTTCTGTCCATTGAG 
IL-6 ACAGAGGATACCACCCACAACAG AACTCCAGAAGACCAGAGCAGATT 
IL-10 TTTCTGGGCCATGGTTCTCT CCTTACTGCAGGACTTTAAGGGTTA 
GRO ATCCAGAGTTTGAAGGTGATGC CGACCATTCTTGAGTGTGGCTAT 
CINC-2α GCTTCTGCTGCTTCTGCTGATG TGGCTATGACTTCTGTCTGGGTG 
MIP-2 AACATCCAGAGCTTGACGGTGAC GCCTTGCCTTTGTTCAGTATCTT 
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 described above, stained with hemotoxylin and eosin (H&E) and examined in a blinded 
manner at 400× magnification. 
 
6.2.9. Statistical analyses  
The results are expressed as the mean ± SEM.  Multiple groups’ comparisons were 
made using one-way analysis-of-variance (ANOVA) and two-group comparisons were 
made using student’s t-tests (two-tailed).  
 
6.3. RESULTS 
6.3.1. The superior mesenteric artery ischemia/reperfusion injury model in rats 
We surgically induced intestinal ischemia for one hour by ligature of the superior 
mesenteric artery (SMA), and then removed the clamp to allow reperfusion of the affected 
tissues.  A vascular clamp was set in place around the artery also for one hour in the sham 
I/R injury animals, but not tightened to occlude blood flow.  Two hours after surgical 
closing of the abdominal cavity we assessed the impact of these challenges on the animals 
(Fig. 6.1.).  On gross examination, the jejunum of the sham I/R injury animals was a 
healthy pink colour, firm and largely empty of contents (pathology score, 0.3).  On the 
other hand, the jejunum of the I/R injury animals was dark red-purple in colour and 
edematous, fragile to the touch, and contained a substantial volume of bloody fluid 
(pathology score, 3.5).  Histologically, the mucosal epithelium within the jejunum of the 
sham I/R injury animals was intact, as were the villi, while the jejunal epithelium of the 
saline-treated I/R injury rats were entirely destroyed (Fig. 6.2.).  The damage to the villous 
processes of the I/R injury animals extended deep into the crypts such that very little 
villous architecture remained.  There were no inflammatory cells within the lamina propria 
of the sham-surgical animals.  The residual lamina propria of the I/R injury animals 
contained modest numbers of necrotic inflammatory cells and these appeared also within 
the amorphous contents of the gut lumen.  
On gross examination of the remaining organ systems of our animals, we found 
that in the I/R- injury animals the pleural surface of the lungs appeared slightly hyperemic, 
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 but otherwise healthy, while all other organ systems appeared healthy.  We did 
bronchoalveolar lavages (BAL) on each animal and found few neutrophils in the BAL 
fluids of the SMA I/R-injury animals (~1% of WBC, data not shown).  However, 
significant numbers of neutrophils were found in lung tissues of the I/R-injury, but not 
sham surgery animals (p≤0.01; Fig. 6.1B).  As a further assessment of the extent of 
pulmonary involvement in SMA I/R injury pathology, we also assessed transcapillary 
vascular leakage in the lungs, using BAL fluid protein levels and red blood cell (RBC) 
numbers as surrogate markers (Middelveld and Alving 2001).  We found significantly 
more protein in the BAL of the experimental animals than the sham surgical controls 
(p≤0.01; Fig. 6.1C) and also increased numbers of RBC (Fig. 1D).  
 
6.3.2. ELR-CXC chemokine antagonism ameliorates local and distant organ 
pathology in SMA I/R injury    
A large number of inflammatory mediators have been implicated in I/R injury 
pathology, including the ELR-CXC chemokines (Caty, Guice et al. 1990; Sekido, Mukaida 
et al. 1993; Miura, Fu et al. 2001). For that reason we tested the impact of broadly 
antagonizing the ELR-CXC chemokines expressed in our I/R injury animals by systemic 
delivery of CXCL8(3-72)K11R/G31P (G31P).  G31P treatment at the time of ischemia 
induction had a sparing effect on loss of jejunal integrity induced by I/R injury.  The extent 
of the gross jejunal pathology, as determined by the tissue edema, discolouration, and the 
lumen contents, was modestly lower in the G31P-treated animals (pathology score, 2.6) 
compared to the saline-treated I/R injury cohort (Fig. 6.1A).  Histologically, in contrast to 
the saline-treated I/R injury animals, much of the mucosal epithelium and villous 
architecture in the G31P-treated animals was intact, although the tips of some villi were 
damaged and the lumen contained modest amounts of amorphous material (Fig. 6.2).   
As the jejunal mucosa and crypts were largely destroyed by the I/R injury in the 
saline-treated group, we were unable to directly assess neutrophil involvement in this 
pathology.  We therefore assessed the levels of myeloperoxidase (MPO) and matrix 
metalloproteinase-9 (MMP-9), markers of neutrophil primary and tertiary granule release, 
respectively, within the gut tissue.  The results show that the levels of these two markers  
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Figure 6.1.  G31P can prevent local (gut) and remote (lung) tissue injury after 
superior mesenteric artery ischemia and reperfusion.  
 
Ischemia-reperfusion injury was induced in male Sprague-Dawley rats (n=5/group) 
by total occlusion of the superior mesenteric artery (SMA) for 1hour followed by 
reperfusion for 2 hour.  At this time sham-surgical rats (control), saline-treated ischemia-
reperfusion animals (I/R), and G31P-treated I/R animals were sacrificed.  (A) The gross 
levels of jejunum (local organ) pathology was determined by direct examination of the gut 
tissues (hemorrhage, edema), as noted in the Material and Methods. (B)  The numbers of 
neutrophils present in lung tissue sections were enumerated by direct counting at 400x 
power, while (C)(D) the bronchoalveolar lavage fluid (BALF) levels of protein (µg/ml) 
and red blood cell (RBC) numbers were assessed by protein microassay and direct 
counting as surrogate measures of pulmonary vascular leakage.  The mesenteric I/R 
dramatically augmented gut pathology, neutrophil infiltration of the lung tissues, and loss 
of vascular integrity in the lungs, and the G31P treatments significantly reduced these 
effects. The result is representative one of two independent experiments. **, p ≤ 0.01, 
relative to the saline-treated I/R-operated rats.  
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Sham I/R  
I/R+G31P 
 
 
Figure 6.2. Photomicrographs of the jejunal injury in sham-surgical and saline- or 
G31P-treated I/R injury animals.  
 
The jejunum from all the animals in Fig. 6.1 were processed to paraffin sections, 
stained with standard H& E stain, and representative sections photographed.   The sham 
surgery animals did not suffer any appreciable jejunal pathology (left panel).  On the other 
hand, the villie and crypts of the I/R animals suffered massive loss of integrity (middle 
panel), and G31P treatment had very significant sparing effects on this I/R-I-induced 
mucosal and crypt erosion (right panel). Original magnification × 200.  
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 increased in the jejunal tissues of the I/R injury animals (Fig. 6.3A, B) and that the G31P 
treatment reduced the levels of both by 70-80%.  We also assessed the levels of MMP-2 (a 
product of activated epithelial cells(Fligiel, Standiford et al. 2006)), and found that I/R 
injury induced a three-fold increase of the levels of MMP-2 in the gut, while the G31P 
treatment reduced its expression by ≈50% (Fig. 6.3B). 
Antagonizing the ELR-CXC chemokines also had protective effects on the distant 
organ pathology in our animals.  The numbers of lung parenchymal neutrophils was ≈70% 
lower in the G31P-treated animals than in the saline-treated I/R injury animals (p≤0.01; Fig. 
6.1B).  And this reduction in inflammatory cell involvement in the G31P-treated animals 
was reflected by a similar reduction in transcapillary vascular leakage (BAL fluid protein 
levels and RBC numbers; Fig. 6.1C, 1D). Compared with the levels of MMP-9 and -2 in 
the jejunum, there were very low levels of these two gelatinases in the lung tissues, such 
that the zymogram signals were not easily discernible (data not shown).  We also assessed 
whether I/R injury led to a peripheral neutrophilia in our animals, but found that the total 
WBC and neutrophil counts were not significantly elevated in the I/R injury animals (Fig. 
6.4A, 4B, 4C).  We did however observe a significant increase in the percentage of 
circulating neutrophils in the G31P-treated I/R injury animals, relative to the saline-treated 
I/R injury animals (Fig. 6.4B). Taken together, our data confirm that distant organ 
involvement was a significant event in our model of SMA I/R injury and that ELR-CXC 
chemokine antagonism significantly reduced this pathology. 
 
6.3.3. ELR-CXC chemokine blockade reduces local and remote organ inflammatory 
mediator expression   
Our G31P treatments reduced neutrophil influx into the affected tissues and also 
reduced the gut pathology scores, though somewhat less dramatically so.  We wished to 
determine whether these effects were correlated with local expression of inflammatory 
cytokines and chemokines.  Thus we measured the tissue levels of TNFα, IL-1β, IL-6, IL-
10, GRO, CINC-2α, and MIP-2 expression in both the gut and lungs of our animals using 
qRT-PCR.  In the jejunum, I/R injury markedly induced expression of IL-6, GRO, CINC-
2α and MIP-2, but only modestly upregulated expression of TNFα (Fig. 6.5.).   IL-1β was  
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Figure 6.3.  G31P treatments modestly ameliorate local neutrophilic inflammation in 
I/R injury animals. 
 
The jejunal tissues of the animals in Fig. 6.2 were homogenized and the levels of 
neutrophil myeloperoxidase (MPO) and matrix metalloproteinase-9 (MMP-9), as well as 
MMP-2 were assessed by colorimetric assay (MPO) and gel zymography (MMP-9 and 
MMP-2).  MPO and MMP-9 were employed as surrogate measures of neutrophil influx 
into these tissues, the integrity of which was almost completely compromised.  All three 
markers were increased in the I/R injury animals and G31P treatment reduced each of them. 
The MMP-9 and -2 levels are presented as relative units. The results depicted are from one 
experiment that is representative of two independent experiments.  
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Figure 6.4.  Impact of G31P treatments on circulating neutrophils in I/R injury 
animals. 
 
Peripheral blood from the animals in Fig. 1 were obtained and (A) the numbers of 
white blood cells (WBC)/ml blood were determined by direct counting using a 
hemocytometer.  Blood smears were generated from this blood and stained with Wright’s 
solution, then (B) the proportion of neutrophils in the WBC were determined by direct 
counting, then (C) the total blood neutrophils calculated using this data.  The data are 
expressed as the mean number of WBC, percent neutrophils, and numbers of neutrophils 
(± SEM), respectively. The data indicate that G31P treatment did not change total WBC, 
but slightly increased total neutrophils in the blood versus saline treatment led to a 
significant increase in the proportion of circulating neutrophils.  These results are from one 
experiment that is representative of two independent experiments. *, p<0.05, versus the 
saline-treated, I/R-injury animals.  
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 not significantly upregulated as a consequence of the I/R injury.  ELR-CXC chemokine 
blockade decreased IL-6 and IL-10 expression by 20% and 44% respectively, but had no 
discernible effect on TNFα expression. Interestingly, the G31P treatment also reduced 
MIP-2 and GRO, but not CINC-2α, expression. 
In the lungs, we observed markedly reduced inflammatory mediator expression 
relative to the gut, with some of these not achieving expression levels two-fold greater than 
the sham surgical controls (our internal cut-off for significantly increases in qRT-PCR 
signals).  Thus, we consider that there were no significant increases in TNF, IL-6, GRO, or 
CINC-2α expression in the I/R injury animals relative to the sham surgical controls (data 
not shown).  On the other hand, the levels of IL-1β, MIP-2, and IL-10 were increased 
approximately three-fold with the tissue injury.  G31P treatments reduced the expression of 
MIP-2 to near background and reduced IL-1β and IL-10 expression by 50 and 30%, 
respectively, relative to the saline control animals (Fig. 6.6.).  These results indicate that 
G31P treatment did reduce ELR-CXC chemokine expression in the inflamed lung tissues 
following intestinal ischemia and reperfusion. 
 
6.4. DISCUSSION 
Trauma-associated multiple organ failure (MOF) is a recognized sequel to 
intestinal ischemia-reperfusion (I/R) injury, and neutrophil sequestration is known to play 
a critical role in mediating both local and remote organ dysfunction (Schmeling, Caty et al. 
1989; Koike, Moore et al. 1993; Cerqueira, Hussni et al. 2005).  Therapies for such MOF 
have focused on blocking neutrophil recruitment, with positive experimental outcomes 
being realized through antagonism of individual ELR-CXC chemokines.  Simultaneous 
targeting of two of these chemokines (e.g., GRO and MIP-2) provides superior protection 
over targeting only one (Miura, Fu et al. 2001).  On the other hand, antagonizing alternate 
neutrophil ligands (e.g., C5a, LTB4, and PAF) reportedly only partially inhibits neutrophil-
mediated I/R injury (Souza, Cara et al. 2000; Souza, Coutinho et al. 2000; Arumugam, 
Shiels et al. 2002; Kohtani, Abe et al. 2002).  Despite the reports of a critical role for 
neutrophils in intestinal I/R injury, there are reports that depleting circulating neutrophils 
before experimental induction of I/R injury does not reduce either local or remote organ  
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Figure 6.5.  Effect of G31P treatments on expression of proinflammatory cytokine 
and chemokine in I/R injury gut tissues.  
 
Jejunal tissues obtained as in Fig. 6.3 were also processed for total RNA extraction, 
and the levels of TNFα, IL-β, IL-6, IL-10, GRO, CINC-2α, and MIP-2 expression were 
assayed by qRT-PCR, as in the Materials and Methods section.  The data are expressed as 
the relative quantities of mRNA relative to a calibrator sample (a representative sham 
surgical group sample).  The results indicate that I/R injury differentially increased 
expression of TNFα, IL-6, IL-10, GRO, MIP-2, and CINC-2 relative to the sham-surgical 
animals.  The G31P treatments can modestly reduced IL-6 and IL-10, as well as GRO 
expression and more effectively reduced MIP-2 expression.  Thes results depicted are from 
one experiment that is representative of two independent experiments.  
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Figure 6.6.  Effect of G31P treatments on expression of proinflammatory cytokine 
and chemokine in I/R injury lung tissues.  
 
Lung tissues obtained as in Fig. 6.1 were also processed for total RNA extraction, 
and the levels of cytokine and chemokine expression were assayed by qRT-PCR, as in Fig. 
5.  The data are expressed as the relative quantities of mRNA relative to a calibrator 
sample (a representative sham surgical group sample).  The results indicate that I/R injury 
differentially increased expression of IL-1β, IL-10, and MIP-2, but not TNF, IL-6, GRO, 
or CINC-2 (data not shown), relative to the sham-surgical animals.  The G31P treatment 
modestly reduced IL-6 and IL-10 expression, and reduced MIP-2 expression to 
background.  These results are from one experiment that is representative of two 
independent experiments.  
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 injury (de Vries, Kohl et al. 2003), and that macrophage depletion instead substantially 
ameliorates such pathology (Chen, Lui et al. 2004).  Nevertheless, we observed very 
significant sparing of local and remote tissue injury by simultaneous blockade of all ELR-
CXC chemokines. 
We have generated multiple isoforms of the ELR-CXC chemokine antagonist, 
CXCL8(3-72)K11R/G31P (i.e., G31P) and each of these are equally effective in blocking 
human ELR-CXC chemokine-dependent neutrophil activation (bG31P, hbG31P, hG31P; 
ref (Li, Zhang et al. 2002; Zhao, Li et al. 2007) and footnote a).  In vitro, G31P 
antagonizes CXCR1 and CXCR2 ligand-induced intracellular Ca2+ flux, ROI production 
and chemotaxis in neutrophils, as well as over-riding their anti-apoptotic influence on these 
cells.  But G31P also dampens neutrophil activation (i.e., intracellular Ca2+ flux, 
chemotaxis) induced by ligands for heterologous G protein-coupled receptors (GPCR), 
including those for LTB4, C5a, and f-Met-Leu-Phe (Zhao, Town et al. 2009).  Potentially 
also of relevance in the present study, G31P mitigates full activation of epithelial cells that 
are challenged with endotoxin, reducing their secretion of CXCL1, CXCL8, and IL-6, 
perhaps by interrupting an ELR-CXC chemokine-dependent autologous activation cascade 
(Zhao, Town et al. 2009).  Interestingly, it has been reported that TLR4 is a critical element 
in I/R injury pathology (Wu, Chen et al. 2007), which raises the question of whether 
G31P’s protective effects could have been in part related to its ability to antagonize 
endotoxin-induced epithelial cell activation.  It is known that epithelial cell apoptosis is 
prominent in intestinal I/R injury (Coopersmith, O'Donnell et al. 1999) and our 
histopathology data confirms that the intestinal epithelium suffered catastrophic damage in 
our I/R injury animals, but that the G31P treatment significantly ameliorated this. 
G31P was developed to target neutrophils and, more specifically, their responses to 
ELR-CXC chemokines.  As such, it dampens the pathologic outcomes of the neutrophilic 
inflammatory responses that are prominent in experimental airway endotoxemia (Gordon, 
Li et al. 2005), environmental pollutant exposure (Podechard, Lecureur et al. 2008), and 
aspiration pneumonia (Chapter 5).  Herein, we used a rat superior mesenteric artery (SMA) 
I/R model to examine the impact of ELR-CXC chemokine antagonism on intestinal I/R-
induced local and remote organ injury. We found that G31P significantly blocked SMA 
I/R-induced neutrophil sequestration in the lung and modestly inhibited neutrophil marker 
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 MPO and its pathologic sequellae in the gut.  Given that the jejunal tissues were so 
severely disrupted in our saline-treated I/R injury animals we were not able to assess 
neutrophil infiltration directly, but our surrogate markers (MPO, MMP-9) clearly 
suggested that they had been recruited.  MPO is routinely used as a marker of neutrophil 
sequestration (Souza, Bertini et al. 2004), although it would not differentiate between 
intravascular and extravascular neutrophils.  Our data confirms however that ELR-CXC 
chemokine antagonism had a decided sparing effect on neutrophil recruitment from the 
vasculature into the lung tissues.  Analogous effects on tissue MPO levels have been 
reported previously with the small molecule allosteric CXCR1/CXCR2 inhibitor, 
repertaxin (30 mg/kg), although it apparently is not active against alternate GPCR (i.e., 
LTB4 or fMLP) (Souza, Bertini et al. 2004).  We query whether G31P’s effectiveness at 
the doses employed herein (i.e., 500 µg/kg) could be related to its ability to simultaneously 
block the CXCR1/CXCR2 and heterologous GPCR (Zhao, Town et al. 2009).  
Neutrophils have been confirmed to be critically involved in remote organ injury, 
e.g., lung (Hernandez, Grisham et al. 1987; Chen, Lui et al. 2004), but their role in 
mediating gut injury in intestinal I/R injury is still uncertain (Hernandez, Grisham et al. 
1987; Simpson, Alon et al. 1993; Chen, Lui et al. 2004). We measured the gut tissue levels 
of the neutrophil tertiary granule marker MMP-9 as well as MMP-2 expression and found 
that the G31P treatments effectively inhibited both of these.  Others have reported high 
level expression of MMP-9, largely in neutrophils, following intestinal I/R injury 
(Robinson, Kelly et al. 2008).  They concluded that MMP-9 induction contributes 
importantly to I/R injury pathology.  Our histological data indicates that intestinal I/R 
induced severe intestinal mucosal injury which was significantly attenuated by G31P 
treatment.  This suggests that the neutrophils were causally involved in this injury, perhaps 
in part through release MMP-9.  MMP-2 is a product of both leukocytes and resident cells 
such as fibroblasts and epithelial cells (Lempinen, Inkinen et al. 2000; Robinson, Kelly et 
al. 2008).  That G31P blocked its expression may provide further (circumstantial) evidence 
that this antagonist may act on neutrophils and other resident cells in this model system.  
We have already documented that G31P acts on bronchial epithelial cells, dampening their 
responses to bacterial endotoxin (Zhao, Town et al. 2009). 
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 Marked expression of the inflammation-associated cytokines TNFα, IL-1β and IL-6 
has been reported previously in both local and remote organ tissues during I/R injury (Caty, 
Guice et al. 1990; Cuzzocrea, De Sarro et al. 1999; Souza, Cassali et al. 2001; Souza, 
Bertini et al. 2004).  We observed little in the way of IL-1 or TNF expression in either the 
lung or gut in our animals, although IL-6 expression was strongly upregulated in the gut 
(but not lungs).  Given that IL-6 reportedly facilitates TNFα and IL-1β production 
(Cuzzocrea, De Sarro et al. 1999), it is possible that our 2 h time-frame for reperfusion was 
too brief to allow significant upregulation of IL-1 and TNF.  IL-6 is reportedly integral to 
loss of gut barrier function after hemorrhagic shock (Yang, Han et al. 2003), and others 
have reported that anti-CINC antibodies significantly reduce circulating levels of IL-6 in 
such models (Kaneko, Tamura et al. 2007).  Our data confirms that intestinal I/R injury 
augments IL-6 expression in the gut, and that ELR-CXC chemokine antagonism can 
effectively decrease this IL-6 expression.  This opens up the question of whether G31P’s 
effects in maintaining jejunal integrity were related to its effects on IL-6.  Expression of 
IL-10, an anti-inflammatory cytokine, was increased significantly in the gut and modestly 
so in the lungs of our I/R injury animals and the G31P treatments had marginal impact on 
its production in either compartment.  It has been reported that blocking the ELR-CXC 
chemokines by either CXCR1/CXR2 antagonists or with anti-CINC-1 antibodies slightly 
increases lung, but not the gut, tissue IL-10 expression (Souza, Bertini et al. 2004).  
However, other studies suggest that IL-10 does not play a significant role in protecting 
against intestinal I/R injury, but rather that it may exacerbate the tissue injuries (Stallion, 
Kou et al. 2002; Nussler, Muller et al. 2003). 
In conclusion, our results indicate that treatment with G31P, a CXCR1 and CXCR2 
antagonist that also dampens responses across heterologous GPCR (i.e., C5aR, BLT1, FPR) 
on ELR-CXC chemokine receptor-positive cells, has potent effects on local and remote 
organ tissue neutrophil sequestration, and thereby protects against related tissue injury.  
This suggests that the approach of broadly blocking the ELR-CXC chemokines may be 
effective at preventing ischemia and reperfusion injuries in clinical situations.  
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CHAPTER 7 : GENERAL DISCUSSION AND CONCLUSION 
 
Excessive neutrophil recruitment and activation have been considered a hallmark of 
acute lung injury (ALI) and the more severe form of disease, acute respiratory distress 
syndrome (ARDS).  These two disorders are responsible for 40-60% of mortality in 
clinical intensive care units (Repine and Beehler 1991; Ware and Matthay 2000; Martin 
2002).  ALI/ARDS can be caused by a variety of direct (e.g., aspiration of gastric content) 
and indirect (e.g., ischemia and reperfusion) insults (Bernard, Luce et al. 1987; Gerkin, 
Oldham et al. 1993).  ELR-CXC chemokines (e.g., CXCL8) play a pivotal role in these 
situations so that their blockade significantly attenuates pathology and mortality (Shanley, 
Davidson et al. 2000; Souza, Bertini et al. 2004).  Although there are a large number of 
ELR-CXC chemokines, there are only two ELR-CXC chemokine receptors, CXCR1 and 
CXCR2.  It is understandable that blockade of these receptors would be a more efficient 
approach than the blockade of any single chemokine.  It is also known that CXCL8 binds 
these two receptors with higher affinity than other members of this chemokine family 
(Mukaida 2003) so that CXCL8 was an ideal candidate to be developed into a competitive 
CXCR1 and CXCR2 antagonist. 
The purpose of this research project was to develop a humanized or human form of 
the ELR-CXC chemokine antagonist, bovine CXCL8(3–74)K11R/G31P (bG31P).  bG31P 
was previously developed by a postdoctoral fellow (Dr. Fang Li) in our lab.  Her data have 
substantially demonstrated that bG31P is a very high affinity broad-spectrum ELR-CXC 
chemokine antagonist (Li and Gordon 2002; Li, Zhang et al. 2002).  This antagonist 
effectively blocked CXCL8 binding to, and its activation of, neutrophils in vitro.  It fully 
antagonized pulmonary neutrophil responses to intradermal or airway endotoxin challenge 
of cattle or guinea pigs, respectively.  It also blocked pyrexia and pleural hemorrhagic 
consolidation in endotoxin-challenged animals (Li, Zhang et al. 2002; Gordon, Li et al. 
2005).  While bG31P could perhaps be useful in the humans, it goes without saying that a 
human equivalent thereof would be of significantly more use.  
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 Prior structure-function studies have indicated that human CXCL8(3-72)K11R is not 
a particularly high affinity neutrophil agonist, and that a combined G31P/P32G 
substitution within human CXCL8(4-72) only marginally reduces its neutrophil agonist 
activities (Clark-Lewis, Dewald et al. 1994), suggesting that human CXCL8(3-
72)K11R/G31P (i.e., the human counterpart of bG31P) would perhaps not be an effective 
chemokine antagonist as discussed above (Chapter 2 rational).  To develop a human form 
of this bovine ELR-CXC chemokine antagonist, my study began with the humanization of 
bG31P.  A human-bovine chimeric protein, bovine CXCL8(3-44)K11R/G31P-hCXC8(45-72) 
(i.e., hbG31P), was generated and its antagonist activities were characterized.  To further 
humanize hbG31P, one-by-one we made substitutions of the remaining amino acids that 
were discrepant between human and bovine CXCL8 (i.e., T3/K, H13/Y, H15/K, E35/A, 
and S37/T).  The antagonist activities of these new molecules were also assessed.  As 
shown in Chapter 3, hbG31P fully retained the antagonist activity of bG31P for human 
neutrophils and its further humanized analogues did not show significantly better blocking 
activity.  
Based on these findings, we began to characterize a fully human form of bG31P, 
human CXCL8 (3-72)K11R/G31P (hG31P) that was generated in our laboratory.  hG31P 
was also tested in guinea pig models of airway endotoxemia and aspiration pneumonia, as 
well as a rat model of  intestinal ischemia and reperfusion injury.  As shown in Chapters 4, 
5, and 6, hG31P potently blocks ELR-CXC chemokine-induced neutrophil activation.  The 
anti-inflammatory effects of hG31P extended to reversing ELR-CXC chemokine-induced 
delays in neutrophil apoptosis, desensitizing heterologous GPCRs and inhibiting 
endotoxin-induced chemokine expression by epithelial cells.  In in vivo systems, hG31P 
was highly effective in blocking the pathology associated with airway endotoxemia, 
aspiration pneumonia, and intestinal ischemia and reperfusion injury, including neutrophil 
recruitment into, and activation within, the airways or gut, chemokine or cytokine 
expression, and pulmonary vascular complications.  The blockade of neutrophil 
recruitment by hG31P in aspiration pneumonia animals did not foster airway bacterial 
outgrowth.  hG31P treatment was also protective in both mesenteric artery I/R-induced 
local and romote organ injury.    
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 To summarize the findings of this thesis, it is clear that:  
1. The chimeric protein hbG31P and its analogues effectively block chemotactic 
responses, ROI release, and calcium infux of human neutrophils stimulated by 
human ELR-CXC chemokines in vitro.  hbG31P has also been shown to have 
potent antagonist activity in blocking pulmonary neutrophil infiltration, as well as 
the loss of vascular integrity in endotoxin-induced acute lung injury in a standard 
guinea pig endotoxemia model.  hbG31P fully retains the antagonist activity of 
bG31P. 
2. A fully human form of bG31P, CXCL8(3-72)K11R/G31P (hG31P), was successfully 
generated.  hG31P was shown to be a CXCR1/CXCR2 antagonist by its abilities to 
inhibit IL-8-induced chemotactic responses and intracellular Ca2+ mobilization in 
CXCR1-transfected HEK cells and human neutrophils, and responses induced by 
CXCR2-exclusive ligands.  hG31P also desensitized heterologous GPCRs (e.g., 
BLT, C5aR, and FPR) on neutrophils and blocked LPS-induced ELR-CXC 
chemokine (e.g., CXCL1, CXCL8) production by bronchial epithelial cells.  The 
anti-inflammatory effects of hG31P extended also to reversing the anti-apoptotic 
influence of ELR-CXC chemokines on neutrophils.  In a guinea pig model of 
airway endotoxemia, hG31P also effectively blocked neutrophil infiltration into, 
and activation within, the airways.  We conclude that the beneficial effects of ELR-
CXC chemokine receptor blockade by hG31P treatment occur at multiple levels, 
including epithelial cells, neutrophils, and alternate GPCRs. 
3. When hG31P was applied in an aspiration pneumonia model, the treatment 
dramatically attenuated the pulmonary vascular complications and pulmonary 
neutrophilia, and reduced airway levels of neutrophil degranulation products.  The 
blocking effect of hG31P also extended to reducing lung tissue CXCL1 and 
CXCL8 expression.  This attenuation of the neutrophil response was not associated 
with rampant airway bacteria outgrowth at 20 h after gastric content challenge.  
Therefore, these data suggest that alternate bacterial clearance mechanisms may 
operate efficiently in the absence of this overt pathology or at least efficiently 
enough to hold bacteria growth in check. 
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 4. The antagonist activities of hG31P treatment were also demonstrated in a rat 
superior mesenteric artery (SMA) I/R injury model. hG31P significantly inhibited 
neutrophil infiltration into the lung as well as pulmonary vascular leakage, and 
significantly decreased neutrophil margination in the circulation of I/R challenged 
animals. The hG31P treatment also partially reduced the loss of mucosal integrity 
and proteinase expression within the jejunum.  Moreover, hG31P treatment blocked 
intestinal I/R-induced local and remote organ expression of inflammatory cytokines 
and ELR-CXC chemokines. These findings suggest that ELR-CXC chemokine 
antagonism has significant protective effects against I/R-induced local and remote 
organ injury. 
In general, these findings suggest that G31P (hereafter, all types of G31P): can 
significantly blunt neutrophil activation (e.g., calcium flux, ROI release, degranulation) 
and recruitment; can effectively ameliorate animal pyrexia and vasculature leakage; and 
also can dramatically decrease tissue chemokine (e.g., CXCL1, -8, MIP-2) and cytokine 
(e.g., IL-6) expression.   
As reviewed in Chapter 1 (§1.2.3.4.), CXCL8 binds the CXCR1 or CXCR2 on 
neutrophils via two major sites, the ELR (Glu4-Leu5-Arg6) motif preceding the first 
cysteine and the receptor recognition loop region (residues 10-17) between the second and 
the third cysteines (the Gly31-Pro32 motif).  The loop region functions as a docking domain 
which determines the chemokine’s binding affinities (Baggiolini 2001).  During the 
process of developing G31P, our intitial truncation of first two amino acids and 
substitution of Lys11 (within the loop region) of CXCL8 with an Arg residue dramatically 
increased its (i.e., bCXCL8(3-74)K11R) binding affinity (Li and Gordon 2001).  Further 
substitution of Gly31 with a Pro residue turned CXCL8(3-72)K11R into a potent antagonist 
(Li and Gordon 2002).  Recent studies by David Cheng group indicated that  the 
substitution of Gly31 with Pro changes the three-dimensional structure of CXCL8 by 
affecting the Cys7-Cys34 disulfide bridge, resulting in a conformational change to the ELR 
motif (Clark-Lewis, Dewald et al. 1994) and thereby dampening ELR motif signaling.   
Prior to developing a human form of bG31P, we found that CXCL8(3-72)K11R does 
not have a much higher binding affinity than wild type CXCL8 (Clark Lewis, Dewald et al. 
 142
 1994).  We also found that CXCL8(4-72)G31P/P32G has much lower binding affinity than 
wild type CXCL8 (Clark Lewis, Dewald et al. 1994), which raised the question of whether  
human CXCL8(3-72)K11R/G31P could be a practical antagonist clinically. Thus we   
generated a human-bovine chimeric ELR-CXC chemokine antagonist, i.e. hbG31P, but 
also a fully human G31P.  I undertook the humanization of bG31P, others generated 
hG31P.  Despite our supposition, the data from hbG31P and its analogues suggested that 
fully human form of bG31P might be a functional antagonist (Zhao, Li et al. 2007), and 
indeed we demonstrated that hG31P is a potent ELR-CXC chemokine antagonist.  Why 
hG31P turned to be an antagonist could potentially be because the substitutation of Gly for 
Pro31 affects the scaffold structure of CXCL8, particularly when this was in concert with 
the Arg substitution for Lys.  The effect of this substitution could differentially affects 
CXCL8(4-72) and CXCL8(3-72).   
As hG31P was shown to be effective in blocking several important inflammatory 
responses, there is substantial interest in understanding how it does this.  The most 
impressive finding of this thesis is the potent effects of G31P on blocking neutrophil 
infiltration into, and activation within, the inflamed tissues.  Neutrophil migration and 
activation can be attributed to several groups of important inflammatory mediators, such as 
proinflammatory cytokines (e.g., TNFα, IL-1), chemoattractants (e.g., C5a, LTB4, PAF, 
ELR-CXC chemokines, fMLP), and adhesion molecules (e.g., β2-integrin, P-, L-selectin, 
ICAM-1).  These molecules are found within or expressed by plasma (e.g., C5a), 
leukocytes (e.g., monocytes, neutrophils), and resident cells (e.g., endothelial cells, 
epithelial cells, macrophages).   
G31P may directly block neutrophil activation induced by proinflammatory 
mediators (e.g., ELR-CXC chemokines, C5a).  We knew that G31P blocks ELR-CXC 
chemokine-induced neutrophil activation.  We had shown that bG31P has higher affinity 
for neutrophils than CXCL8 and binds via both the CXCR1 and CXCR2 (Li and Gordon 
2002).  Given that CXCL8 has higher affinity for these receptors than their other ligands 
(e.g., CXCL1, CXCL5), it is easy to understand that G31P also has a higher binding 
affinity for the CXCR1 and CXCR2 than other ELR-CXC chemokines.  G31P, therefore, 
can competitively bind both receptors and block ELR-CXC chemokine binding and 
thereby inhibit their agonist activities.  We propose that this process occurs when the 
 143
 neutrophils are still in the blood stream.  In ex vivo experiments, our results showed that 
circulating neutrophils from hG31P-treated and gastric content-challenged guinea pigs 
were hyporesponsive to CXCL8-induced chemotactic responses (Chapter 5).  Our lab also 
has previously shown similar results when using bG31P treatment in airway endotoxemic 
animals (Gordon, Li et al. 2005).  This desensitization of neutrophil responses to 
environmental ELR-CXC chemokines may also happen in the tissue.  When using 
neutrophil chemotaxis assays, we have also confirmed that bG31P strongly antagonizes 
neutrophil responses to CXCL8 (Li and Gordon 2002).  In our recent studies, hbG31P and 
hG31P were also shown to effectively block neutrophil chemotactic responses to CXCL8, 
CXCL1, and CXCL5 (Chapters 3 and 4).  We also found that hbG31P and hG31P can 
inhibit CXCL8-induced white blood cell ROI release and CXCL8- and CXCL1-induced 
neutrophil calcium mobilization.  Taken together, G31P can competitively bind both the 
CXCR1 and CXCR2 receptors and can effectively antagonize ELR-CXC chemokine-
induced neutrophil activation and chemotactic responses.  
Secondly, through binding the CXCR1 and CXCR2, G31P may desensitize the 
alternate receptors on neutrophils for other chemoattractants and prevent excessive 
neutrophil activation by these molecules.  Some studies showed that CXCL8 can 
heterologously desensitize neutrophil receptors for fMLP, C5a, LTB4 and PAF through 
binding the CXCR1 (Richardson, Pridgen et al. 1998; Ali, Richardson et al. 1999).  Given 
that G31P has a higher affinity for the CXCR1 and CXCR2 than wild type CXCL8, it is 
reasonable that G31P also would desensitize neutrophil receptors for fMLP, C5a, LTB4, 
and PAF.  Our results in Chapter 4 confirmed that G31P inhibits fMLP-, C5a-, and LTB4-
induced neutrophil chemotactic and calcium flux responses, which suggests that G31P may 
heterologously desensitize their respective GPCRs.  Although we did not test if G31P can 
block PAF-induced neutrophil activation, the heterologous desensitization effect of G31P 
may also extend to the PAF receptor inasmuch as CXCL8 can do so.  Based on these 
findings, we conclude that G31P can also block fMLP-, C5a-, LTB4-, and PAF-induced 
neutrophil activation and chemotactic responses.  In summary, G31P may block both ELR-
CXC chemokines- and other neutrophil chemoattractant-induced neutrophil migration and 
activation, which could explain why G31P has such potent effects on blocking neutrophils 
recruitment into and activation within the airway.  
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 Besides the blockade of neutrophil calcium mobilization and ROI release, G31P 
may also block other aspects of neutrophil activation, such as degranulation, integrin 
activation and L-selectin shedding.  bG31P was shown to effectively inhibit CXCL8-
induced β-glucuronidase (neutrophil primary granule) release (Li and Gordon 2002).  
Other study also showed that an anti-CXCR2 antibody or nonpeptide CXCR2 antagonist 
can effectively block IL-8-induced MMP-9 (neutrophil tertiary granule) release 
(Chakrabarti and Patel 2005).  In our in vivo systems, we have demonstrated that hG31P 
treatment can dramatically reduce the levels of neutrophil granule markers MPO, 
lactoferrin, and MMP-9 production in the airway or lung tissue, which may thereby reduce 
the granule enzyme-induced tissue damage.  As MMP-9 can also facilitate neutrophil 
transendothelial cell migration through its collagenase activities, the reduction of the 
release of this enzyme may contribute to the blockade of neutrophil recruitment.  Our 
results did not provide direct evidence that G31P can affect expression of integrin and L-
selectin on neutrophils,  but ELR-CXC chemokines have been shown to induce neutrophil 
β2-integrin (Mac-1) up-regulation and L-selectin shedding (Bajt, Farhood et al. 2001).  As 
expression of these two molecules is dependent on neutrophil calcium mobilization, and as 
hG31P blocks CXCL1- and CXCL8-induced neutrophil calcium flux, it seems likely that it 
also decreases the expression of adhesion molecules, resulting in decreased neutrophil 
transmigration.  In addition to the inhibition of excessive neutrophil activation, our data 
indicate that G31P also can reverse CXCL1- and CXCL8-induced anti-apoptotic effects on 
neutrophils and thereby inappropriate prolongation of their life-span in the circulation or 
tissue, which in turn may reduce the tissue damage brought by activated neutrophils.  The 
mechanisms involved in G31P-induced blockade of neutrophil activation will be discussed 
below. 
Given that CXCL8 can homologously desensitize CXCR1 and CXCR2 responses 
to CXCL8 and other ELR-CXC chemokines, and that G31P has a higher binding affinity, 
the reason that G31P can effectively block ELR-CXC chemokine-induced neutrophil 
activation may be attributed to a higher ability for homologous desensitization of CXCR1 
and CXCR2. CXCL8- or G31P-induced receptors homologous desensitization is mainly 
caused by CXCR1 and CXCR2 phosphorylation and internalization.  Sustained G31P-
induced CXCR1 and CXCR2 desensitization may lead to the blockade of neutrophil 
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 activation by wild type ELR-CXC chemokines.  As discussed above, CXCL8 is also able 
to heterologously desensitize the GPCRs for C5a, fMLP, LTB4 and PAF.  The ability of 
CXCL8 to desensitize the C5a and fMLP receptors is more limited than those of C5a and 
fMLP to desensitize CXCR1 (Richardson, Pridgen et al. 1998; Ali, Richardson et al. 1999).   
The reason is because CXCL8 signals neutrophils mainly through the PI3K/Akt pathway, 
whereas fMLP and C5a mainly use the p38MAPK-dependent pathway.  In inflammatory 
settings, when facing different signals, neutrophils adopt hierarchical responses to fMLP 
and C5a, which activate MAPK, downstream signaling of which dampens PI3K/Akt 
signaling.  CXCL8 was also shown to heterologously desensitize fMLP and C5a receptors, 
which may be because CXCL8-stimulated PI3K/Akt signaling is reciprocally able to 
dampen MAPK signaling, but at reduced levels, or it may activate MAPK signaling cause 
MAP kinase phosphorylation and thereby reduced responsive to C5a or fMLP stimulation.  
Upon CXCL8 binding, heterotrimeric G-protein can be activated by the exchange of GDP 
for GTP, which disassociates into GTP-bound α and βγ subunits.  The βγ subunit, which 
can activate PI3K signaling pathway, may also activate MAPK signaling (Baggiolini 2001; 
Thelen 2001).  CXCL8 provides weaker signals for heterologous desensitization than 
fMLP and C5a possibly because of  less resistance of phosphorylation of CXCR1 and 
CXCR2 than FPR and C5aR do (Ali, Richardson et al. 1999).  The reasons that G31P 
improved the strength of heterologous desensitization compared with CXCL8 may be that, 
firstly, its high affinity binding to the receptors possibly strengthens the interference of 
PI3K signaling with MAPK signaling or directly increases stronger phosphorylation of 
MAPK and thereby leads to reduced neutrophil responses to fMLP and C5a.  Secondly, the 
CXCR1 and CXCR2 may become more resistant to phosphorylation induced by fMLP and 
C5a after higher affinity binding by G31P.  
 The airway epithelium, as a primary interface between the host and the 
environment, plays a crucial role in the innate immune response (Becker, Diamond et al. 
2000).  We have evidence that G31P treatment can decrease tissue cytokine and chemokine 
expression in vivo.  We also showed that hG31P dose-dependently decreases LPS-induced 
cytokine (e.g., IL-6) and chemokine (e.g., CXCL1, CXCL8) expression by pulmonary 
epithelial cells.  We speculate that G31P may indirectly block epithelial cell activation 
induced by LPS through interrupting LPS-TLR4 signaling (e.g., MAPK, ERK 
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 phosphorylation) through its activated PI3K signaling pathway, which is similar to 
heterologues desensitization of other GPCR, and it may also directly block ELR-CXC 
chemokines (e.g., CXCL8)-induced epithelial cell activation.  Pulmonary epithelial cells 
may express CXCR2, which is found to be important in neutrophil recruitment and 
increased pulmonary permeability in LPS-induced acute lung injury (Reutershan, Morris et 
al. 2006).  Since epithelial cells are the important sources of CXCL8 (Fujii, Hayashi et al. 
2002; Sha, Truong-Tran et al. 2004), which may bind their CXCR2 in an autocrine fashion 
and further activate these cells, CXCL8 production in the airway presumably forms part of 
an autocrine system.  G31P, as a CXCR1 and CXCR2 antagonist, may block CXCL8-
induced epithelial cell activation, reducing its own expression.  The LPS-TLR4 signaling 
pathway also mediates LPS-induced epithelial cell activation, which involves a signaling 
complex including the kinases interleukin-1 receptor-associated kinase, p38, Jnk, and 
ERK1/2 (Guillot, Medjane et al. 2004).  The results from a postdoctoral fellow (Dr. 
Wenjun Wang) in our lab have indicated that G31P blocks CXCL8-induced ERK1/2 
phosphorylation in neutrophils (unpublished data), which suggest that G31P may also be 
able to block the ERK1/2 phosphorylation in epithelial cells and reduce their activation 
(e.g., cytokine and chemokine expression). 
Our results also showed that G31P dramatically reduced the release of 
inflammatory mediators (e.g., IL-6, IL-8) during neutrophil-epithelial cell interactions.  We 
only examined IL-6 and IL-8 expression in the neutrophil and A549 epithelial cell co-
cultures, and do not know which population of cells was activated and therefore 
responsible for the cytokine and chemokine release.  Some studies have demonstrated that 
neutrophil elastase played an important role in inducing airway epithelial cells to produce 
IL-8 (Devaney, Greene et al. 2003; Chen, Lin et al. 2004).  Neutrophil defensins and TNFα 
also can induce a dramatic level of IL-8 and ENA-78 expression from alveolar epithelial 
cells (e.g., A549 cell) and increase expression of IL-8 and IL-6 from bronchial epithelial 
cells (van Wetering, Mannesse-Lazeroms et al. 2002).  Epithelial-derived IL-8 and ENA-
78 can further activate neutrophils to degranulate and release more pro-inflammatory 
mediators (e.g., IL-1β, TNFα) and therefore amplify these reciprocal inflammatory 
responses.  Neutrophil elastase can also induce airway epithelial cell apoptosis, which may 
lead to epithelial barrier disruption, increasing alveolar epithelial permeability and thereby 
 147
 causing alveolar edema (Moraes, Zurawska et al. 2006).  G31P can inhibit further 
neutrophil activation by blocking chemokine signaling or may also block the activation of 
epithelial cells and reduce further IL-8 production. Either way of G31P does interrupt these 
intercellular interactions sufficiently to ameliorate their mutually expanding inflammatory 
responses.   
As examined in the literature review (§1.2.2.1.2.), vascular endothelial cells play 
important roles in mediating neutrophil migration during neutrophilic inflammation. Once 
activated by bacterial products (e.g., LPS), proinflammatory cytokines (e.g., TNFα, IL-1β), 
or chemoattractants (e.g., C5a, IL-8, MIP-2), they can express large amounts of selectins 
(P-selectin, E-selectin), proinflammatory cytokines (e.g., TNF, IL-1) and chemoattractans 
(e.g., PAF, IL-8) (Nawroth, Bank et al. 1986; Grace 1994; Ranta, Orpana et al. 1999).  
These inflammatory mediators are essential in the process of neutrophil transendothelial 
migration (Smart and Casale 1994), but they also amplify the inflammatory responses, 
resulting in endothelial cell damage and disruption of vascular integrity (Mantovani, 
Bussolino et al. 1992).  In LPS-induced animal airway endotoxemia, we found dramatic 
areas of hemorrhagic consolidation on the pleural surface and substantial RBC 
extravasation into the airways.  G31P treatments very significantly ameliorated these two 
pathologic features.  As mentioned above, neutrophil transendothelial migration 
contributes significantly to vascular endothelial damage and the increased vascular 
permeability in a variety of ways. In the case of LPS-induced acute lung injury, LPS can 
stimulate endothelial cells and other resident cells to release TNFα and IL-1β, which can 
induce the release of vasodilatory factor, PGI2, leading to increasing vascular permeability 
(Mantovani, Bussolino et al. 1992).  These two molecules can also stimulate neutrophils 
and epithelial cells to produce MMP-9, which can degrade basement membrane 
constituents of the endothelium, resulting in endothelial damage (Corbel, Boichot et al. 
2000).  TNFα and IL-1β may directly induce endothelial injury by the end-products (HO*) 
of the Fenton’s (oxidization) reaction and/or the generation of prostanoids in endothelial 
cells, which is not yet fully understood (Lentsch and Ward 2000).  Neutrophil-derived 
elastase can facilitate endothelial cell ROI generation and release and further induce 
endothelial cytotoxity.  Neutrophil-derived ROI can induce phosphorylation of focal 
adhesion kinase in endothelial cells, resulting in disruption of intercellular tight junctions, 
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 redistribution of focal adhesions, and thereby cause vasulature damage (Usatyuk and 
Natarajan 2005).  Thus, the endothelial cell damage induced by activated neutrophils 
requires products from both the neutrophil (e.g., ROI, elastase, MMP-9) and the 
endothelial cell (e.g., ROI) (Lentsch and Ward 2000).  In summary, all the damage to 
vascular endothelial cells, basement membrane, and matrix components induced by the 
above-mentioned mediators during neutrophil and endothelial cell interaction can lead to 
loss of pulmonary vascular integrity and result in pulmonary edema and microvascular 
haemorrhage.  The effects of G31P on blocking neutrophil activation have been discussed 
above.  Next, the possible roles of G31P in inhibiting endothelial cell activation will be 
discussed below.  
 Similar to neutrophils, ELR-CXC chemokines activate endothelial cells through 
binding to the CXCR1 and CXCR2, which are expressed in human umbilical vein 
endothelial cells (HUVEC) and human lung microvascular endothelial cells (HMVEC).  
IL-8 leads to endothelial cell cytoskeletal reorganization, which may contribute to the 
increased vascular permeability (Schraufstatter, Chung et al. 2001). This notion was 
confirmed in a LPS-induced acute lung injury model (Reutershan, Morris et al. 2006). The 
effect of G31P on CXCR2 signaling may ameliorate the vascular permeability changes and 
hemorrhage induced by LPS challenge in the lung tissue.  ELR-CXC chemokines (e.g., 
MIP-2, KC) also play important roles in mediating P-selectin expression on endothelial 
cells, presumably also through CXCR2 signaling (Zhang, Liu et al. 2001).  As reviewed in 
Chapter 1, P-selectin is one of the major selectins mediating neutrophil rolling.  Blocking 
of P-selectin expression can inhibit neutrophil rolling (Johnston, Walter et al. 1997).  G31P 
might play an important role in blocking ELR-CXC chemokine-induced P-selectin 
expression therefore preventing neutrophil migration.  Studies have also found that IL-6 
plays critical roles in increasing endothelial permeability during tissue hypoxia and I/R 
injury (Ali, Schlidt et al. 1999; Klein, Hoke et al. 2008).  The effect of G31P on IL-6 
production during neutrophil-epithelial cell interactions or by LPS-induced epithelial cells 
may contribute to the reduction of lung permeability changes.  In our intestinal I/R model, 
we had evidence that G31P treatment can dramatically reduce IL-6 expression in lung and 
gut tissues.  In conclusion, neutrophil transendothelial migration activates endothelial cells 
and cause vascular damage and cytokines, chemokines, and adhesion molecules play 
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 important roles in this process.  The antagonist activities of G31P in blocking the 
expression these molecules can ameliorate vascular damage. 
G31P treatment was also demonstrated in our aspiration pneumonia and I/R injury 
models to effectively reduce chemokine (e.g., IL-8, MIP-2) and cytokine (e.g., TNF, IL-1, 
IL-6) responses.  Epithelial cells are known to be a primary source of cytokines and 
chemokines in inflammatory settings.  As discussed above, firstly, our results have 
documented that G31P can significantly inhibit IL-8 and IL-6 release from LPS-challenged 
epithelial cells and during neutrophil-epithelial cell interactions.  Its blockade of neutrophil 
activation may also inhibit the expression of other chemokines, such as ENA-78, because 
neutrophil defensins can induce ENA-78 production from epithelial cells (van Wetering, 
Mannesse-Lazeroms et al. 2002).  In endothelial-epithelial cell co-cultures, the endothelial 
cells stimulated the epithelial cells to release IL-6 and reciprocally, the epithelial cells 
enhanced the release of IL-8 from the endothelial cell, which facilitates neutrophil 
transmigration (Mul, Zuurbier et al. 2000).  G31P blockade of neutrophil activation, 
particularly CXCR1 or CXCR2 signaling, may reduce this reciprocal effect and decrease 
cytokine and chemokine expression. As reviewed in Chapter 1 (§ 1.2.1.4), LPS induces 
macrophages/monocytes, neutrophils, endothelial cells and epithelial cells to produce 
proinflammatory cytokines, ELR-CXC chemokines and adhesion molecules.  We have 
evidence that G31P blocks LPS-induced cytokine and chemokine expression from 
epithelial cells, but we do not have direct evidences on its effects on other cell types.  It is 
not surprising that G31P would reduce LPS-induced neutrophil and endothelial cell 
activation as their expression of CXCR1 and CXCR2 is critical in their activation. But 
further studies are required to confirm these proposals.   
To give an overview of G31P therapeutic functions, I summarized the possible 
mechanisms of G31P in blocking neutrophil or other resident cell activation in airway 
enodoxemia and intestinal I/R injury in figures 7.1. and 7.2..  
Our results suggest that G31P-mediated inhibition of neutrophil recruitment does 
not dampen bacterial clearance in the airway, which was assessed at 20 h after gastric 
content challenge. As neutrophils are major effector cells that phagocytose foreign 
pathogens, we would need to examine bacterial outgrowth after 96 h or more to see if 
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 neutrophil blockade by G31P affects longer term outcomes.  It is also worth determining if 
the functions of other cell types (e.g., macrophages/monocytes) are changed or if alternate 
defense weaponary (e.g., epithelial defensins) are functionally increased or otherwise 
altered.  
We evaluated the antagonist activities of G31P in several model systems, including 
airway endotoxemia, aspiration pneumonia, and mesenteric I/R injury.  It seems that the 
effects of G31P on neutrophil infiltration into the gut and its amelioration of gut pathology 
in the I/R injury model were somehow less pronounced than its effects in the other two 
models. The question raised here is in which kinds of diseases G31P can be effective and 
via which route it should be administered.  Our lab has previously demonstrated that G31P 
given intramuscularly (i.m.) and subcutaneously (s.c.) is more effective than when given 
i.v. in dermal LPS challenge reactions (Li, Zhang et al. 2002).  In mesenteric I/R injury, 
G31P was shown to ameliorate neutrophilic pathology but not as profoundly as during 
aspiration pneumonia or airway endotoxemia, when given by the same route.  Other ELR-
CXC chemokine antagonists, such as repertaxin, have been given i.v. to I/R injury animals.  
(Souza, Bertini et al. 2004).  When it was used in a rat liver I/R injury model (1 h of 
ischaemia and 12 h of reperfusion) and given via both s.c. and i.v., before and after 
reperfusion, respectively, it was effective in blocking neutrophil infiltration into the liver. 
In the same report, in a cecal ligation and puncture (CLP) model, when it is given s.c 
multiple times (e.g., before and after the CLP), it significantly reduced neutrophil 
infiltration into the peritoneal cavity (Bertini, Allegretti et al. 2004).  Another drug, 
GROα(8 –73) (i.e., GROα without a complete ELR motif, which thereafter functions as 
aPMN antagonist), was given via i.p. in a peritonitis model and also shown to effectively 
block neutrophil infiltration (McColl and Clark Lewis 1999).  All of these suggest that 
G31P could perhaps also be effective in blocking neutrophilic pathology when given via 
i.v. or i.p. in these settings.  The reason may be that i.v. or i.p. delivery may help the drug 
work at the inflammation site, such as the ischemic organ, and prevent the exacerbation of 
inflammatory responses.  Considering that the I/R injury occurs in a matter of several 
hours, G31P given via these two ways may be more effective. 
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Figure 7.1.  The effects of G31P in blocking neutrophilia pathology in airway 
endotoxemia.   
 
During airway endoxemia, LPS can bind to LPS-binding proteins (LBP) and form a 
LPS-LBP complex, which interacts with CD14 and later with TLR4 on airway 
macrophages (AM), leading to activation via TLR4 signaling. LPS-TLR4 signaling and 
C5a (e.g., generated by LPS-induced alternative pathway) can activate AM to produce 
ELR-CXC chemokines (e.g., CXCL8/IL-8) and proinflammatory cytokines (TNF, IL-1, 
and IL-6).  LPS-TLR4 signaling can also activate airway epithelial cells to release the 
aforementioned chemokines and cytokines.  Cytokines by themselves can further induce 
chemokine expression by epithelial cells.  As airway epithelial cells express CXCR1, ELR-
CXC chemokines may bind these receptors inducing further activation and IL-8 expression, 
and presumably forming an autocrine system. LPS-TLR4 signaling, C5a, and cytokines 
can also stimulate vascular endothelial cells to produce IL-8 and PAF, which are 
immobilized on the endothelial cell surface via binding to glycosminoglycans (GAG).  The 
chemokines and other chemoattractants (e.g., PAF and LTB4) can bind to CXCR-1 and -2 
or their relative GPCRs (e.g., PAFR, BLT) on neutrophils.  This activates β2 integrin and 
L-selectin expression, degranulation and ROI release, which facilitates neutrophil 
transendothelial migration and results in vascular damage. Our findings suggest that G31P 
has anti-inflammatory activities at multiple levels.  (1) In circulation, G31P binding 
CXCR-1 and -2 on neutrophils can prevent ELR-CXC chemokine activation and dampen 
activation of other chemoattractants through desensitization of their relative GPCRs, which 
plays a major role in preventing neutrophil transendothelial migration and reducing the 
vascular damage.  (2) G31P may also block neutrophil chemotaxis, ROI release, Ca2+ flux 
and reverse anti-apoptotic effects induced by ELR-CXC chemokines or other 
chemoattractants (e.g., C5a, LTB4) during their transendothelial migration and migration 
into the interstitial tissue.  (3) G31P can also block LPS-induced ELR-CXC chemokine 
and cytokine expression by epithelial cells, presumably via breaking chemokine autocrine 
systems; however this needs to be investigated further. (4) G31P may also block 
endothelial cell activation and the expression of adhesion molecules, chemokines 
stimulated by ELR-CXC chemokines, LPS, or other chemoattractants.  Whether or not 
endothelial cells are affected and by what mechanisms is an interesting area for future 
study.   
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Figure 7.2.  The effects of G31P in blocking neutrophilia pathology in intestinal I/R 
injury.   
 
Hypoxia during intestinal I/R injury can induce endothelial cell necrosis, which in 
turn initiates complement (e.g., C5a) production mainly via alternative pathways in the 
circulation and interstitial tissue (Markiewski and Lambris 2007). C5a can bind its 
receptors, C5aR or C5L2, on the surface of endothelial cells and stimulate IL-8 and 
expression other chemoattractants (e.g., PAF, LTB4).  C5a can activate residential AM to 
produce ELR-CXC chemokines (e.g., CXCL8/IL-8) and proinflammatory cytokines (TNF, 
IL-1, and IL-6), which can further activate airway epithelial cells to release the 
aforementioned chemokines and cytokines.  Cytokines by themselves can also induce 
chemokine expression by epithelial cells.  As airway epithelial cells express CXCR1, ELR-
CXC chemokines may bind it and further activate epithelial cells to induce IL-8 expression 
and presumably form an autocrine system.  The proinflammatory cytokines can also 
stimulate vascular endothelial cells to produce IL-8 and PAF, which are immobilized on 
the endothelial cell surface via binding to glycosminoglycans (GAG). The chemokines and 
other chemoattractants (e.g., PAF and LTB4) can bind to CXCR-1 and -2 or their relative 
GPCRs (e.g., PAFR, BLT) on the neutrophils.  This activates β2 integrin and L-selectin 
expression, degranulation and ROI release, which facilitates neutrophil transendothelial 
migration and results in vascular damage.  Similarly, G31P may have the following anti-
inflammatory activties. (1) In circulation, G31P binding of CXCR1 and CXCR2 on 
neutrophils can prevent ELR-CXC chemokine activation and dampen activation and 
expression of other chemoattractants through desensitization of their relative GPCRs. This 
prevents neutrophil transendothelial migration and reduces vascular damage.  (2) G31P 
may also block neutrophil chemotaxis, ROI release, Ca2+ flux and reverse anti-apoptotic 
effects induced by ELR-CXC chemokines or other chemoattractants (e.g., C5a, LTB4) 
during their transendothelial migration and migration in the interstitial tissue.  (3) G31P 
may block ELR-CXC chemokine stimulated epithelial cell activation, presumably via 
breaking chemokine autocrine systems, however this needs further investigation. (4) G31P 
may also block endothelial cell activation and the expression of adhesion molecules, 
chemokines stimulated by ELR-CXC chemokines, LPS, or other chemoattractants.  
Whether or not endothelial cells are affected and by what mechanisms is an interesting area 
for future study.   
 
 
 
 
 
 
 
 154
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAG&PAF
ROI release, Ca2+ flux,
delayed apoptosis
AM
Epithelial cells
PMN
Other type of cells
Endothelial cells
IL-8, LTB4, PAF
CXCR1/2 C5aR,BLT,FPR
ELR-CXC chemokines (e.g., IL-8)
TNF, IL-1
C5a,LTB4, 
PAF gradient
G31P
TNF, IL-1, IL-8
G31P
IL-8
1
2
GAG& IL-8 GAG&G31P
β2 integrin
G31P/CXCR1
I/R C5a
C5a
IL-8
3
G31P
G31P
CXCR1/2/G31P 4
IL-8?
?
ELR-CXC chemokine
G31P
TNF,IL-1
C5a,LTB4,PAF
Airway
 
 
 
 
 155
 Like repertaxin, G31P may be also useful in treating sepsis, an important 
contributor for ARDS, if given at optimal times via s.c. or i.p. routes.  It is well established 
that CXCR2 expression on neutrophils is down-regulated in sepsis patients, which seems 
to indicate that CXCR2 ligands play a minor role in mediating neutrophil migration.  But 
CXCR1 is normally expressed and IL-8 still can induce chemotactic responses in 
neutrophils from ARDS patients (Cummings, Martin et al. 1999).  Recently study found 
that neutralization of CXCR2 before CLP surgery significantly protected mice against 
CLP-induced mortality. CXCR2 knockout mice were also protected against CLP-induced 
mortality compared with wild type mice.  However, blocking CXCR2 after the CLP 
procedures was not beneficial to survival (Ness, Hogaboam et al. 2003), which indicates 
that blocking CXCR2 is only effective before CXCR2 signaling leading to cellular 
activation.  In other words, when neutrophils are already activated during sepsis, blockade 
of CXCR2 alone may not be enough to protect against mortality in sepsis.  Therefore, as a 
CXCR1 and CXCR2 antagonist, G31P would be effective in blocking neutrophil 
infiltration into the peritoneal cavity and decrease mortality in the CLP model if given 
before and after CLP surgery.  It may be also effective after sepsis is already developed 
given that it also blocks CXCR1 signaling on neutrophils. In addition, C5a- and fMLP-
induced neutrophil activation is also important in sepsis pathology (Czermak, Sarma et al. 
1999).  The combined effects of G31P on the CXCR1 and CXCR2 and the alternate 
receptors for C5a and fMLP may contribute to inhibit neutrophil activation and migration 
and reduce pathology in sepis patients.  But these combined effects of G31P may not be 
effective in treating those sepsis patients wherein their neutrophils have already been fully 
activated.  These speculations need to be further examined.   
G31P may not be beneficial in some infections.  One study found that CXCR2 is 
important in protection from some bacterial infection, such as from Pseudomonas 
aeruginosa.  Blockade of ELR-CXC chemokines can only modestly reduce neutrophil 
infiltration and has no effect on bacterial clearance or survival.  Blockade of CXCR2 
resulted in a marked increase in mortality, which was associated with dramatic decreases in 
neutrophil recruitment and bacterial clearance (Tsai, Strieter et al. 2000).  Similarly, 
CXCR2 also has protective functions in Aspergillus fumigatus  infections (Mehrad, Strieter 
et al. 1999).  Therefore, G31P treatment may be not beneficial in these settings.  The 
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 reason may be because ELR-CXC chemokines and their receptors are less important for 
activating neutrophils, but necessary and protective in severe infections.  This is also 
suggested in the finding that fMLP seems to be important in situations with high bacterial 
inocula in inducing neutrophil migration and activation, whereas chemokines are important 
in low bacterial inoculum situations and contribute to more sustained neutrophil responses 
(Gauthier, Fortin et al. 2007).  
 As discussed above, G31P perhaps would be effective in treating ALI/ARDS 
patients.  It may be beneficial in treating neutrophil-mediated chronic diseases, such as RA 
and COPD, which may need long-term treatment.  This brings the question whether using 
G31P for long-term treatment will cause any adverse effects for the body.  It has been 
indicated that anti-TNF antibody treatment can cause malignacies and serious infections 
(Bongartz, Sutton et al. 2006).  It may also increase the risk of developing some other 
diseases, such as tuberculosis, neurological disease, autoimmune disease, and cardiac 
disease (Hyrich, Silman et al. 2004).  There were concerns about the risk of these diseases 
when using anti-TNF treatment because TNFα has a crucial role in the body’s defense 
against foreign pathogens such as bacteria, viruses, and fungi, particularly in the 
recruitment of neutrophils and monocytes to the site of infection.  Similarly, G31P 
treatment via binding CXCR1 and CXCR2 has a potent effect on blocking neutrophil 
recruitment.  The question that may be brought here is whether G31P treatment will 
increase the risk of serious infection.  Our results suggest that bacterial growth did not 
increase after treatment with G31P in an aspiration pneumonia model, but the effect of its 
long-term use will need to be investigated critically.  In addition, CXCR2 is protective 
during infection by some microorganisms, such as Pseudomonas aeruginosa and 
Aspergillus fumigatus (Mehrad, Strieter et al. 1999; Tsai, Strieter et al. 2000).  Blockade of 
the CXCR2 using G31P may increase the risk of infection by these kinds of pathogens.  
  
 General conclusion: 
  We successfully developed a human ELR-CXC chemokine antagonist, human 
CXCL8(3-72)K11R/G31P (hG31P).  It can effectively block neutrophil chemotactic 
responses and activation induced by ELR-CXC chemokines and othe neutrophil 
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 chemoattractants in vitro.  It also effectively blocks neutrophil recruitment and activation, 
increased vascular permeability, and cytokine and chemokine expression in in vivo systems, 
including experimental models of airway endotoxemia, aspiration pneumonia, and 
mesenteric I/R injury.  hG31P could potentially be a viable therapeutic approach for 
inflammatory diseases such as ALI/ARDS. 
 
Future directions 
We have shown that G31P effectively blocks neutrophil chemotaxis and calcium 
flux responses to ELR-CXC chemokine, including CXCL8 and CXCR2-exclusive 
chemokines (e.g., CXCL1, CXCL5), and ROI release stimulated by CXCL8, which 
indicates that G31P can competively bind CXCR1 and CXCR2 on neutrophils. But it 
would be ideal to have direct evidence regarding the affinity of G31P for the CXCR1 and 
CXCR2, relative to IL-8, GRO, or GCP-2.  
Neutrophil chemoattractants employ different intracellular signaling pathways, 
wherein IL-8, PAF, and LTB4 are dependent on PI3K, whereas p38 MAK-dependent 
signaling mediates neutrophil responses to fMLP and C5a. There is a need to know how 
G31P binding to the CXCR1 or CXCR2, or both receptors, heterologously desensitizes 
alternative ligand receptors.  What other pathways does G31P blunt and possibly employ 
to effect heterologous desensitization of receptors for C5a and fMLP?  Elucidating these 
details will help us further understand the mechanism of how G31P works in vivo. 
There is a similar need for studies on how G31P affect LPS challenged-epithelial 
cell activation and cytokine and chemokine expression.  As discussed in the literature 
review (§1.2.1.4), LPS activation of neutrophils through TLR4 can down-regulate the 
CXCR1 and CXCR2 expression, although CXCR1 expression is more resistant to the 
down-regulation.  It would be interesting to know whether G31P binding to CXCR1 or 
CXCR2 negatively affects TLR4 expression, resulting in decreased cytokine and 
chemokine expression by epithelial cells or if this is accomplished by some other 
mechanism.  Also, it will be interesting to determine whether G31P can block LPS-induced 
cytokines and chemokines expression from neutrophils and endothelial cells.  If so, what 
would be the operative mechanisms? 
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